

Hum Genet (2013) 132:1077–1130
DOI 10.1007/s00439-013-1331-2

REVIEW PAPER

Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease

David N. Cooper · Michael Krawczak ·
Constantin Polychronakos · Chris Tyler-Smith ·
Hildegard Kehrer-Sawatzki

Received: 3 May 2013 / Accepted: 15 June 2013 / Published online: 3 July 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract Some individuals with a particular disease-causing mutation or genotype fail to express most if not all features of the disease in question, a phenomenon that is known as ‘reduced (or incomplete) penetrance’. Reduced penetrance is not uncommon; indeed, there are many known examples of ‘disease-causing mutations’ that fail to cause disease in at least a proportion of the individuals who carry them. Reduced penetrance may therefore explain not only why genetic diseases are occasionally transmitted through unaffected parents, but also why healthy individuals can harbour quite large numbers of potentially disadvantageous variants in their genomes without suffering any obvious ill effects. Reduced penetrance can be a function of the specific mutation(s) involved or of allele dosage.

It may also result from differential allelic expression, copy number variation or the modulating influence of additional genetic variants in *cis* or in *trans*. The penetrance of some pathogenic genotypes is known to be age- and/or sex-dependent. Variable penetrance may also reflect the action of unlinked modifier genes, epigenetic changes or environmental factors. At least in some cases, complete penetrance appears to require the presence of one or more genetic variants at other loci. In this review, we summarize the evidence for reduced penetrance being a widespread phenomenon in human genetics and explore some of the molecular mechanisms that may help to explain this enigmatic characteristic of human inherited disease.

D. N. Cooper (✉)
Institute of Medical Genetics, School of Medicine,
Cardiff University, Heath Park, Cardiff CF14 4XN, UK
e-mail: cooperDN@cardiff.ac.uk

M. Krawczak
Institute of Medical Informatics and Statistics,
Christian-Albrechts University, 24105 Kiel, Germany
e-mail: krawczak@medinfo.uni-kiel.de

C. Polychronakos
Department of Pediatrics/Human Genetics,
McGill University Health Center, Montreal, Canada
e-mail: constantin.polychronakos@mcgill.ca

C. Tyler-Smith
The Wellcome Trust Sanger Institute, Wellcome Trust
Genome Campus, Hinxton, Cambridge CB10 1SA, UK
e-mail: cts@sanger.ac.uk

H. Kehrer-Sawatzki
Institute of Human Genetics, University of Ulm,
Albert-Einstein-Allee 11, 89081 Ulm, Germany
e-mail: hildegard.kehrer-sawatzki@uni-ulm.de

Introduction

One old conundrum in human genetics is that not everyone with a given pathological mutation (or mutations) will eventually develop the disease in question. The proportion of those individuals harbouring a particular pathogenic mutation or genotype who exhibit clinical signs of the associated disorder within a specific and clearly defined time period is termed the *penetrance* of that disorder. If this proportion equals 100 %, the disease and/or disease genotype(s) are said to show complete penetrance. If not, they are said to exhibit reduced (or incomplete) penetrance. Reduced penetrance is likely to be a consequence of the combination of a variety of different genetic and environmental factors. A classic example is phenylketonuria, where inactivating mutations in the *PAH* gene encoding the enzyme phenylalanine hydroxylase lead to severe intellectual disability in the context of a normal diet, whereas a life-long phenylalanine-restricted diet makes possible a relatively healthy life (Blau et al. 2010). Regrettably, few

other examples of reduced penetrance are as simple, well understood or clinically manipulable as this one, and the precise mechanisms by which different factors give rise to reduced penetrance remain largely unknown (Zlotogora 2003).

In formal terms, penetrance measures the proportion of individuals in a given population with a specific disease-associated genotype who also express the corresponding disease phenotype. Large family/population studies have traditionally been considered necessary to measure penetrance, either for specific mutations/genotypes or as a disease average. ‘Cascade genetic screening’, whereby relatives of previously identified carriers are screened both for the mutation(s) in question and for the presence/absence of clinical symptoms, is one means to determine the degree of penetrance for a given genotype (Berge et al. 2008). As we discuss below, large-scale sequencing and genotyping studies of apparently healthy individuals from the general population provide a powerful new approach to understanding the penetrance of pathological mutations/genotypes. The outcomes of such studies should allow us to predict how likely it is that a given disease will manifest itself in an individual who carries a specific genotype.

Reduced penetrance is most obviously evident in disorders that follow an autosomal dominant mode of inheritance. In these instances, reduced penetrance is a characteristic of the underlying mutation, rather than a genotype. However, reduced penetrance can also occur in autosomal recessive disorders where one and the same mutation can have different phenotypic effects, depending at least in part upon the second disease allele present. Irrespective of the mode of inheritance, in most cases penetrance is likely to be a function of the specific mutation(s) involved. Thus, in some conditions normally characterized by an autosomal dominant mode of inheritance, two incompletely penetrant (or otherwise non-penetrant) alleles may act in recessive fashion while mimicking the normal dominant form of the disease (e.g. Grundy et al. 1991; Croxen et al. 2002; Kowalewski et al. 2007; Castaman et al. 2007; Rossetti et al. 2009; Vujic et al. 2010; Schaaf et al. 2011a). For a dominantly inherited condition, one consequence of reduced penetrance is that the clinical phenotype may not be evident in one generation, but can nevertheless still be transmitted (through an apparently unaffected parent) to subsequent generations where it again manifests itself; specimen examples of this from clinical practice include hereditary hyperekplexia (Kwok et al. 2001), cherubism (Preda et al. 2010), retinitis pigmentosa (Rio Frio et al. 2009), rhabdoid tumour predisposition syndrome (Ammerlaan et al. 2008), autism spectrum disorder (Fujita-Jimbo et al. 2012) and hypercholesterolaemia (García-García et al. 2011). For all the above reasons, reduced penetrance presents a major challenge to genetic

counsellors attempting to interpret the medical history of a patient’s family to quantify the disease risk to the patient’s offspring (Emery 1986; Otto and Maestrelli 2000).

Reduced penetrance is not uncommon; indeed, there are many known examples of bona fide disease-causing variants or genotypes that fail to cause disease in at least a proportion of individuals who carry them (Zlotogora 2003; Waalen and Beutler 2009). By definition, penetrance refers to the black and white issue of whether the clinical phenotype associated with a certain genotype is present or not. We routinely distinguish it from variable expressivity which refers to the degree of variation of the clinical phenotype in those individuals with a particular genotype. Although, in principle, penetrance and expressivity are distinct terms with specific meanings (depending upon the way a given clinical phenotype is defined), in practice they are closely inter-related and likely to manifest via similar mechanisms. We also distinguish reduced penetrance from small effect size. Thus, most carriers of the risk alleles discovered by genome-wide association studies (GWAS) may never develop the disease in question; this is because these variants generally only make a small contribution to the multifactorial aetiology of the condition. To be able instead to say that the variant is non-penetrant in some individuals, we require the same variant in other individual(s) to make the crucial difference between the phenotype being manifested or not. In what follows, we shall focus specifically on the molecular mechanisms that could account for the phenomenon of reduced penetrance. This notwithstanding, the discussion of genetic variants that modulate the expressivity of a particular disease has sometimes also been deemed appropriate.

In this review, we present the evidence for reduced penetrance being a widespread phenomenon in human genetics, evidence that comes not only from a plethora of case studies of monogenic disorders but also more recently from the next generation sequencing of entire exomes or genomes of apparently normal healthy individuals from the general population. Here, we have attempted to explore the individual genetic components that contribute to the complexity of primarily monogenic disorders with reduced penetrance. This notwithstanding, the action of modifier genes is one of the mechanisms responsible for reduced penetrance, and one that has increasingly become recognized as blurring the distinction between monogenic conditions and complex disease (Nadeau 2003; Badano and Katsanis 2003; Sidransky 2006). Finally, we explore some of the molecular mechanisms which could account for the reduced penetrance of many human inherited disorders and provide evidence to support the view that, at least in some instances, complete penetrance requires the presence of one or more genetic variants at other loci.

Deleterious and disease alleles in the general population

In the wake of the sequencing of multiple human genomes, it has become apparent that healthy individuals can harbour quite large numbers of potentially disadvantageous variants without suffering any obvious ill effects (The 1000 Genomes Project Consortium 2010; MacArthur et al. 2012; Xue et al. 2012; Shen et al. 2013a). The underlying reasons are likely to be many and varied: thus, the variants may damage the protein in question but the intact protein may not be necessary for the health of the carrier; individuals may be asymptomatic carriers of single-mutant alleles that could, in homozygosity or compound heterozygosity, cause recessive disease; the mutation may be dominant but the clinical phenotype might only be mild and classed as lying within the range of normal healthy variation; the disorder might be late in onset with expression being age- or sex-dependent; or the disorder may require additional genetic and/or environmental factors for it to manifest clinically.

Assessing the magnitude of the ‘genetic burden’ imposed on the general population by the presence of deleterious alleles has been a key aim of medical and population genetics for many decades. With the advent of large-scale sequencing technologies, it has become possible to estimate the number of amino acid substitutions in the human exome that would be predicted *in silico* to be damaging (Kryukov et al. 2007; Lohmueller et al. 2008; Boyko et al. 2008; Goode et al. 2010). However, personal genome sequences have not only provided estimates of the number of disease variants carried by each subject (Asan et al. 2011), but have also given us a glimpse of the likely complexity of the functional interpretation of such data (Ashley et al. 2010; Strom and Gorin 2013). More recently, Tennessen et al. (2012) suggested that 2.3 % of the 13,595 single nucleotide variants carried by the average person impact upon protein function, involving ~313 genes per human genome. Adopting an alternative approach, Bell et al. (2011) surveyed 437 genes known to be related to a recessive Mendelian disease and identified 2.8 mutations per individual (range 0–7). Taken together, these studies suggest that individuals typically carry hundreds of mildly disadvantageous variants and perhaps several tens of potentially severe disease alleles.

In a pilot study for the 1000 Genomes Project Consortium (2010), we reported the prevalence of disease alleles, defined by reference to the disease-causing mutations (DMs) listed in the Human Gene Mutation Database (HGMD; <http://www.hgmd.org>; Stenson et al. 2009), in population samples of African, European and East Asian origin. These numbers were surprisingly high: 57–80 disease alleles per individual in a sample of 179 participants. Moreover, further examination of these data showed that 191 disease alleles were present in the homozygous state in

at least one individual, and hence were not simply present because their phenotypic/clinical effects had been masked by a normal allele. Although little phenotypic information other than sex, ethnicity, place of origin and relationship to other participants is available for the 1000 Genomes Project donors, the Project’s ethical framework requires that sample donors are non-vulnerable adults who are competent to consent to participation in the project and hence are likely to lack any obvious severe disease phenotype. Instead, we need to seek some other explanation for the high number of DMs present. One possibility is that the penetrance of disease alleles and genotypes could be much lower and more variable than previously realized. Conventionally, most studies of human inherited disease that have contributed mutation data to HGMD have sought to identify a disease genotype, given a clinical phenotype (Cooper et al. 2010). This is a very different scenario from identifying a phenotype given a (potentially disease associated) genotype. Indeed, the former strategy inevitably avoids the whole issue of penetrance because, by definition, it focuses exclusively upon those individuals in whom the mutation of interest has been penetrant. It follows that a given variant could be genuinely causative in a set of individuals manifesting a particular disease, yet may also be present in a set of healthy individuals who differ in any one of a number of ways to be discussed below.

Since the 1000 Genomes Project Consortium paper was published in 2010, two further reports have appeared that served to improve our knowledge of deleterious mutations in the genomes of apparently healthy individuals. The most readily recognized deleterious variants in the human genome are those that disrupt a protein-coding gene, either by leading to a loss of function (e.g. a nonsense or frameshift variant) or by altering an amino acid in the encoded protein (missense variants). The former category of mutation has been studied by MacArthur et al. (2012) who identified 1,285 putative loss-of-function variants (i.e. nonsense mutations, splice site-disrupting single nucleotide variants, micro-insertions/micro-deletions, etc.) in the genome sequences of 185 humans from the 1000 Genomes Project. From these data, they estimated that an average human genome typically contains ~100 genuine loss-of-function variants with ~20 genes having both copies inactivated. Following on from this study, Xue et al. (2012) focused on missense mutations, ascertaining the numbers of potentially deleterious missense variants in the genomes of apparently healthy individuals using low-coverage whole-genome sequence data from 179 individuals in the 1000 Genomes Pilot Project. Each individual was found to carry 281–515 missense substitutions predicted with a high degree of confidence to be damaging to the gene product, 40–85 of which were present in the homozygous state. Taken together, these studies suggest that a typical healthy

individual has about 80 of their genes severely damaged or inactivated in both copies, further emphasizing the stark contrast between damage to gene and protein on the one hand, and damage to health on the other. The 1000 Genomes Project participants also carried 40–110 variants (3–24 homozygous) classified by HGMD as DMs. Whereas many of these DMs could conceivably represent disease attribution errors of some kind, between 0 and 8 DMs per individual (0–1 homozygous) were predicted to be highly damaging.

Among the missense DMs, Xue et al. (2012) identified known pathological variants such as *HBB* (c.20A>T; p.Glu7Val), which leads to increased resistance to malaria in heterozygotes but to sickle cell disease in homozygotes [confined to Africans (Yoruba, YRI) in whom there were

12 heterozygotes and 1 homozygote]. In addition, Xue et al. (2012) identified an *USH2A* variant (c.2138G>C; p.Gly713Arg), previously reported as being causal for Usher syndrome type 2, a recessive disorder characterized by combined deafness and blindness; three homozygotes were noted in the YRI. Manual curation of the HGMD-1000GP overlap revealed the presence of three types of DM: (1) plausible severe disease-causing variants, (2) variants convincingly causative for pathological conditions, yet quite compatible with adult life and (3) variants probably incorrectly assigned as disease causing. After applying various filtering criteria designed to enrich for true disease alleles, the list was reduced to 45 candidates (Xue et al. 2012). Of these putative disease alleles, 34 were present in the heterozygous state and were deemed likely to

Table 1 Disease variants potentially capable of either causing dominant disease, or causing recessive disease and observed in the homozygous state, detected in 1000 Genomes Project participants (data from Xue et al. 2012)

Disease (MIM number)	Inheritance	Gene	HGVS cDNA mutation	Protein alteration	Total homozygotes	Total heterozygotes	Comments
Ataxia telangiectasia (MIM# 607585)	AR	<i>ATM</i>	NM_000051.3: c.4258C>T	p.Leu1420Phe	1	3	Low-penetrance breast cancer susceptibility allele
Usher syndrome type IIA (MIM# 276901)	AR	<i>USH2A</i>	NM_206933.2: c.2137G>C	p.Gly713Arg	3	22	Probable complex pathogenicity; neutral in YRI?
Nephronophthisis 4 (MIM# 606966)	AR	<i>NPHP4</i>	NM_015102.3: c.2542C>T	p.Arg848Trp	1	2	Growth retardation; adult-onset renal disease
Cushing syndrome (MIM# 607397)	AR	<i>MC2R</i>	NM_000529.2: c.833T>G	p.Phe278Cys	1	10	Hormonal disorder; variable gender-specific symptoms; variant functionally defective in vitro
Low-phospholipid-associated cholelithiasis (MIM# 171060)	AR	<i>ABCB4</i>	NM_000443.3: c.2363G>A	p.Arg788Gln	2	9	Adult onset
Cardiomyopathy, hypertrophic (MIM# 115197)	AD	<i>MYBPC3</i>	NM_000256.3: c.1519G>A	p.Gly507Arg	0	2	Late onset; incomplete penetrance
Glaucoma, primary open angle (MIM# 609887)	AD	<i>WDR36</i>	NM_139281.2: c.1586G>A	p.Arg529Gln	0	1	Adult onset; variant functionally defective in vitro
Colorectal cancer, nonpolyposis (MIM# 609310)	AD	<i>MLH1</i>	NM_000249.3: c.1742C>T	p.Pro581Leu	0	1	Adult onset; variant functionally defective in vitro
Renal cell carcinoma (MIM# 144700)	AD	<i>FLCN</i>	NM_144997.5: c.715C>T	p.Arg239Cys	0	1	Late onset
Heparin cofactor 2 deficiency (MIM# 612356)	AD	<i>SERPIND1</i>	NM_000185.3: c.623G>A	p.Arg208His	0	2	Deficiency state, but no overt disease; risk factor for thrombophilia
Lp(a) deficiency (MIM# 152200)	AD	<i>LPA</i>	NM_005577.2: c.4289+1G>A	essential splice site	0	5	Late onset; risk factor for heart disease

be present in asymptomatic carriers. Among the remaining 11 (Table 1), the 6 linked to dominant disorders were explicable in terms of either late onset (e.g. Gly507Arg in *MYBPC3*) or covert disease (Arg208His in *SERPIND1*). In similar vein, the presence of homozygotes for four of the five recessive disorders could be explicable in terms of late onset and/or reduced penetrance of disease. The *USH2A* mutation (Gly713Arg) was, however, intriguing: this variant was predicted to be damaging to the protein, and pathogenic in some populations but not in others (e.g. YRI). One explanation put forward to explain this apparent contradiction was that, in the YRI population, the *USH2A* locus is subject to copy number variation (Matsuzaki et al. 2009) that could provide functional complementation of the mutant gene. In the majority of cases, however, the most likely explanation for the absence of disease at the time of recruitment was considered to be the probable late onset of disease, although clinical penetrance was often variable, and some phenotypes, such as loose anagen hair syndrome [caused by Glu337Lys in *KRT75* (MIM 600628)], might not even be regarded as “diseases” sensu stricto. These factors notwithstanding, the findings of Xue et al. (2012) suggest that incidental findings which are potentially relevant to health and well-being might be made in as many as 11 % of individuals sequenced.

Reduced penetrance is one of several possible explanations for why some variants of putative pathological significance, listed in HGMD and/or Locus-specific Mutation Databases, nevertheless occur in apparently healthy individuals (Ashley et al. 2010; Bell et al. 2011; Xue et al. 2012; Golbus et al. 2012; Wang et al. 2013a; Kenna et al. 2013; Shen et al. 2013a). It is not hard to see why reduced penetrance might be much more common among described mutations than originally thought: whereas known pathological mutations have almost invariably been identified through retrospective analyses of families or well-defined groups of clinically symptomatic patients, relatively few prospective studies of asymptomatic carriers have so far been performed to derive estimates of penetrance (e.g. Jensen et al. 2013; Mavaddat et al. 2013). Indeed, establishing that a specific mutation identified in a particular patient with a given disease is the pathological lesion responsible for that individual’s clinical phenotype does not allow one automatically to judge whether this mutant genotype will invariably give rise to the same clinical phenotype in all other individuals harbouring it. This can only be established (or refuted) empirically by comprehensive, ideally prospective, studies of the genotype in question.

One fairly obvious reason why comparing the output of genome sequencing projects (e.g. the 1000 Genomes Project) with a comprehensive database of putatively pathological mutations (e.g. HGMD) is likely to generate a considerable number of potentially pathogenic mutations in

the general population, is that many such mutations are quite frequent in the population at large. In particular, carrier frequencies for mutations underlying recessive conditions can often be quite high. Thus, the *ABCA4* Gly863Ala mutation causing Stargardt disease has a carrier frequency of 1.8 % in Europe (Maugeri et al. 2002), the *GJB2* 35delG mutation causing congenital deafness has a carrier frequency of 2.9 % in southern Europe (Gasparini et al. 2000), the *ERCC8* Tyr322Term mutation causing Cockayne syndrome has a carrier frequency of 6.8 % in Israeli Christian Arabs (Khayat et al. 2010) and the *SPG7* Ala510Val mutation associated with adult-onset neurogenetic disease has a carrier frequency of 3–4 % in the UK population (Roxburgh et al. 2013). Disease allele frequencies can be as high as 10 % in certain ethnic groups, e.g. Jews (Zlotogora et al. 2007; Ostrer and Skorecki 2013). A recent screen of the Korean population for 20 common mutations contributing to six autosomal recessive disorders yielded a combined carrier frequency of 6.7 % (Song et al. 2012). Screening an ethnically diverse US population sample ($N = 364,890$) for 87 different *CFTR* mutations responsible for causing cystic fibrosis yielded a combined carrier frequency of 2.6 % (Rohlf et al. 2011). As part of the NHLBI-Go Exome Sequencing Project, a screen of 5,400 individuals from the general population for variants in eight long QT syndrome genes yielded a total of 33 different missense mutations (affecting 173 alleles), representing a carrier frequency of 3.2 % (Refsgaard et al. 2012). A similar screen for cardiomyopathy-associated gene variants yielded combined carrier frequencies for mutations reported to be disease associated of 25 % (1,474/5,810) for hypertrophic cardiomyopathy, 15 % (963/6,334) for dilated cardiomyopathy and (22 %) 1,393/6,359 for arrhythmogenic right ventricular cardiomyopathy (Andreasen et al. 2013); the high number of detected cardiomyopathy-associated gene variants suggests, however, that many are only modest disease modifiers or even non-pathogenic. Nishiguchi and Rivolta (2012) screened 46 complete genome sequences from the general population for mutations in 106 genes associated with recessively inherited retinal degeneration and identified null mutations in ten individuals (22 %). Finally, a routine screen of 23,453 individuals for 417 pathogenic mutations associated with a total of 108 recessive diseases concluded that 24 % of individuals were carriers of at least one disorder, whilst 5.2 % were carriers of two or more disorders (Lazarin et al. 2013). Clearly, there is a veritable abundance of actual and potential pathological variants segregating in the general population.

The examples that we cite in the text that follows and in the accompanying tables are by no means comprehensive and have been provided simply to illustrate the many and varied mechanisms that are already known to underlie the phenomenon of reduced penetrance in relation to clinical disorders. However, these examples also demonstrate that

it is often very hard for authors, diagnosticians and mutation database curators alike to classify the pathogenicity of identified variants with any degree of certainty. Thus, is a given missense mutation a bona fide pathological lesion that exhibits greatly reduced penetrance, or is it essentially a neutral or near-neutral variant that occasionally finds itself in *cis* to other variants that are responsible for conferring the disease phenotype upon the individual concerned, or is it a variant with small effect that is sometimes present in affected individuals whose major causative lesions remain unknown?

Incomplete penetrance in dominant and recessive conditions

A considerable number of autosomal dominant disorders are characterized by incomplete penetrance. Well-studied examples include the hair disease monilethrix (*KRT86*; De Cruz et al. 2012), congenital cataract (*GJA3*; Burdon et al. 2004), different types of retinitis pigmentosa (*PRPF8* and *PRPF31*; Maubaret et al. 2011; Saini et al. 2012), *LMNA* mutation-associated muscular phenotypes (Rankin et al. 2008) and long QT syndrome (Giudicessi and Ackerman 2013; Mathias et al. 2013).

One rather well-understood example of incomplete penetrance of a dominantly inherited mutation is factor V Leiden (*F5*, Arg534Gln; Arg506Gln in legacy nomenclature; rs6025) which occurs at polymorphic frequencies (2–5 %) in European populations, but is associated with a sixfold increased risk of venous thrombosis and a two- to threefold increased risk of pregnancy loss (Kujovich 2011). Despite these very evident disease associations, the vast majority of factor V Leiden carriers appear to be clinically unaffected. This could help to account for the high frequency of this variant in the general population, together perhaps with the survival advantage conferred by factor V Leiden carriership in various other clinical contexts including severe sepsis (Kerlin et al. 2003; van Mens et al. 2013). In similar vein, the asymptomatic (clinically covert) state is much more common than the clinically overt state in several other dominant disorders of haemostasis, including protein C deficiency (Tait et al. 1995; McColl et al. 1996), protein S deficiency (Dykes et al. 2001), antithrombin deficiency (Tait et al. 1994; McColl et al. 1996) and von Willebrand disease (Rodeghiero et al. 1987; Castaman et al. 2003). Thus, in disorders of haemostasis and thrombosis, even with well-characterized variants that are known to confer a significantly increased disease risk, the clinical penetrance is often so low that more healthy individuals carry the variant than those who actually manifest disease.

Reduced or incomplete penetrance has also been described for autosomal recessive disorders. Probably the best characterized example of incomplete penetrance in a recessive

disorder is provided by the Cys282Tyr (rs1800562) mutation in the haemochromatosis (*HFE*) gene (Beutler 2003). The Tyr282 homozygous genotype is present in approximately 1 in 200 people of Northern European origin and is responsible for 80–90 % of hereditary haemochromatosis (Weiss 2010; Rochette et al. 2010). Although Tyr282 homozygosity displays a relatively high biochemical penetrance (i.e. iron accumulation), its clinical penetrance is low (McCune et al. 2006). Available data suggest that 38–50 % of Tyr282 homozygotes develop iron overload and 10–25 % develop some type of haemochromatosis-associated morbidity (Whitlock et al. 2006). However, these statistics conceal what appears to be a gender effect: large-scale studies of newly diagnosed Tyr282 homozygotes, in whom liver disease had been specifically assessed, revealed that disease manifested in 24–43 % of males, but only 1–14 % of females (Rossi et al. 2008). Various genetic modifiers have been identified as influencing the clinical expression of haemochromatosis. These include mutations in the *HAMP*, *HFE2* and *TFR2* genes and polymorphisms in the *BMP2*, *BMP4*, *CYBRD1*, *HP*, *LTA*, *MPO*, *TMPRSS6* and *TNF* genes (Milet et al. 2007; Rochette et al. 2010; Valenti et al. 2012; Pelucchi et al. 2012). In addition, several environmental modifiers (e.g. diet, alcohol intake) are also known to affect the penetrance of the *HFE* genotype.

In another recessive disorder, Gaucher disease, the most common *GBA* mutation, Asn370Ser (Asn409Ser in HGVS nomenclature; rs76763715), is also characterized by low penetrance and exhibits extensive phenotype heterogeneity even in the homozygous state (Sibille et al. 1993; Horowitz et al. 1998; Fairley et al. 2008). However, close examination of asymptomatic Ser370 homozygotes, serendipitously diagnosed by prenatal carrier screening, revealed a variety of previously unidentified disease manifestations indicating that the clinical penetrance of this disease genotype may be greater than previously appreciated (Balwani et al. 2010).

Influence of mutation type on penetrance

Clinical penetrance is in part a function of the mutation(s) in question. For a given disease, some causal mutations may exhibit complete clinical penetrance, whereas other mutations in the same gene show incomplete or even very low penetrance. Thus, whereas the penetrance of the most common *CFTR* gene lesion, Δ Phe508 (rs113993960), in cystic fibrosis is very high, the penetrance of the *CFTR* Arg117His (rs78655421) mutation (in any allele combination) appears to be so low as to call into question its putative role as a pathological mutation (Thauvin-Robinet et al. 2009).

As yet, relatively few studies have been performed on low-penetrance mutations with a view to identifying the features responsible at the molecular level for their low

penetrance. One exception is in retinoblastoma where it has been found that low-penetrance *RBI* mutations tend either to lead to a reduction in the amount of Rb protein produced (through promoter or splice site mutations) or yield a partially functional Rb molecule through missense mutation or in-frame deletion (Onadim et al. 1992; Kratzke et al. 1994; Bremner et al. 1997; Otterson et al. 1997; Scheffer et al. 2000; Genuardi et al. 2001; Harbour 2001; Klutz et al. 2002; Lefèvre et al. 2002; Valverde et al. 2005; Sánchez-Sánchez et al. 2005; Sampieri et al. 2006; Gámez-Pozo et al. 2007; Park et al. 2008; Hung et al. 2011). Of particular interest is the category of temperature-sensitive mutations in the Rb pocket domain (Δ Asn480, Arg661Trp, Cys712Arg) whose ‘reversible fluctuations’ in a threshold level of Rb pocket-binding activity could be responsible for their characteristic low penetrance (Otterson et al. 1999). On the basis of studies performed to date, it would appear that a high proportion of *RBI* mutations with reduced penetrance are splice site mutations, although not all splice site mutations display low penetrance.

Some mutations are associated with specifically reduced penetrance as compared to other mutations of the same type in the same gene. For example, *BRCA1* Arg1699Gln is characterized by a cumulative risk of breast or ovarian cancer by the age of 70 years of only 24 % (Spurdle et al. 2012), much lower than for the average pathogenic *BRCA1* mutation (~71 %; van der Kolk et al. 2010). Individuals with *GJB2*-associated deafness who harbour two nonsense/truncating mutations exhibit a much more severe clinical phenotype, and hence are more likely to come to clinical attention, than those harbouring two missense mutations (Azaiez et al. 2004). This serves to illustrate that, in recessive disorders, the clinical penetrance of one mutation may be strongly influenced by the nature of the other mutation in *trans*. In Ehlers–Danlos syndrome type IV, however, null *COL3A1* mutations tend to exhibit lower penetrance than missense and splicing mutations (Leistriz et al. 2011); this is presumably because a faulty gene product can disrupt the entire triple helical collagen molecule, whereas a null mutation merely reduces the amount of normal collagen produced (Arnold and Fertala 2013). In the same vein, patients with heritable pulmonary arterial hypertension, due to missense mutations in the *BMP2* gene, present earlier and with more severe disease than patients harbouring truncating mutations (Austin et al. 2009a). It is thought that the missense mutations are associated with stable *BMP2* transcripts encoding BMP2 protein which exerts a dominant negative effect on BMP signalling, thereby rendering missense mutations more detrimental than truncating mutations. The majority of *BMP2* missense mutations were penetrant prior to the age of 36 years, whereas the majority of truncating mutations became penetrant only after the age of 36 years

(Austin et al. 2009a). With mutations of the *TNFRSF1A* gene causing TNF receptor-associated periodic syndrome, missense mutations in cysteine residues have been reported to be more penetrant than missense mutations in non-cysteine residues (Aksentijevich et al. 2001; Aganna et al. 2001). Intriguingly, a *SOD1* Leu117Val missense mutation which yields a mutant protein indistinguishable from wild-type SOD1 (in terms of its activity, stability and folding) causes amyotrophic lateral sclerosis, but with unusually low penetrance and slow progression (Synofzik et al. 2012). Finally, clinical penetrance may vary not only with the mutation type, but also with the location of the mutation in the gene/protein (Jackson et al. 1999; Risch et al. 2001; Yatsenko et al. 2001; van der Werf et al. 2012; Ho et al. 2012).

In autosomal dominant hereditary pancreatitis, the penetrance of the *PRSSI* Arg122His mutation has been calculated to be 86 %, whereas that of *PRSSI* Ala16Val is of the order of 55–65 % (Grocock et al. 2010; Joergensen et al. 2010). It is thought that the comparatively low penetrance of this latter mutation may be related to its particularly mild biochemical phenotype. The Ala16Val substitution alters the *N*-terminal residue of the trypsinogen activation peptide, thereby increasing the rate of *N*-terminal processing by chymotrypsin C by ~5.8-fold (Szabó and Sahin-Tóth 2012). Since the activation peptide is released during the activation process, the Ala16Val mutation is absent from active trypsin and hence cannot influence trypsin function.

Missense mutations in the *MEFV* gene responsible for familial Mediterranean fever can differ quite dramatically in terms of their clinical penetrance. For example, Met694Val is generally characterized by high penetrance, whereas both Glu148Gln and Val726Ala exhibit reduced penetrance (Shohat and Halpern 2011). In this disorder, the carrier frequency is higher than would be expected from the prevalence of the disease, suggesting that the penetrance of pathogenic *MEFV* mutations may often be incomplete in the compound heterozygous state (Gershoni-Baruch et al. 2002; Zaks et al. 2003; Caglayan et al. 2010; Camus et al. 2012; Soriano and Manna 2012).

Double missense mutations in *cis* are not infrequently encountered in patients with an inherited disease. One of the two mutations may represent a hypomorphic (i.e. less functional) allele, as for example with the *GLA* Asp313Tyr occurring in *cis* to the pathogenic Gly411Asp in patients with Fabry disease (Yasuda et al. 2003). Double missense mutations in *cis* may however be associated with a highly variable clinical phenotype (e.g. *MEFV*, Pro369Ser/Arg408Gln as a cause of familial Mediterranean fever; Ryan et al. 2010). A low-penetrance missense mutation may be associated with a particularly severe clinical phenotype when it occurs in *cis* with a second known pathogenic mutation, e.g. *MYH7* Val606Met and Ala728Val in hypertrophic cardiomyopathy (Blair et al. 2001). Similarly,

two missense mutations in *cis*, each individually exerting a comparatively mild or no effect on the clinical phenotype, can act in concert leading to a more severe effect on the phenotype than either acting alone (e.g. *CFTR* Arg347His and Asp979Ala in cystic fibrosis; Clain et al. 2001 or *RET* Cys634Tyr and Tyr791Phe resulting in pheochromocytoma with high penetrance; Toledo et al. 2010). By contrast, Brugnoli et al. (2013) have intriguingly claimed that two different *CLCN1* mutations do not give rise to myotonia congenita when they occur in *cis* on the same allele, although both lesions cause the disease when inherited on their own.

In diseases that exhibit locus heterogeneity, clinical penetrance may vary between mutations in different genes. For example, in pancreatitis, penetrance may vary from virtually 100 % in the case of the most common mutations in the cationic trypsinogen gene (*PRSS1*) gene, via an intermediate level for *SPINK1* and *CFTR* mutations, to the much more subtle risk conferred by the disease modifiers, namely variants in the chymotrypsin C (*CTRC*), calcium-sensing receptor (*CASR*) and anionic trypsin (*PRSS2*) genes, which can only be identified through large cohort studies (Lerch et al. 2010). It should, however, be noted that in cases where mutations in the *SPINK1* and *CASR* genes (Felderbauer et al. 2003) or *SPINK1* and *CFTR* genes (Masson et al. 2007) are co-inherited, chronic pancreatitis can ensue. Other such examples of digenic inheritance are discussed below (see *digenic mutations and disease penetrance*).

Reduced penetrance alleles are also characteristic of many triplet repeat expansion disorders. For example, in Huntington disease, the possession of intragenic (*HTT*) CAG repeats of 36–39 copies (in 0.01 % of controls and ~5 % of consultands) is often associated with reduced penetrance manifesting as a later onset of clinical symptoms (McNeil et al. 1997; Quarrell et al. 2007; Sequeiros et al. 2010; Panegyres and Goh 2011; Huntington Study Group COHORT Investigators 2012). Contractions of the expanded CAG repeat length below a certain threshold can occasionally be responsible even for the non-occurrence of Huntington disease in a given at-risk individual (Nahhas et al. 2009). However, it should be appreciated that a substantial proportion of the variance in age of onset in Huntington disease is due either to variation in genes other than *HTT* or in the environment (Wexler et al. 2004). Other repeat expansion disorders characterized by reduced penetrance of alleles of intermediate size include fragile X-associated tremor/ataxia syndrome (Jacquemont et al. 2004; Sévin et al. 2009), spinocerebellar ataxia types 10 (Alonso et al. 2006; Rankin et al. 2008) and 17 (Oda et al. 2004; Nolte et al. 2010), inherited prion disease (Kaski et al. 2011) and amyotrophic lateral sclerosis (Boeve et al. 2012; Ogaki et al. 2012).

Modulating influence of additional allelic variants in *cis* or in *trans*

Some allelic variants may influence the expression of their host gene so as to alter the penetrance of a potentially pathological mutation in the same gene. Such modulatory variants may reside within exons, introns or regulatory regions. For example, the common Arg413Gln *F7* polymorphism (Arg353Gln in legacy nomenclature; rs6046), which serves to reduce the level of secreted coagulation factor VII by ~25 % (Arbini et al. 1994; Hunault et al. 1997), is over-represented among individuals with clinically symptomatic factor VII deficiency (Millar et al. 2000). This is consistent with the view that Arg413Gln is a functional polymorphism and that the presence of Gln413 increases the likelihood that an individual, whose haemostatic potential is already compromised by a heterozygous *F7* mutation, will come to clinical attention due to a bleeding diathesis. The same principle applies to the functional Arg202Gln *MEFV* polymorphism (rs224222) where the Gln202 allele occurs in the homozygous state at a disproportionately higher frequency (15 %) in familial Mediterranean fever patients than in normal controls (2.7 %) (Yigit et al. 2012). In similar vein, the T allele of a functional C/T polymorphism (rs11024595) in the promoter region of the *SAA1* gene is significantly over-represented in familial Mediterranean fever patients as compared with normal controls (Migita et al. 2013). The *MLH1* Lys618Ala mutation (AAG>GCG; rs35502531), initially supposed to be a benign polymorphism, has been found to be significantly over-represented in sporadic cancers associated with Lynch syndrome; *MLH1* Ala618 appears to have a reduced ability to bind PMS2, one of the *MLH1* protein's mismatch repair partners (Medeiros et al. 2012). Finally, the functional *KCNE1* Asp85Asn polymorphism (rs1805128), which occurs in the general population with a frequency of 0.8 %, occurs at a frequency of 3.9 % in long QT syndrome patients (Nishio et al. 2009).

Various reported examples of the modulation of the impact of pathogenic missense mutations by allelic single nucleotide polymorphisms (SNPs) are given in Table 2. Thus, the missense polymorphism Asp216His (rs1801968) in the *TORIA* (*DYT1*) gene serves to moderate the clinical impact, in both *cis* and in *trans*, of the *TORIA* c.904-906 del GAG mutation, the major mutation underlying early-onset dystonia (Kock et al. 2006; Risch et al. 2007; Martino et al. 2013). Similarly, in long QT syndrome, the genotype of a missense polymorphism (Lys897Thr; rs1805123) in the *KCNH2* gene appears to distinguish symptomatic from asymptomatic individuals carrying a low-penetrance Ala1116Val pathogenic mutation (Crotti et al. 2005). Another example of the modulatory effect of a missense polymorphism on disease allele penetrance is provided by

Table 2 Examples of pathogenic microlesions whose penetrance has been found to be modulated by allelic SNPs

Disease	Gene	Pathological mutation	Modifying SNP	Reference
Factor VII deficiency	<i>F7</i>	Various	NM_000131.3: c.1238G>A Arg413Gln (rs6046)	Millar et al. (2000)
Brugada syndrome	<i>SCN5A</i>	NM_198056.2: c.5243G>A Gly1748Asp	NM_198056.2: c.1673A>G His558Arg (rs1805124)	Núñez et al. (2013)
Familial sick sinus syndrome	<i>SCN5A</i>	Various	NM_198056.2: c.1673A>G His558Arg (rs1805124)	Gui et al. (2010)
Early-onset dystonia	<i>TOR1A</i>	NM_000113.2: c.907-909delGAG	NM_000113.2: c.646G>C Asp216His (rs1801968)	Kock et al. (2006) and Risch et al. (2007)
Familial Mediterranean fever	<i>MEFV</i>	Various	NM_000243.2: c.605G>A Arg202Gln (rs224222)	Yigit et al. (2012)
Lynch syndrome	<i>MLH1</i>	Various	NM_000249.3: c.1852_1853delAAinsGC Lys618Ala (rs35502531)	Medeiros et al. (2012)
Long QT syndrome	<i>KCNH2</i>	NM_000238.3: c.3347C>T Ala1116Val	NM_000238.3: c.2690A>C Lys897Thr (rs1805123)	Crotti et al. (2005)
Long QT syndrome	<i>KCNH2</i>	NM_000238.3: c.1468G>A Ala490Thr	NM_000238.3: c.2690A>C Lys897Thr (rs1805123)	Zhang et al. (2008)
Creutzfeld–Jakob disease/fatal familial insomnia	<i>PRNP</i>	NM_000311.3: c.532G>A Asp178Asn	NM_000311.3: c.385A>G Met129Val (rs1799990)	Goldfarb et al. (1992) and Apetri et al. (2005)
Cardiac conduction abnormalities/sudden death	<i>SCN5A</i>	NM_198056.2: c.4262G>A Trp1421Term	NM_198056.2: c.3578G>A Arg1193Gln (rs41261344)	Niu et al. (2006)
Sudden unexplained death	<i>SCN5A</i>	NM_198056.2: c.2039G>A Arg680His	NM_198056.2: c.3308C>A Ser1103Tyr (rs7626962)	Cheng et al. (2011)
Syncope	<i>SCN5A</i>	NM_198056.2: c.5851G>T Val1951Leu	NM_198056.2: c.1673A>G His558Arg (rs1805124)	Shinlapawittayatorn et al. (2011)
Medullary thyroid carcinoma	<i>RET</i>	NM_020975.4: c.1996A>G Lys666Glu	NM_020975.4: c.2071G>A Gly691Ser (rs1799939)	Borrello et al. (2011)
Medullary thyroid carcinoma	<i>RET</i>	NM_020975.4: c.1597G>T Gly533Cys	NM_020975.4: c.74-126G>T (rs2565206)	Tamanaha et al. (2009)
Homocystinuria	<i>MTRR</i>	NM_002454.2: c.166G>A Val56Met	NM_002454.2: c.66G>A Ile22Met (rs1801394)	Gherasim et al. (2007)
Childhood absence epilepsy	<i>CACNA1H</i>	NM_021098.2: c.2318G>A Gly773Asp	NM_021098.2: c.2362C>T Arg788Cys (rs3751664)	Vitko et al. (2005)
Primary hyperoxaluria type 1	<i>AGXT</i>	NM_000030.2: c.731T>C Ile244Thr	NM_000030.2: c.32C>T Pro11Leu (rs34116584)	Santana et al. (2003)
Hereditary spherocytosis	<i>SPTA1</i>	NM_003126.2: c.7134G>A Gln2377Gln, alters splicing of exon 51	c.4339-99C>T (rs200830867)	Delaunay et al. (2004)
Erythropoietic protoporphyria	<i>FECH</i>	Various	NM_000140.3: c.315-48T>C (rs2272783)	Gouya et al. (2006)
Autosomal dominant osteopetrosis type II	<i>CLCN7</i>	Various	NM_001287.4: c.1252G>A Val418Met (rs12926089)	Chu et al. (2005)
Haemolytic uraemic syndrome	<i>CFH</i>	Various	NM_000186.3: c.2808G>T Glu936Asp (rs1065489)	Caprioli et al. (2003)
Hereditary spastic paraplegia	<i>SPAST</i>	NM_014946.3: c.1687G>A, (alters splicing of exon 15)	NM_014946.3: c.131C>T Ser44Leu (rs121908515)	Pantakani et al. (2008)
GM1 gangliosidosis	<i>GLB1</i>	NM_000404.2: c.601C>T Arg201Cys	NM_000404.2: c.1306C>T Leu436Phe (rs34421970)	Caciotti et al. (2003)
Primary cortisol resistance	<i>NR3C1</i>	NM_001018077.1: c.2035G>A Gly679Ser	NM_001018077.1: c.68G>A Arg23Lys (rs6190)	Raef et al. (2008)
Atopic dermatitis	<i>SPINK5</i>	NM_006846.3: c.2468dupA	NM_006846.3: c.1258G>A Glu420Lys (rs2303067)	Di et al. (2009)
Hyperinsulinism	<i>HADH</i>	NM_005327.4: c.636+471G>T	NM_005327.4: c.636+385A>G (rs732941)	Flanagan et al. (2013)

the His558Arg substitution (rs1805124) in the *SCN5A* gene in a case of Brugada syndrome type 1 caused by compound heterozygous mutations (Asp1690Asn and Gly1748Asp) in

SCN5A. Both mutations reduced the peak Na⁺ current density due to limited trafficking of the *SCN5A* protein towards the membrane, but Gly1748Asp also profoundly

affected channel gating. The His558Arg polymorphism was found to be capable of rescuing the defective trafficking of SCN5A Asn1690 towards the membrane when present in *cis* to the pathological lesion (Núñez et al. 2013). Intriguingly, cotransfection with Asn1690, either alone or together with the modulatory His558Arg polymorphism, completely restored the gating defect associated with the pathogenic Gly1748Asp mutation in *trans*, although it only slightly rescued its trafficking.

In passing, it is perhaps pertinent to note that interplay between functional SNPs may, depending upon the precise combination of alleles involved, also be sufficient to bring about disease in the absence of a pathogenic mutation *sensu stricto*. Thus, a particular allele of one SNP may contribute to pathogenesis, but only in the presence of specific allele of another SNP. These SNPs may be neighbouring, as in the case of Glu918Asp (rs16022) and Glu993Val (rs16023) in the *CACNA1A* gene, which appear to contribute to migraine susceptibility (D'Onofrio et al. 2009). In the same way, when they occur together in *cis*, two otherwise neutral missense polymorphisms in the *FMO3* gene [Glu158Lys (rs2266782) and Glu308Gly (rs2266780)] result in a decrease in *FMO3* enzymatic activity that is sufficient to give rise to a mild form of trimethylaminuria (Akerman et al. 1999; Zschocke et al. 1999; D'Angelo et al. 2013). However, the interacting SNPs can also be located within different genes as in the case of Pro589Ser (rs1049296) in the transferrin (*TF*) gene and Cys282Tyr (rs1800562) in the haemochromatosis (*HFE*) gene which interact so as to increase the risk of Alzheimer disease (Robson et al. 2004; Kauwe et al. 2010). A further example of the combined effect of two unlinked SNPs is provided by an intronic SNP in the thrombospondin 2 (*THBS2*) gene (c.1478-8C>T; rs 9406328) and a missense SNP in the metalloproteinase 9 (*MMP9*) gene (Gln279Arg; rs17576), which together increase the risk of lumbar disc herniation (Hirose et al. 2008). This type of situation may occupy the middle ground between monogenic and complex disorders.

The modifying SNP may also be regulatory in nature and can serve to render the pathogenic coding mutation more or less deleterious (and hence more or less penetrant) depending upon whether the allele harbouring it is more or less expressed than the wild-type allele. An example of this is provided by the -30C>T variant (rs17249141) in the *LDLR* gene promoter that has been shown to act in concert with a low-penetrant missense mutation in *cis* so as to give rise to an unusually severe form of familial hypercholesterolaemia (Snozek et al. 2009). The modulating influence of regulatory SNPs on the penetrance of coding mutations located in *cis* appears to be a widespread phenomenon in medical genetics, with the high expressing SNP allele usually increasing the clinical penetrance of the linked coding mutation (Lappalainen et al. 2011). One regulatory SNP is thought to act as a low-penetrance cancer

susceptibility factor in its own right: homozygosity for the intronic 309T>G *MDM2* variant (rs2279744), which leads to enhanced binding of the Sp1 transcription factor and *MDM2* up-regulation, appears to increase the risk for many types of tumour, presumably in concert with other lesions (Hu et al. 2007).

Introns may also harbour SNPs that are capable of modulating the clinical penetrance of a given pathogenic mutation. Thus, a short tract of five thymidines (5T) in intron 8 of the *CFTR* gene, found in ~10 % of individuals from the general population, can give rise to either congenital absence of the vas deferens (CAVD), non-classical cystic fibrosis or a normal phenotype when found in *trans* to a severe *CFTR* mutation (Kiesewetter et al. 1993; Cuppens et al. 1998). The number of TG repeats immediately adjacent to 5T is not only significantly associated with the level of alternative splicing of exon 9 of the *CFTR* gene (Cuppens et al. 1998; Niksic et al. 1999), but also influences clinical penetrance both in the context of cystic fibrosis and CAVD (Groman et al. 2004; Buratti et al. 2004; Lebo and Grody 2007). Another intronic modifying polymorphism is found in the *FECH* gene responsible for erythropoietic protoporphyria, an autosomal dominant disorder characterized by incomplete penetrance. This polymorphism (c.315-48T>C; rs2272783) modulates the use of a cryptic acceptor splice site, yielding an aberrantly spliced *FECH* mRNA which is degraded via nonsense-mediated mRNA decay (Gouya et al. 1999, 2002). The hypomorphic C allele increases the penetrance of erythropoietic protoporphyria when it occurs in *trans* to a pathogenic *FECH* mutation (Gouya et al. 2002, 2006). Finally, in a family with hyperinsulinism, a c.636+385A>G SNP (rs732941) in intron 5 of the *HADH* gene, which creates a cryptic acceptor splice site, acts in concert with a pathogenic *HADH* mutation (c.636+471G>T) in the same intron, which creates a cryptic donor splice site, to generate a 141-bp pseudoexon that leads to premature termination of translation (Flanagan et al. 2013).

A common C>T variant within an enhancer in intron 1 of the *RET* gene (rs2435357) serves to increase the clinical penetrance of *RET* coding sequence mutations (Emison et al. 2005). The T allele disrupts a SOX10-binding site, thereby reducing *RET* transactivation (Emison et al. 2010). A comparable example is provided by an intronic enhancer SNP (rs2596623) in the thyroid hormone receptor β (*THRB*) gene, which was found to be responsible for the pituitary cell-specific over-expression of a mutant thyroid hormone receptor $\beta 2$ (Arg338Trp) in a case of pituitary cell-specific resistance to thyroid hormone (Alberobello et al. 2011).

Variants in the 3' untranslated region (3'UTR) of the *KCNQ1* gene reportedly modify disease severity in individuals with type 1 long QT syndrome resulting from *KCNQ1* gene mutations (Amin et al. 2012). These variants

serve to reduce *KCNQ1* gene expression, such that patients with one or more variants on their mutated *KCNQ1* alleles have a shorter QT interval and a milder clinical phenotype, whereas patients with the variants on their normal *KCNQ1* alleles exhibit significantly longer QT intervals and a more severe clinical phenotype. Another example of a modifying 3'UTR variant is provided by the G>A polymorphism (rs1799963) at position 20210 in the prothrombin (*F2*) gene, which increases the risk of venous thrombosis by enhancing *F2* mRNA 3' end formation efficiency, thereby boosting thrombin formation (Gehring et al. 2001). This *F2* 20210G>A polymorphism has been claimed to interact with a common *F13A1* Val34Leu (rs5985) variant to confer a greatly increased risk of myocardial infarction (Butt et al. 2003). Some 3'UTR variants are located within microRNA-binding sites and may constitute low-penetrance risk factors for disease in their own right (Ahluwalia et al. 2009; Kontorovich et al. 2010; Qiu et al. 2011; Arnold et al. 2012). Finally, various SNPs in other non-coding RNAs (e.g. lincRNAs; Jendrzewski et al. 2012; Kumar et al. 2013) appear to be disease associated and may therefore also influence disease penetrance.

Influence of the gene expression level on mutation penetrance

Humans are characterized by marked inter-individual differences in the expression levels of their genes (Stranger et al. 2007; Skelly et al. 2009; Cowley et al. 2009; Cheng et al. 2012). Since gene expression is controlled by a combination of *cis*- and *trans*-acting regulatory factors, one means by which heritable differences in gene expression may be mediated is through polymorphism either of *trans*-acting regulatory (transcription) factors or of the *cis*-acting target sequences to which they bind. In the case of disease genes, such inter-individual variation in gene expression levels and patterns can influence the penetrance of pathological mutations. However, it should be appreciated that there are also substantial environmental and stochastic (non-genetic) components to gene expression that are likely to contribute to variable penetrance, even between monozygotic twins (Grundberg et al. 2012).

Differential allelic expression is a widespread phenomenon and is thought to be relevant to as many as 50 % of all human genes (Williams et al. 2007; Cheung and Spielman 2009; Palacios et al. 2009). In autosomal dominant conditions where the two alleles of the disease gene are expressed at different levels, this discrepancy can favour either the mutant or the wild-type allele and hence may influence clinical penetrance in either direction (de la Chapelle 2009). Thus, in pulmonary arterial hypertension, a disease caused by mutations in the bone morphogenetic protein receptor

type 2 (*BMPR2*) gene, the penetrance of the *BMPR2* disease allele is dependent upon the level of expression of the wild-type *BMPR2* allele (Hamid et al. 2009a). Similarly, in erythropoietic protoporphyria, an autosomal dominant condition caused by mutations in the ferrochelatase (*FECH*) gene, the penetrance of the pathogenic *FECH* allele is influenced by the level of expression of the wild-type *FECH* allele (Gouya et al. 1999; 2002; Di Pierro et al. 2007). Other examples of autosomal dominant conditions where the degree of clinical penetrance is modulated by differential expression of the wild-type and mutant alleles include hereditary elliptocytosis (*SPTA1*, Wilmotte et al. 1993), Marfan syndrome (*FBNI*, Hutchinson et al. 2003), retinoblastoma (*RBI*, Taylor et al. 2007), colorectal cancer (*APC*, Yan et al. 2002; *TGFBR1*, Valle et al. 2008) and breast and ovarian cancer (*BRCA1*, Ginolhac et al. 2003).

Perhaps, the best understood example of penetrance depending upon the level of expression of the wild-type allele is retinitis pigmentosa type 11 (Utz et al. 2013). This autosomal dominant condition is caused by mutations in the pre-mRNA processing factor 31 (*PRPF31*) gene located on chromosome 19q13.42. The clinical penetrance of the underlying mutations has been shown to depend upon the level of wild-type *PRPF31* mRNA expression displayed by the patient (Vithana et al. 2003; Rivolta et al. 2006; Liu et al. 2008). Cells from asymptomatic carriers of *PRPF31* mutations express a higher level of the wild-type allele than cells from affected patients: high enough for the wild-type *PRPF31* mRNA level to lie within the range of the unaffected general population (Rivolta et al. 2006; Liu et al. 2008). The penetrance of *PRPF31* mutations is reduced by transcriptional repression mediated by the product of the CCR4-NOT transcription complex, subunit 3 (*CNOT3*) gene which is linked to *PRPF31* (McGee et al. 1997; Venturini et al. 2012). *PRPF31* expression has also been found to be strongly influenced by an unlinked eQTL on chromosome 14q21-q23 (Rio Frio et al. 2008). The penetrance of *PRPF31* mutations is therefore determined at least in part by a *trans*-acting modifier located on a different chromosome. The *trans*-acting alleles are inherited from the parent lacking the *PRPF31* mutation; these alleles are presumably present in the general population, but appear only to be relevant to disease when they modulate the penetrance of *PRPF31* mutations.

A slightly different scenario is exemplified by Schimke immune-osseous dysplasia (SIOD), a recessive condition, which appears to result from biallelic mutations in the *SMARCA1* gene. Several examples of SIOD families with incomplete penetrance have been reported (Bökenkamp et al. 2005; Dekel et al. 2008; Elizondo et al. 2009). It has recently been shown that *SMARCA1*, a protein involved in chromatin remodelling, influences the transcription level of many genes (Baradaran-Heravi et al. 2012). Although

SMARCAL1 deficiency is insufficient in itself to cause SIOD in *Drosophila* and mouse models, the addition of environmental (viz. heat shock) and genetic insults affecting transcription can successfully recapitulate the pathophysiology of SIOD (Baradaran-Heravi et al. 2012). The penetrance of SIOD therefore appears to be dependent upon the magnitude of the alteration of gene expression consequent to SMARCAL1 deficiency.

In the case of a splicing mutation (c.291+1 G>A; rs71640277) in intron 3 of the *GHI* gene causing growth hormone deficiency type II, the expression levels of the mutant and wild-type alleles were found to correlate with the penetrance and expressivity of the deficiency state in different members of the same family (Hamid et al. 2009b). Some splicing mutations associated with low penetrance affect splicing in such a way that both normal-length and truncated transcripts are expressed from the same mutant allele, but presumably to different extents in different individuals (e.g. *RBI*, c.2211G>A; Schubert et al. 1997). Other such examples of reduced penetrance due to ‘leaky splicing’ involve splicing mutations in the *SPAST* gene causing hereditary spastic paraplegia (Svenson et al. 2001) and in the *BTK* gene causing X-linked agammaglobulinemia (Kaneko et al. 2005). The reduced penetrance characteristic of some splicing mutations may also result from alternative splicing (Rave-Harel et al. 1997; Chiba-Falek et al. 1998; Nissim-Rafinia and Kerem 2005; Zinman et al. 2009; Szymanski et al. 2011; Cogan et al. 2012; Lee et al. 2012b) or internal translational start site initiation (Sánchez-Sánchez et al. 2007).

Special cases of differential allelic expression are of course provided by X-inactivation (Dobyns et al. 2004) and imprinting (Lo et al. 2003), both of which are discussed below.

Allele dosage and its influence on penetrance

Formally, use of the term ‘autosomal dominant’ implies that the homozygotes exhibit the same or a similar clinical phenotype to the heterozygotes, as is the case in Huntington disease where the length of the expanded *HTT* CAG triplet repeat appears to be predictive of the age of onset irrespective of the presence or absence of a second expanded *HTT* allele (Lee et al. 2012a). However, in practice, for most ‘dominant’ human disorders in which homozygotes have been reported, their clinical symptoms tend to be significantly more severe than in the heterozygotes (Vogel and Motulsky 1997). This would seem to be especially true in the context of low-penetrance mutations such as those identified in the *SCN4A* and *CLCN1* genes, causing muscle channelopathies, conditions which are usually held to be transmitted in an autosomal dominant

fashion. Patients homozygous for sodium channel mutations causing paramyotonia congenita (*SCN4A*, Ile1393Thr), hypokalemic periodic paralysis (*SCN4A*, Arg1132Gln) and myotonia congenita (*CLCN1*, Gly190Ser, Ile556Asn, Ala313Thr, Ile556Asn) display much more severe clinical features than patients heterozygous for these mutations (Plassart-Schiess et al. 1998; Arzel-Hézode et al. 2010; Shalata et al. 2010). The aforementioned mutations were also found to exhibit reduced penetrance in heterozygotes.

Mutations in the *RET* gene, associated with isolated Hirschsprung disease, are dominant loss-of-function mutations with incomplete penetrance and variable expressivity. Basal-Vanagaite et al. (2007) reported a c.1263+5G>A splicing mutation in the homozygous state in three females with severe Hirschsprung disease and in the heterozygous state in a male patient with short-segment Hirschsprung disease. In addition, a hypomorphic *RET*-predisposing allele, rs2435357, located in the first intron of the *RET* gene, was found in the heterozygous state in the male patient but not in the three affected females. Whilst the heterozygous c.1263+5G>A mutation is known to be low penetrance for short-segment Hirschsprung disease, the homozygous state is fully penetrant for total aganglionosis or long-segment Hirschsprung disease. Thus, the penetrance of *RET* gene mutations in Hirschsprung disease depends not only on the nature of the mutation but also on the allele dosage.

Influence of copy number variation on mutation penetrance

Estimates of the clinical penetrance of recurrent pathogenic copy number variants (CNVs) vary quite widely, depending upon CNV size, genomic location and the disorder in question (Ben-Shachar et al. 2009; Vassos et al. 2010; Breckpot et al. 2011; Čiuladaitė et al. 2011; Hosak et al. 2012; Klopocki et al. 2012; Rosenfeld et al. 2013; Vaags et al. 2012; Weischenfeldt et al. 2013; Dabell et al. 2013; Carvill and Mefford 2013; Tropeano et al. 2013). In their study of children known to carry a CNV associated with intellectual disability and congenital abnormalities, Girirajan et al. (2012) reported synergy between multiple large CNVs leading to a particularly severe clinical presentation. Such a two-hit model, or ‘oligogenic heterozygosity’ as it has been termed, also appears to be characteristic of autism (Pinto et al. 2010; Schaaf et al. 2011b; Klei et al. 2012; Gau et al. 2012).

The penetrance of a given CNV may also be influenced by genetic variants in the vicinity. Thus, a submicroscopic deletion of 1q21.1 (encompassing the *RBM8A* gene) has been reported to interact with a low-frequency functional SNP in the regulatory region of the wild-type *RBM8A* allele to cause thrombocytopaenia with absent radii (Albers et al. 2012).

Several papers have now suggested that CNVs can also act as genetic modifiers of phenotype severity in a variety of different disease contexts (Beckmann et al. 2007; Chaudru et al. 2009; El-Hattab et al. 2010; Mulley et al. 2011; Jiang et al. 2011; Carvalho et al. 2012; Shen et al. 2013b). CNVs may influence the penetrance of a clinical phenotype indirectly as well as directly. For example, a mutant gene might be ‘covered’ by a CNV in a given individual, so that the expected clinical phenotype would be masked by the presence of an additional wild-type copy in *cis* to the gene in question. Consistent with this postulate, Ng et al. (2008) reported that ~30 % of nonsense SNPs occur in genes residing within segmental duplications, a proportion some threefold larger than that noted for synonymous SNPs. Genes harbouring nonsense SNPs were also found to belong to larger gene families (Ng et al. 2008) suggesting that some functional redundancy could also exist between paralogous human genes. In support of this idea, Hsiao and Vitkup (2008) reported that those human genes which have a homologue with >90 % sequence similarity are ~3 times less likely to harbour disease-causing mutations than genes with less closely related homologues. Hsiao and Vitkup (2008) interpreted their findings in terms of ‘genetic robustness’ against null mutations, with the duplicated sequences providing ‘backup’ by potentiating the functional compensation/complementation of homologous genes in the event that the latter acquired deleterious mutations. The capacity to be functionally compensated appears to vary, in the order non-disease genes > monogenic disease genes > polygenic disease genes (Podder and Ghosh 2011). One example of how a CNV can ameliorate the clinical phenotype is spinal muscular atrophy where an increased copy number of the *SMN2* gene can greatly reduce the severity of the disease caused by the homozygous deletion of the *SMN1* gene, because the *SMN2* gene, which lacks a splicing enhancer, can nevertheless generate some functional product thereby compensating functionally in a copy number-dependent fashion for the loss of the *SMN1* gene (Vitali et al. 1999; Harada et al. 2002; Wirth et al. 2006). Another example of how the clinical and/or phenotypic impact of a mutant gene can be nullified by a CNV is provided by a foetus that possessed paternal (Gln318Term) and maternal (Arg356Term) nonsense mutations of the *CYP21A2* gene but lacked the normal clinical sequelae of congenital adrenal hyperplasia; this was found to be due to a duplication of the *CYP21A2* gene on the paternal allele (Kleinle et al. 2009; Lekarev et al. 2013).

Influence of modifier genes on disease penetrance

“For a so-called single gene disorder, there is one gene that may be primarily responsible for the

pathogenesis with one or more independently inherited modifier genes that influence the phenotype. On the other hand, for a complex trait, the primacy of any individual gene is not perceptible, and the interaction of two or more independently inherited pairs of alleles, most likely influenced by additional modifier genes, results in the disease. The consequence of this conceptual framework is that there is no such thing as a ‘single’ gene disorder. In other words, there is no obvious clear distinction between simple Mendelian and complex traits: genetic diseases represent a continuum with diminishing influence from a single primary gene influenced by modifier genes, to increasingly shared influence by multiple genes”.

Dipple and McCabe (2000)

It is sometimes claimed that sickle cell anaemia is the simplest of all Mendelian disorders in that it is caused by one specific mutation (Glu7Val) in the β -globin (*HBB*) gene. However, this single-mutation monogenic disorder is not as simple as it might at first appear; indeed, it is characterized by marked clinical heterogeneity and incomplete penetrance of subphenotypes which is due in part to allelic variation and in part to variants in unlinked modifier genes (Steinberg and Sebastiani 2012). If we extrapolate from the archetypal example of sickle cell disease to other Mendelian disorders, it is not unreasonable to expect the action of modifier genes to be the rule rather than the exception. Indeed, variants in unlinked modifier genes have been reported to influence penetrance in a variety of different inherited diseases including pancreatitis (Khalid et al. 2006), breast cancer (Wolf et al. 2010; Wang et al. 2010a; Walker et al. 2010; Antoniou and Chenevix-Trench 2010; Esteban Cardenosa et al. 2012; Harlid et al. 2012), Gaucher disease (Taddei et al. 2009; Zhang et al. 2012), retinitis pigmentosa (Rio Frio et al. 2008; Venturini et al. 2012), haemochromatosis (Krayenbuehl et al. 2010), hypertrophic cardiomyopathy (Daw et al. 2007), fronto-temporal lobar degeneration (Finch et al. 2011) and amyloid polyneuropathy (Soares et al. 2005) among others. In familial late-onset Alzheimer disease, modifying loci may either influence the risk (Sleegers et al. 2009; Cruchaga et al. 2012) or the age of onset of disease (Wijdsman et al. 2005; Marchani et al. 2010). Importantly, a significant excess of rare coding *APP*, *PSEN1* and *PSEN2* variants was noted in probands from late-onset Alzheimer disease families even though these variants did not actually co-segregate with the disease; this suggests that the variants in question may nevertheless serve to modulate the risk of disease (Cruchaga et al. 2012). An excess of rare variants as compared to controls has also been noted in patients with various other disorders including hypertriglyceridaemia (Johansen et al. 2012; Talmud 2007), hypertrophic

cardiomyopathy (Lopes et al. 2013) and autism spectrum disorder (Mondal et al. 2012).

A typical example of a modifier gene in action is provided by long QT syndrome. The clinical penetrance of *KCNQ1* (potassium voltage-gated channel, KQT-like subfamily, member 1) mutations in this disorder is influenced by two coding sequence polymorphisms [Ser49Gly (rs1801252) and Arg389Gly (rs1801253)] in the *ADRB1* gene. Individuals homozygous for the Arg389 allele tend to have shorter QT intervals, whereas individuals homozygous for Ser49 tend to have longer QT intervals than those with other genotypes (Paavonen et al. 2007). Interestingly, those individuals doubly homozygous for Arg389 and Ser49 were found to be indistinguishable from the remainder of the patient cohort, both in terms of their QT intervals and in terms of clinical penetrance.

The minor allele of a variant in the complement receptor 1 (*CRI*) gene, Ser1610Thr (rs4844609), which has a population frequency of 0.02, is associated with episodic memory decline and susceptibility to Alzheimer disease (Keenan et al. 2012). However, this effect appears largely dependent upon an interaction with APOE- ϵ 4, itself an important risk factor for Alzheimer disease (Mayeux et al. 1993).

Hirschsprung disease is one of the most complex genetic disorders in terms of the number of modifier genes (Garcia-Barcelo et al. 2009; Tang et al. 2010) known to influence the penetrance of its causative mutations, which has been estimated to be of the order of 50–70 % (Bolk et al. 2000). The best characterized of these modifier genes is the neuregulin 1 gene (*NRG1*; Tang et al. 2011, 2012a); however, most probably still remain to be identified. Some Bardet–Biedl syndrome patients also present with Hirschsprung disease. It appears that *RET*, the major gene involved in the aetiology of Hirschsprung disease, acts as a modifier of the Hirschsprung disease phenotype in Bardet–Biedl syndrome (de Pontual et al. 2007). Some families with Hirschsprung disease and Bardet–Biedl syndrome harbour mutations in their *BBS4*, *BBS5*, *BBS7* and *RET* genes (de Pontual et al. 2009). Sánchez-Mejías et al. (2009) reported a Hirschsprung disease family in which mutations in three different genes (*RET*, *NTRK3* and *EDN3*) contributed to the disease phenotype; the *RET* and *NTRK3* mutations were both necessary and sufficient to give rise to the clinical phenotype, whereas the *EDN3* mutation appeared to act as a modifier. More recently, copy number variations in various neurodevelopmental genes (*MAPK10*, *ZFHX1B*, *SOX2* and *NRG2*) have been shown to modify the penetrance of Hirschsprung disease (Jiang et al. 2011; Tang et al. 2012b). Taken together, these findings are consistent with an impact of both common and rare variants on the inheritance (and hence penetrance) of this highly complex disorder (Sánchez-Mejías et al. 2009; Núñez-Torres et al. 2011; Alves et al. 2013).

Table 3 lists a number of well-characterized examples of specific variants in modifier genes that serve to modulate the clinical penetrance of diseases caused by mutation(s) at unlinked loci.

The plastin 3 (*PLS3*) gene acts as a modifier of the clinical penetrance of autosomal recessive spinal muscular atrophy, caused by the homozygous deletion of the *SMN1* gene. Oprea et al. (2008) studied spinal muscular atrophy-discordant families with affected and unaffected *SMN1*-deleted siblings and found that all unaffected *SMN1*-deleted siblings were characterized by a high *PLS3* expression level in blood cells, considerably higher than in their affected counterparts (and despite high PLS expression being evident in only 5 % of healthy controls). Although it is still unclear whether *PLS3* expression is regulated by *cis*- or *trans*-acting factors, it would appear that high *PLS3* expression serves to rescue the spinal muscular atrophy patient from the detrimental effects of *SMN1* deletion by promoting axonogenesis through elevation of the level of F-actin (Oprea et al. 2008) and ultimately by improving neuromuscular transmission (Ackermann et al. 2013).

A unique kind of modifying effect is exemplified by α -thalassaemia/mental retardation syndrome, caused by mutations of the *ATRX* gene. The *ATRX* protein binds to variable number tandem repeat sequences (VNTRs) in the human genome, and genes associated with these VNTRs are dysregulated when *ATRX* is mutated (Law et al. 2010). Law et al. (2010) identified 917 *ATRX* targets in primary human erythroid cells, including one in the α -globin (*HBA*) locus. This $\psi\delta$ VNTR was found to be highly polymorphic in terms of its length and acted as a length-dependent negative regulator of gene expression, its length serving to influence the degree of α -thalassaemia observed in an α -thalassaemia/mental retardation syndrome patient. Thus, the length of the $\psi\delta$ VNTR could explain the incomplete penetrance of α -thalassaemia noted in individuals with identical *ATRX* mutations. A similar mechanism could underlie other genetic traits characterized by reduced penetrance.

Digenic mutations and disease penetrance

In a typical autosomal Mendelian condition, a single mutation (dominant) or two mutations (recessive) at a specific locus give rise to a clinical phenotype. By contrast, digenic inheritance occurs in cases where the interaction of mutations in two different genes is required for the expression of the clinical phenotype. In this situation, a mutation in one copy of each gene is required for the full clinical phenotype to manifest. In the absence of one of the component mutations, the other mutation may be non-

Table 3 A selection of well-characterized examples of polymorphic variants in modifier genes that serve to modulate the clinical penetrance and/or severity of an inherited disease caused by mutation(s) at an unlinked locus

Disease	Primary disease gene	Modifier gene/variant	Reference
X-linked retinitis pigmentosa	<i>RPGR</i>	<i>IQCB1</i> /NM_001023570.2:c.1178T>A Ile393Asn (rs1141528)	Fahim et al. (2011)
X-linked retinitis pigmentosa	<i>RPGR</i>	<i>RPGRIP1L</i> /NM_015272.2:c.2231G>A Arg744Gln (rs2302677)	Fahim et al. (2011)
Retinal generation in ciliopathies	<i>RPGR</i> or <i>NPHP5</i>	<i>RPGRIP1L</i> /NM_015272.2:c.685G>A Ala229Thr (rs61747071)	Khanna et al. (2009)
Retinoblastoma	<i>RBI</i>	<i>MDM2</i> /NM_002392.4:c.14+309T>G (rs2279744)	Castéra et al. (2010)
Familial hypercholesterolaemia	<i>LDLR</i>	<i>PCSK9</i> /NM_174936.3:c.63_65dupGCT (rs35574083)	Abifadel et al. (2009)
Familial hypercholesterolaemia	<i>LDLR</i>	<i>APOB</i> /NM_000384.2:c.10580G>A Arg3527Gln (rs5742904)	Benlian et al. (1996) and Taylor et al. (2010)
Familial hypercholesterolaemia	<i>LDLR</i>	<i>CFH</i> /NM_000186.3:c.1204T>C Tyr402His (rs1061170)	Koeijvoets et al. (2009)
Familial hypercholesterolaemia	<i>LDLR</i>	<i>APOH</i> /NM_000042.2:c.1204T>C Leu266Val (rs4581)	Takada et al. (2003a)
Familial hypercholesterolaemia	<i>LDLR</i>	<i>GHR</i> /NM_000163.4:c.1630A>C Ile544Leu (rs6180)	Takada et al. (2003b)
Familial hypercholesterolaemia	<i>LDLR</i>	<i>EPHX2</i> /NM_001979.4:c.860G>A Arg287Gln (rs751141)	Sato et al. (2004)
Breast cancer	<i>BRCA2</i>	<i>RAD51</i> /NM_002875.4:c.-98G>C (rs1801320)	Antoniou et al. (2007)
Ovarian cancer	<i>BRCA1</i> or <i>BRCA2</i>	<i>IRS1</i> /NM_005544.2:c.2911G>A Gly971Arg (rs801278)	Ding et al. (2012)
Lynch syndrome	<i>MSH2</i> or <i>MLH1</i>	<i>RNASEL</i> /NM_021133.3:c.1385G>A Arg462Gln (rs486907)	Krüger et al. (2007)
Prostate cancer	<i>MSH2</i> or <i>MLH1</i>	<i>RNASEL</i> /NM_021133.3:c.1385G>A Arg462Gln (rs486907)	Krüger et al. (2005)
Lynch syndrome	<i>MSH2</i> or <i>MLH1</i>	<i>TP53</i> /NM_000546.3:c.215G>C Arg72Pro (rs1042522)	Krüger et al. (2007)
Cystic fibrosis	<i>CFTR</i>	<i>TGFB1</i> /NM_000660.4:c.29C>T Pro10Leu (rs1800470)	Drumm et al. (2005)
Familial pulmonary arterial hypertension	<i>BMP2</i>	<i>TGFB1</i> /NM_000660.4:c.-1347C>T (rs1800469) & NM_000660.4:c.29C>T Leu10Pro (rs1800470)	Phillips et al. (2008)
Paget's disease	<i>SQSTM1</i>	<i>TNFRSF11A</i> /NM_003839.2:c.575T>C Val192Ala (rs1805034)	Gianfrancesco et al. (2012)
X-linked variable immunodeficiency	<i>XIAP</i>	<i>CD40LG</i> /NM_000074.2:c.655G>A Gly219Arg (rs148594123)	Rigaud et al. (2011)
Haemochromatosis	<i>HFE</i>	<i>CYBRD1</i> /NM_024843.3:c.-399T>G (rs884409)	Constantine et al. (2009)
Parkinson's disease	<i>GBA</i>	<i>MTX1</i> /NM_002455.3:c.187T>A Ser63Thr (rs760077)	Gan-Or et al. (2011)
Recessive dystrophic epidermolysis bullosa	<i>COL7A1</i>	<i>MMP1</i> /NM_002421.3:c.-1673delG (rs1799750)	Titeux et al. (2008)
Amyotrophic lateral sclerosis	<i>SOD1</i>	<i>CHGB</i> /NM_001819.2:c.1238C>T Pro413Leu (rs742710)	Gros-Louis et al. (2009)
Huntington disease	<i>HTT</i>	<i>HAPI</i> /NM_177977.2:c.1322C>T Thr441Met (rs4523977)	Metzger et al. (2008)
Fatal kernicterus	<i>G6PD</i>	<i>UGT1A1</i> /(TA) ₆ /(TA) ₇ (rs8175347), HGVS nomenclature not available	Zangen et al. (2009)
Atypical haemolytic uraemic syndrome	<i>MCP</i> or <i>CFH</i>	<i>C4BPA</i> /NM_000715.3:c.719G>A Arg240His (rs45574833)	Blom et al. (2008)
Spinal muscular atrophy	<i>SMN1</i>	<i>SMN2</i> /NM_017411.3:c.859G>C Gly287Arg (rs121909192)	Prior et al. (2009)
Long QT syndrome	<i>KCNQ1</i>	<i>KCNH2</i> /NM_000238.3:c.2690A>C Lys897Thr (rs1805123)	Cordeiro et al. (2010)
Long QT syndrome	<i>KCNQ1</i>	<i>ADRB1</i> /NM_000684.2:c.145A>G Ser49Gly (rs1801252) & NM_000684.2:c.1165G>C Arg389Gly (rs1801253)	Paavonen et al. (2007)
Long QT syndrome	<i>KCNQ1</i>	<i>NOS1AP</i> /NC_000001.10:g.162029907A>T (rs4657139)	Crotti et al. (2009)

Table 3 continued

Disease	Primary disease gene	Modifier gene/variant	Reference
Familial venous thrombosis	<i>PROC</i>	<i>F5/NM_000130.4:c.1601G>A</i> Arg534Gln (rs6025; Factor V Leiden)	Koeleman et al. (1994); Gandrille et al. (1995) and Cafolla et al. (2012)
Familial venous thrombosis	<i>PROS1</i>	<i>F5/NM_000130.4:c.1601G>A</i> Arg534Gln (rs6025; Factor V Leiden)	Koeleman et al. (1995)
Familial venous thrombosis	<i>SERPINC1</i>	<i>F5/NM_000130.4:c.1601G>A</i> Arg534Gln (rs6025; Factor V Leiden)	Van Boven et al. (1996)
Hypertrophic cardiomyopathy	<i>MYBPC3</i> or <i>MYH7</i>	<i>CALM3/NM_005184.2:c.-157T>A</i> (rs150954567)	Friedrich et al. (2009)
Familial Mediterranean fever	<i>MEFV</i>	<i>SAAI/NM_000331.4:c.-197C>T</i> (rs11024595)	Migita et al. (2013)

penetrant (digenic inheritance sensu stricto) or could be responsible for a less severe clinical phenotype (digenic inheritance sensu lato). At least 100 cases of probable and possible examples of digenic inheritance causing human inherited disease have been reported to date (Table 4).

Digenic inheritance may occur as a result of mutations in genes encoding different subunits of the same multimeric protein (e.g. *PRPH2* and *ROM1*), an oligomeric protein complex (e.g. *KCNJ10* and *SLC26A4*; *KRT14* and *KRT5*) or simply two proteins that interact functionally with each other (*CDH23* and *PCDH15*; *DSG2* and *DSC2*; *PARK7* and *PINK1*). However, mutations in receptor/ligand pairs can also give rise to digenic inheritance (e.g. *PROK2* and *PROKR2*). Alternatively, digenic inheritance can involve mutations located in different genes, but compromising the same regulatory (e.g. *HFE* and *HAMP*), biosynthetic (e.g. *ZMPSTE24* and *LMNA*; *CPOX* and *PPOX*; *MYOC* and *CYP11B1*) or degradative (e.g. *PCSK9* and *LDLR*) pathway. Finally, the combination of a mutation in a transcription factor with a mutation in a target gene of that transcription factor can also serve to reduce the amount of the protein in question to a level sufficient to cause a disease phenotype (e.g. *MITF* and *TYR*; *FOXC1* and *PITX2*).

In practice, it is not always clear if a given situation constitutes true digenic inheritance (e.g. Kajiwarra et al. 1994) or whether it is simply the coinherance of two mutations in different genes (e.g. Gruber et al. 2009; Serrano-Fernández et al. 2009; Ekvall et al. 2011). In the former case, the expression of the disease phenotype actually requires the presence of both gene lesions. In the latter case, coinherance of the two gene lesions may serve to aggravate the clinical phenotype, but each lesion is independently associated with its own characteristic clinical sequelae. In true digenic inheritance, mutations in both genes must be present for the genetic disorder to be manifest. Since many of the disorders reported (in Table 4) to be characterized by digenic inheritance also have monogenic forms in which just one of the two genes has been

mutated (whether in the heterozygous or homozygous/compound heterozygous state), it is unclear how many of the examples listed really represent digenic inheritance sensu stricto. However, in many of the listed examples, the doubly heterozygous probands exhibit earlier onset or a more severe clinical phenotype than their singly heterozygous relatives (although this is not invariably so; Marras et al. 2010). Further, whereas the truly ‘digenic’ patients tend to be characterized by complete penetrance, the monogenic disease genotypes often exhibit reduced penetrance as in e.g. normosmic idiopathic hypogonadotropic hypogonadism (see Table 4).

In some of the cases listed in Table 4, the digenic inheritance may be confined to a single proband and hence it is not always straightforward to distinguish true digenic inheritance from the chance coinherance of two mutations in unlinked genes. This notwithstanding, the requirement for the involvement of a second mutated gene may depend upon the specific mutations that are segregating in the pedigrees. If digenic inheritance eventually turns out to be more frequent than previously appreciated, it could provide yet another reason why some potentially pathogenic alleles are present in the general population in the absence of overt disease. At the very least, in many cases the clinical penetrance of the condition in question is likely to be greater when two relevant genes have been functionally compromised by mutation than if only one had been mutated.

Oligogenic inheritance and its implications for disease penetrance

Triallelic inheritance has been described as being “a bridge between Mendelian and multifactorial traits” (Eichers et al. 2004). There are a burgeoning number of reported examples of digenic triallelic inheritance including nephronophthisis (Hoefele et al. 2007), venous thrombosis (Formstone et al. 1996; Brenner et al. 1996) and cortisone

Table 4 Examples of digenic mutations causing human inherited disease

Disease	Gene 1	Gene 2	Reference
Waardenburg syndrome type 2*	<i>MITF</i>	<i>PAX3</i> or <i>OCA3</i> or <i>TYR</i> or <i>GJB2</i>	Morell et al. (1997); Chiang et al. (2009); Yan et al. (2011) and Yang et al. (2013)
Retinitis pigmentosa*	<i>PRPH2</i>	<i>ROM1</i> or <i>RHO</i> or <i>PDE6B</i>	Kajiwara et al. (1994); Loewen et al. (2001); Sullivan et al. (2006) and Jin et al. (2008)
Retinitis pigmentosa	<i>RHO</i>	<i>PRPF31</i>	Lim et al. (2009)
Retinitis pigmentosa*	<i>PDE6B</i>	<i>GPR98</i>	Hmani-Aifa et al. (2009)
Progressive cone dystrophy	<i>CNGA3</i>	<i>CNGB3</i>	Thiadens et al. (2010)
Frontotemporal dementia*	<i>PSEN1</i>	<i>PRNP</i>	Bernardi et al. (2011)
Leber congenital amaurosis*	<i>RPE65</i>	<i>GUCY2D</i>	Silva et al. (2004)
Idiopathic hypogonadotropic hypogonadism*	<i>FGFR1</i>	<i>GNRHR</i> or <i>NELF</i>	Pitteloud et al. (2007)
Bilateral cystic renal dysplasia	<i>DACHI</i>	<i>BMP4</i>	Schild et al. (2013)
Glaucoma, early onset*	<i>MYOC</i>	<i>CYP1B1</i> or <i>LTBP2</i>	Vincent et al. (2002), Geyer et al. (2011) and Azmanov et al. (2011)
Severe insulin resistance	<i>PPARG</i>	<i>PPP1R3A</i>	Savage et al. (2002)
Usher syndrome type 2*	<i>PDZD7</i>	<i>GPR98</i>	Ebermann et al. (2010)
Usher syndrome type 1-associated deafness	<i>CDH23</i>	<i>PCDH15</i>	Zheng et al. (2005)
Hidrotic ectodermal dysplasia	<i>GJB2</i>	<i>GJA1</i>	Kellermayer et al. (2005)
Non-syndromic deafness*	<i>GJB2</i>	<i>GJB3</i>	Liu et al. (2009)
Hearing loss	<i>GJB2</i>	<i>SLC26A4</i>	Sagong et al. (2013)
Non-syndromic hearing loss associated with an enlarged vestibular aqueduct/Pendred syndrome	<i>KCNJ10</i>	<i>SLC26A4</i>	Yang et al. (2009)
Porphyria*	<i>CPOX</i>	<i>PPOX</i>	van Tuyll van Serooskerken et al. (2011)
Atypical haemolytic uremic syndrome	<i>CFI</i>	<i>CD46</i> or <i>C3</i> or <i>CFB</i> or <i>CFHR1</i>	Esparza-Gordillo et al. (2006), Westra et al. (2010) and Bresin et al. (2013)
Atypical haemolytic uraemic syndrome	<i>CFH</i>	<i>CD46</i> or <i>CFI</i> or <i>C3</i> or <i>THBD</i>	Sullivan et al. (2011), Bresin et al. (2013) and Fan et al. (2013)
Epidermolysis bullosa simplex*	<i>KRT14</i>	<i>KRT5</i>	Padalon-Brauch et al. (2012)
Junctional epidermolysis bullosa	<i>COL17A1</i>	<i>LAMB3</i>	Floeth and Bruckner-Tuderman (1999)
Long QT syndrome*	<i>KCNQ1</i>	<i>KCNH2</i> or <i>KCNE1</i> or <i>SCN5A</i>	Schwartz et al. (2003), Westenskow et al. (2004), Tester et al. (2005) and Itoh et al. (2010)
Long QT syndrome*	<i>KCNH2</i>	<i>SCN5A</i> or <i>KCNE1</i>	Schwartz et al. (2003), Westenskow et al. (2004) and Tester et al. (2005)
Long QT syndrome*	<i>SCN5A</i>	<i>SNTA1</i> or <i>KCNE1</i>	Westenskow et al. (2004) and Hu et al. (2013)
Haemochromatosis*	<i>HFE</i>	<i>HAMP</i> or <i>TFR2</i>	Merryweather-Clarke et al. (2003), Jacolot et al. (2004), Island et al. (2009), Altès et al. (2009) and Del-Castillo-Rueda et al. (2012)
Kallmann syndrome*	<i>PROK2</i>	<i>PROKR2</i>	Cole et al. (2008), Sarfati et al. (2010) and Shaw et al. (2011)
Kallmann syndrome	<i>NELF</i>	<i>KALI</i> or <i>TACR3</i>	Xu et al. (2011) and Quaynor et al. (2011)
Kallmann syndrome	<i>PROKR2</i>	<i>KALI</i>	Dodé et al. (2006), Canto et al. (2009) and Shaw et al. (2011)
Kallmann syndrome	<i>KALI</i>	<i>TACR3</i> or <i>WDR11</i> or <i>CHD7</i>	Quaynor et al. (2011) and Shaw et al. (2011)
Normosmic idiopathic hypogonadotrophic hypogonadism	<i>GNRH</i>	<i>KALI</i>	Quaynor et al. (2011)
Normosmic idiopathic hypogonadotrophic hypogonadism	<i>WDR11</i>	<i>GNRHR</i>	Quaynor et al. (2011)
Normosmic idiopathic hypogonadotrophic hypogonadism	<i>FGFR1</i>	<i>GNRHR</i> or <i>PROKR2</i> or <i>FGF8</i> or <i>KALI</i> or <i>GPR54</i>	Raivio et al. (2009), Sykiotis et al. (2010) and Shaw et al. (2011)
Systemic amyloid A amyloidosis	<i>TNFRSF1A</i>	<i>MEFV</i>	Cigni et al. (2006) and Mereuta et al. (2013)

Table 4 continued

Disease	Gene 1	Gene 2	Reference
Familial hypercholesterolaemia*	<i>LDLR</i>	<i>PCSK9</i>	Pisciotta et al. (2006), Noguchi et al. (2010) and Bertolini et al. (2013)
Familial hypercholesterolaemia	<i>LDLR</i>	<i>APOB</i>	Bertolini et al. (2013)
Familial hypercholesterolaemia	<i>LDLR</i>	<i>LDLRAP1</i>	Tada et al. (2011)
Severe congenital neutropenia	<i>ELANE</i>	<i>G6PC3</i> or <i>HAX1</i>	Germeshausen et al. (2010)
McArdle's disease*	<i>PYGM</i>	<i>CPT2</i>	Vockley et al. (2000)
Parkinson's disease, early onset	<i>PINK1</i>	<i>PARK2</i> or <i>PARK7</i>	Tang et al. (2006) and Funayama et al. (2008)
Parkinson's disease	<i>LRRK2</i>	<i>PRKN</i>	Dächsel et al. (2006)
Emery–Dreifuss muscular dystrophy*	<i>LMNA</i>	<i>DES</i>	Muntoni et al. (2006)
Joubert syndrome and nephronophthisis*	<i>NPHP1</i>	<i>NPHP6</i>	Tory et al. (2007)
Axenfeld–Rieger syndrome	<i>FOXC1</i>	<i>PITX2</i>	Kelberman et al. (2011)
Cortisone reductase deficiency	<i>HSD11B1</i>	<i>H6PD</i>	Draper et al. (2003) and San Millán et al. (2005)
Hypertrophic cardiomyopathy*	<i>MYBPC3</i>	<i>TNNT2</i> or <i>TNNI3</i> or <i>MYH7</i> or <i>TPM1</i>	Richard et al. (2003), Van Driest et al. (2004) Ingles et al. (2005), Millat et al. (2010), Kubo et al. (2011) and Zou et al. (2013)
Hypertrophic cardiomyopathy*	<i>MYH7</i>	<i>TNNT2</i> or <i>MYL2</i> or <i>TNNI3</i> or <i>ACTC1</i>	Millat et al. (2010) and Zou et al. (2013)
Restrictive cardiomyopathy*	<i>MYL2</i>	<i>MYL3</i>	Caleshu et al. (2011)
Rasopathy phenotype with severe hypertrophic cardiomyopathy	<i>PTPN11</i>	<i>SOS1</i>	Fahrner et al. (2012)
Arrhythmogenic right ventricular cardiomyopathy	<i>DES</i>	<i>PKP2</i>	Lorenzon et al. (2013)
Arrhythmogenic right ventricular cardiomyopathy*	<i>DES</i>	<i>DSG2</i>	Rasmussen et al. (2013)
Arrhythmogenic right ventricular cardiomyopathy	<i>PKP2</i>	<i>DSP</i> or <i>DSG2</i> or <i>PKP4</i> or <i>DSC2</i>	Xu et al. (2010)
Arrhythmogenic right ventricular dysplasia/ cardiomyopathy	<i>DSG2</i>	<i>DSC</i> or <i>PKP2</i>	Bhuiyan et al. (2009) and Nakajima et al. (2012)
Familial dilated cardiomyopathy*	<i>LMNA</i>	<i>TTN</i>	Roncarati et al. (2013)
Dent's disease	<i>CLCN5</i>	<i>OCRL</i>	Addis et al. (2013)
Amyotrophic lateral sclerosis	<i>SOD1</i>	<i>CNTF</i>	Giess et al. (2002)
Amyotrophic lateral sclerosis	<i>VAPB</i>	<i>C9orf72</i>	van Blitterswijk et al. (2012b)
Dravet syndrome	<i>PCDH19</i>	<i>TSPYL4</i>	Kwong et al. (2012)
Dravet syndrome*	<i>SCN9A</i>	<i>SCN1A</i>	Singh et al. (2009)
Dravet syndrome*	<i>CACNA1A</i>	<i>SCN1A</i>	Ohmori et al. (2013)
Severe myoclonic epilepsy	<i>CACNB4</i>	<i>SCN1A</i>	Ohmori et al. (2008)
Severe myoclonic epilepsy	<i>POLG</i>	<i>SCN1A</i>	Bolszak et al. (2009)
Progressive external ophthalmoplegia	<i>POLG</i>	<i>SLC25A4</i>	Galassi et al. (2008)
Bartter syndrome	<i>CLCNKA</i>	<i>CLCNKB</i>	Nozu et al. (2008)
Chronic pancreatitis	<i>SPINK1</i>	<i>CASR</i> or <i>CFTR</i> or <i>CTRC</i> or <i>PRSS1</i>	Felderbauer et al. (2003), Masson et al. (2007), Tzetis et al. (2007), Schneider et al. (2011), LaRusch et al. (2012) and Rosendahl et al. (2013)
Oculocutaneous albinism	<i>OCA2</i>	<i>TYRP1</i> or <i>SLC45A2</i> or <i>TYR</i>	Chiang et al. (2008) and Wei et al. (2013)
Oculocutaneous albinism	<i>TYR</i>	<i>SLC45A2</i>	Wei et al. (2013)
Cystinuria	<i>SLC3A1</i>	<i>SLC7A9</i>	Font-Llitjós et al. (2005)
Transposition of the great arteries	<i>ZIC3</i>	<i>FOXH1</i> or <i>NKX2-5</i>	De Luca et al. (2010)
Congenital heart disease	<i>MYH6</i>	<i>NKX2-5</i> or <i>GATA4</i>	Granados-Riveron et al. (2012)
Charcot–Marie–Tooth disease*	<i>PMP22</i>	<i>ABCD1</i> or <i>LITAF</i>	Meggouh et al. (2005), Hodapp et al. (2006)
Charcot–Marie–Tooth disease	<i>GJB1</i>	<i>EGR2</i>	Chung et al. (2005)
Charcot–Marie–Tooth disease*	<i>GDAP1</i>	<i>MFN2</i>	Vital et al. (2012)

Table 4 continued

Disease	Gene 1	Gene 2	Reference
Refractory auto-inflammatory syndrome	<i>TNFRSF1A</i>	<i>CIAS1</i>	Touitou et al. (2006)
Short-rib polydactyly syndrome type 2	<i>NEK1</i>	<i>DYNC2H1</i>	Thiel et al. (2011)
Maturity-onset diabetes of the young	<i>HNFI1A</i>	<i>HNFI1B</i>	Karges et al. (2007)
Maturity-onset diabetes of the young	<i>HNFI1A</i>	<i>HNFI4A</i>	Forlani et al. (2010) and Shankar et al. (2013)
Polycystic kidney disease*	<i>PKD1</i>	<i>PKD2</i>	Pei et al. (2001) and Dedoussis et al. (2008)
Hyperimmunoglobulinaemia D and periodic fever syndrome	<i>MVK</i>	<i>TNFRSF1A</i>	Hoffmann et al. (2005)
Obesity, hyperinsulinaemia and insulin resistance	<i>TCF1</i>	<i>NROB2</i>	Tonooka et al. (2002)
Progressive external ophthalmoplegia	<i>POLG</i>	<i>C10orf2</i>	Van Goethem et al. (2003)
Neuronal ceroid lipofuscinosis	<i>POLG</i>	<i>CLN5</i>	Staropoli et al. (2012)
Chronic lung disease	<i>SFTPC</i>	<i>ABCA3</i>	Bullard and Noguee (2007)
Lafora disease	<i>EPM2B</i>	<i>PPP1R3C</i>	Guerrero et al. (2011)
Congenital erythropoietic porphyria	<i>UROS</i>	<i>ALAS2</i>	To-Figueras et al. (2011)
Familial venous thrombosis*	<i>PROC</i>	<i>PROS1</i>	Formstone et al. (1996), Brenner et al. (1996), Boinot et al. (2003), Knoll et al. (2001) and Hayashida et al. (2003)
Familial venous thrombosis*	<i>PROC</i>	<i>SERPIND1</i>	Bernardi et al. (1996)
Breast cancer*	<i>BRCA1</i>	<i>BRCA2</i>	Leege et al. (2005), Lavie et al. (2011) and Heidemann et al. (2012)
Breast cancer	<i>BRCA1</i>	<i>PALB2</i>	Pern et al. (2012)
Multiple tumours of different types	<i>BRCA1</i>	<i>MLH1</i>	Pedroni et al. (2013)
Familial pulmonary arterial hypertension	<i>BMPR2</i>	<i>THBS1</i>	Maloney et al. (2012)
Hereditary nonpolyposis colorectal cancer	<i>MUTYH</i>	<i>MSH6</i>	Van Puijenbroek et al. (2007) and Giráldez et al. (2009)
Colorectal cancer	<i>EPCAM</i>	<i>MSH2</i>	Li-Chang et al. (2013)
Colorectal cancer, juvenile onset*	<i>APC</i>	<i>MSH2</i>	Uhrhammer and Bignon (2008)
Autoimmune lymphoproliferative syndrome	<i>FAS</i>	<i>CASP10</i>	Cerutti et al. (2007)
Autoimmune lymphoproliferative syndrome*	<i>FAS</i>	<i>PRF1</i>	Clementi et al. (2004)
Steroid-resistant focal segmental glomerulosclerosis	<i>NPHS2</i>	<i>NPHS1</i> or <i>CD2AP</i>	Löwik et al. (2008)
Severe infantile liver disease	<i>AKR1D1</i>	<i>SKIV2L</i>	Morgan et al. (2013)
Ataxia, dementia and hypogonadotropism	<i>RNF216</i>	<i>OTUD4</i>	Margolin et al. (2013)
Paediatric inflammatory bowel disease	<i>NOD2</i>	<i>GSDMB</i> or <i>ZNF365</i> or <i>ERAP2</i> or <i>SEC16A</i> or <i>GMPBB</i>	Christodoulou et al. (2013)
Paediatric inflammatory bowel disease	<i>BACH2</i>	<i>IL10</i>	Christodoulou et al. (2013)
Hutchinson-Gilford progeria syndrome	<i>ZMPSTE24</i>	<i>LMNA</i>	Denecke et al. (2006)

In this table, we considered only those examples of digenic mutations that are unlikely to be merely coincidental and which are predicted to affect genes that are both functionally associated with the disease in question

* Patients, with heterozygous mutations affecting two different genes, exhibiting earlier disease onset or a more severe clinical phenotype than either of their singly heterozygous parents or their siblings

reductase deficiency (Draper et al. 2003). It would not be altogether surprising, in conditions where digenic or even trigenic inheritance has been reported, if the individual component mutations were found to exhibit a reduced clinical penetrance as compared to mutations underlying the monogenic forms of the disease.

In some disorders, incomplete penetrance of a particular mutation can be due to the oligogenic nature of the disease

and hence to the requirement for multiple genes to be mutated for the condition in question to manifest. An inherited predisposition to cancer can be monogenic, but is also very likely to have an oligogenic aetiology in many instances (Fearnhead et al. 2004; Koren-Michowitz et al. 2005; Okkels et al. 2006; Küry et al. 2008; Wasielewski et al. 2010; Martinez and Kolodner 2010; Plon et al. 2011; Morak et al. 2011; Gracia-Aznarez et al. 2013). In

amyotrophic lateral sclerosis, van Blitterswijk et al. (2012a) detected *FUS* and *TARDBP* mutations in combination with *ANG* mutations, and *C9orf72* repeat expansions with *TARDBP*, *SOD1* and *FUS* mutations. At least five relatively common polymorphisms in four different genes, *CFB* (Arg32Gln, rs641153), *C2* (Glu318Asp, rs9332739), *CFH* [Tyr402His (rs1061170) and non-coding variant rs1410996] and *ARMS2* (Ala69Ser, rs10490924), interact so as to confer increased risk of age-related macular degeneration (Maller et al. 2006). Common polymorphisms in the *LEPR* (Gln223Arg, rs1137101) and *ADRB2* [Arg16Gly (rs1042713) and Gln27Glu (rs1042714)] genes jointly confer increased risk of obesity even though none of these polymorphisms exhibits a significant influence on their own (Pereira et al. 2011). Other examples of oligogenic inheritance, involving the mutation or polymorphism of multiple unlinked genes in the same individual, include isolated gonadotropin-releasing hormone deficiency (*KAL1*, *PROK2* and *NELF*; Sykiotis et al. 2010), hypertrophic cardiomyopathy (*MYH7*, *MYBPC3*, *TNNI3* and *TNNT2*; Girolami et al. 2010; Lopes et al. 2013), iminoglycinuria (*SLC36A2*, *SLC6A20*, *SLC6A18*, *SLC6A19*; Bröer et al. 2008), long QT syndrome (*KCNH2*, *SCN5A* and *KCNE1*; Yoshikane et al. 2013), chronic pancreatitis (*SPINK1*, *CFTR* and *CTRC*; Rosendahl et al. 2013), atypical haemolytic uraemic syndrome (*CFH*, *CD46* and *CFI*; Roumenina et al. 2012; Bresin et al. 2013), Parkinson disease (*LRKK2*, *SNCA*, *MAPT*, *GBA*, *BST1*, *PARK16*; Wang et al. 2012), acrocallosal syndrome (*KIF7*, *AH11*, *BBS2* and *BBS4*; Walsh et al. 2013), autism spectrum disorders (Neale et al. 2012) and a low plasma level of HDL cholesterol, a major risk factor for atherosclerosis (Cohen et al. 2004; Wang et al. 2008; Johansen and Hegele 2012).

One of the best characterized oligogenic disorders is Bardet–Biedl syndrome (BBS) where at least 17 genes are known to contribute to the clinical phenotype, and the severity of the disease phenotype may vary as a result of the interaction of mutations in different BBS genes. Although mutations at more than one locus have often been found to segregate with the disease, thereby modulating both its penetrance and expressivity (Badano et al. 2006; Zaghoul and Katsanis 2009; Cardenas-Rodriguez et al. 2013), the jury is still out in relation to claims of digenic triallelic inheritance in BBS (Katsanis et al. 2001; Beales et al. 2003; Badano et al. 2003; Fauser et al. 2003; Smaoui et al. 2006; Chen et al. 2011; Abu-Safieh et al. 2012). This notwithstanding, some common BBS gene variants appear to be detrimental to protein function and may well interact with the much rarer pathogenic BBS mutations so as to influence the severity of the BBS phenotype (Zaghoul et al. 2010).

Some idea of the likely complexity of genotype–phenotype relationships in complex disease has come from the comparative exome sequencing of 237 ion channel genes performed in sporadic idiopathic epilepsy patients and

unaffected controls (Klassen et al. 2011). Both rare and common variants were identified in the two groups. Although these variants were more numerous in the patient group, they were not found to be predictive of disease: as the authors opined, “absolute numerical counts of SNP burden hold little predictive value as a global pathogenic measure”. However, 51 % of cases and 14 % of controls had ≥ 2 non-synonymous variants in their sodium channel genes. In similar vein, 24 % of cases and 6 % of controls had ≥ 2 non-synonymous variants in their GABA receptor alpha genes (Klassen et al. 2011). Such findings are quite consistent with an oligogenic model of sporadic epilepsy (Dibbens et al. 2007). What is required here, however, is not a simple variant number count, but rather an assessment, on an individual basis, of the net effect of an oligogenic variant profile (requiring ascertainment of the various gains or losses of function associated with specific variants and computed with an eye to the nature of potential joint effects) on a clinically or phenotypically relevant output measure such as the electrical signature of a cell type or brain region.

Perhaps, the best characterized oligogenic disorder to date is familial venous thrombosis. The risk of venous thromboembolism is known to be increased in patients who carry more than one genetic variant disrupting the 100+ genes of the ‘hemostaseome’ (Fechtel et al. 2011). Thus, 19 % of symptomatic individuals harbouring a protein C (*PROC*) gene mutation were also found to be heterozygous for factor V Leiden (*F5* Arg534Gln; Koeleman et al. 1994), a functional polymorphism which occurs at a frequency of 2–5 % in European populations. In a replication study, 9.5 % of venous thrombosis patients were found to carry both mutations (Gandrille et al. 1995) suggesting that their co-occurrence increases the likelihood of their coming to clinical attention. Similar findings have been noted in families with protein S (*PROS1*) deficiency; among symptomatic individuals, 38 % also carried the factor V Leiden mutation (Koeleman et al. 1995). Likewise, coinheritance of antithrombin (*SERPINC1*) deficiency and factor V Leiden not only increases clinical penetrance, but also reduces the age of clinical presentation (van Boven et al. 1996). In a larger-scale study involving 132 thrombophilic families, the risk of thrombosis was increased and the age of onset lowered in cases of double heterozygosity for two gene variants (combinations of variants in *PROC*, *PROS1*, *F5* and *F2*) as compared to individuals carrying single variants of these genes (Tirado et al. 2001). ABO blood group is also known to modify the risk of venous thrombosis in individuals with hereditary thrombophilia through an influence on the plasma levels of factor VIII and the factor VIII carrier protein, von Willebrand factor (Tirado et al. 2005; Nossent et al. 2006; Cohen et al. 2012). Such studies provide strong circumstantial

support for the joint impact of multiple mutations in thrombotic disease (Martinelli et al. 2008). The elevation of risk for each individual variant is, however, low, and incomplete penetrance is evident for all prothrombotic variants. This means that the vast majority of individuals bearing these variants do not suffer from thrombotic disease. It is nevertheless reasonable to suppose that patients with recurrent venous thrombosis will tend to have a greater number of prothrombotic variants than those who have experienced a single thrombotic event, with those individuals who never experienced thrombosis harbouring even fewer prothrombotic variants (Fechtel et al. 2011). Since the number of genes known to influence haemostasis is large and the number of variants with potential impact larger still, we may expect that a substantial number of different variant combinations will be capable of conferring an increased risk. This genetic risk will accompany each prothrombotic challenge (such as pregnancy, long haul air travel, contraceptive pill usage and immobilization after surgery), with the greatest risk of venous thrombosis accruing to those possessing the largest number of prothrombotic variants in their genomes (Fechtel et al. 2011). Our task is to come to understand how specific DNA sequence changes in the large number of genes known to play a role in haemostasis and thrombosis act either synergistically or antagonistically so as to confer disease predisposition upon the individual, thereby influencing the clinical penetrance, by shifting their haemostatic balance towards either a prothrombotic or anticoagulant phenotype (Franchini and Mannucci 2009; Westrick and Ginsburg 2009; Fechtel et al. 2011).

Influence of sex on penetrance

The sex dependence of the penetrance of inherited mutations has been reported in a variety of different heritable disorders including haemochromatosis (*HFE*; Rossi et al. 2008), hypertrophic cardiomyopathy (*MYBPC3*, *MYH7*; Michels et al. 2009; Page et al. 2012), arrhythmogenic right ventricular dysplasia/cardiomyopathy (*PKP2*; Dalal et al. 2006), long QT syndrome (*KCNQ1*, *KCNH2*, *SCN5A*; Zareba et al. 2003), hypokalaemic periodic paralysis (*CACNA1S*; Kawamura et al. 2004; Li et al. 2012; *SCN4A*; Ke et al. 2013), familial pulmonary arterial hypertension (*BMPR2*; Austin et al. 2009b), hereditary spastic paraplegia (*SPAST*; Mitne-Neto et al. 2007), hereditary dystonia/dopa-responsive dystonia (*GCHI*; Furukawa et al. 1998), cardiac disease (*LMNA*; van Rijsingen et al. 2013), Hirschsprung disease (*RET*; Emison et al. 2005), autism spectrum disorder (*SHANK1*; Sato et al. 2012), amyotrophic lateral sclerosis (*C9ORF72*; Le Ber et al. 2013; Williams et al. 2013) and familial obesity (*SHP*; Yang et al. 2010). A male-biased effect on the penetrance of duplications

and deletions at 16p13.11 is evident in a range of neurodevelopmental conditions including autism, attention deficit hyperactivity disorder, intellectual disability and schizophrenia (Tropeano et al. 2013). In the case of familial pulmonary arterial hypertension, both genetic and metabolic marker data were consistent with a modifying role for variation in oestrogens and/or oestrogen metabolism upon disease risk (Austin et al. 2009b). The low penetrance of hypokalaemic periodic paralysis due to *SCN4A* mutations in females is also likely to be due to the effect of oestrogens (Ke et al. 2013).

Allelic variation may also influence the clinical phenotype in a sex-specific fashion. Thus, Lahtinen et al. (2011) reported that the common *KCNE1* Asp85Asn (rs1805128) polymorphism was associated with a QT-interval prolongation in male but not female type 1 long QT syndrome patients harbouring the *KCNQ1* Gly589Asp mutation. *KCNE1* Asp85Asn may thus be a sex-specific QT-interval modifier in type 1 LQTS. Similarly, the Ile148Met (rs738409) *PNPLA3* polymorphism is a disease modifier in primary sclerosing cholangitis with bile duct stenosis, but only in male patients (Friedrich et al. 2013). Finally, a Val89Leu polymorphism (rs523349) in the steroid 5 α -reductase type 2 (*SRD5A2*) gene, which serves to reduce the conversion of testosterone to dihydrotestosterone, has been claimed to influence the severity of post-traumatic stress symptoms but in a male-specific fashion (Gillespie et al. 2013).

An intriguing parent-of-origin effect has been noted in two apparently unrelated retinoblastoma families with a heterozygous, low-penetrance splice site mutation (c.607+1G>T) in the *RBI* gene which causes skipping of exon 6 (Klutzn et al. 2002). The abundance of the resulting nonsense (frameshifted) *RBI* mRNA relative to the wild-type was found to vary between members of one and the same family. Those individuals in family #1 who inherited the mutant *RBI* allele from their mother displayed a similar level of nonsense and wild-type *RBI* transcripts, and only one of eight carriers developed retinoblastoma. By contrast, those individuals in family #2 who inherited the mutant *RBI* allele from their fathers displayed a reduced abundance of the nonsense transcript with six of eight carriers developing retinoblastoma, indicating that the mutant transcript has residual function. Assuming that this is not a chance result (Fisher's exact test; $p = 0.04$), it may be that the gender of the transmitting parent can influence the penetrance of the pathogenic mutation.

There is good evidence to suggest that sex-specific genomic architecture can influence the expression of human phenotypes, including disease traits (Ober et al. 2008). It is likely that the underlying mechanism is differential gene regulation in males and females, particularly in relation to sex steroid-responsive genes (Zhang et al. 2007; Dimas et al. 2012).

Another mechanism by which sex influences penetrance is via genomic imprinting. Genomic imprinting results

from the epigenetic modification of a gene or gene region that leads to the mutually exclusive expression of either the maternal or the paternal allele. Imprinted alleles are silenced (by DNA methylation or histone modification), so that the corresponding genes are expressed only from the non-imprinted allele inherited from the other parent. In the case of disease genes, imprinting can influence the penetrance of pathological mutations depending upon whether the wild-type or the mutant allele is imprinted. Genomic imprinting can give rise to markedly different levels of clinical penetrance depending upon the parental origin of the disease allele. Examples include *SGCE* mutations in myoclonus dystonia (Zimprich et al. 2001; Müller et al. 2002; Grabowski et al. 2003) and *SDHD* mutations in paraganglioma (Badenhop et al. 2001; Simi et al. 2005; Baysal et al. 2011). In both cases, maternal imprinting ensures that the pathologically effective mutations are almost invariably inherited from the father. Intriguingly, in one family with pseudohypoparathyroidism type 1b, Jan de Beur et al. (2003) reported a case of the incomplete penetrance of an imprinting mutation. These authors found that both the clinically affected and unaffected siblings had inherited the same *GNAS1* allele from their affected mother, indicating that some dissociation must have occurred between the genetic *GNAS1* defect responsible for the disease and its epigenetic mark. The inconsistent acquisition of a paternal epigenotype on a maternal *GNAS1* allele would appear to provide evidence for the incomplete expression of a reprogramming defect that affects imprinting.

Age-dependent penetrance

Age-dependent penetrance is present if the clinical symptoms of a given disease are increasingly likely to manifest themselves with increasing age of the at-risk individual. Age-dependent penetrance has been reported for mutations in a wide variety of different human disease genes, e.g. *MYBPC3* in hypertrophic cardiomyopathy (Michels et al. 2009; Page et al. 2012), *LMNA* in Emery–Dreifuss muscular dystrophy (Vytopil et al. 2002), *MC4R* in familial obesity due to melanocortin-4 receptor deficiency (Stutzmann et al. 2008), *GBA* in Parkinson disease (Anheim et al. 2012; Rana et al. 2013), *BRCA1* and *BRCA2* in breast cancer susceptibility (Chen and Parmigiani 2007; Al-Mulla et al. 2009; Mavaddat et al. 2013), *MEN1* in multiple endocrine neoplasia type 1 (Machens et al. 2007), *RET* in multiple endocrine neoplasia type 2A (Frank-Raue et al. 2011) and *SDHD* and *SDHB* in predisposition to paragangliomas (Hensen et al. 2010; Hes et al. 2010). The *APOE* $\epsilon 4$ allele (comprising the T allele of rs429358 and the C allele of rs7412 in *cis*) serves to reduce the age of onset of Alzheimer disease from 78.4 years in patients lacking the

allele, to 75.3 in heterozygous carriers to 72.9 in carriers of two *APOE* $\epsilon 4$ alleles (Sando et al. 2008).

Age-dependent penetrance is particularly evident where large numbers of heterozygous carriers harbouring specific gene mutations have been identified by cascade screening, e.g. *LRRK2* Gly2019Ser (rs34637584) in Parkinson disease (Latourelle et al. 2008; Healy et al. 2008; Sierra et al. 2011), *GLUT1* Arg232Cys in familial idiopathic generalized epilepsy (Striano et al. 2012), *RET* Cys634Trp (rs77709286) in multiple endocrine neoplasia type 2A (Milos et al. 2008), *ACADM* Lys329Glu (rs77931234) in medium-chain acyl-CoA dehydrogenase deficiency (Andresen et al. 2012), *PKP2* Gln59Leu in arrhythmogenic right ventricular cardiomyopathy (Lahtinen et al. 2008) and *MYBPC3* c.2308+1G>A (rs112738974) in hypertrophic cardiomyopathy (Oliva-Sandoval et al. 2010). However, there are always anomalous cases; thus, in a family segregating a pathogenic missense mutation (Arg1205His) in the vacuolar protein sorting 35 (*VPS35*) gene, six family members between the ages of 54 and 73 years exhibited signs of Parkinson disease, but one individual was still asymptomatic at age 86 (Nuytemans et al. 2013).

Specific mutations may sometimes differ from each other in terms of the average age of onset of clinical symptoms. Thus, for example, patients with maturity-onset diabetes of the young (MODY) who harbour mutations in exons 9 or 10 of the *HNF4A* gene have been found to develop disease much later (average 40 vs. 24 years) than MODY patients with mutations in exons 2–8 (Harries et al. 2008). This difference in age-related penetrance is thought to be a consequence of the exon 9 and 10 mutations being absent from three of the nine *HNF4A* isoforms encoded by the *HNF4A* gene, whereas the mutations located in exons 2–8 affect all nine isoforms.

In some cases, the clinical penetrance of a particular mutation can change quite dramatically with age. For example, the cumulative incidence among carriers of the Arg1441Gly mutation in the *LRRK2* gene causing Parkinson disease was found to be 12.5 % until the age of 65 years, but 83 % until age 80 (Ruiz-Martínez et al. 2010). However, the penetrance of the common *TTR* Val30Met mutation causing autosomal dominant familial amyloid polyneuropathy has been estimated to be 1.7 % until the age of 30 years, 22 % until the age of 60, but still only 69 % until age 90 (Hellman et al. 2008). Majounie et al. (2011) showed that the pathogenic GGGGCC hexanucleotide expansion in the *C9orf72* gene associated with a high proportion of cases of amyotrophic lateral sclerosis and frontotemporal dementia was non-penetrant in individuals younger than 35 years, 50 % penetrant by age 58 but almost fully penetrant by age 80. Age-dependent penetrance could thus provide another explanation for why some putatively pathological mutations listed in HGMD

are present in apparently healthy individuals from the 1000 Genomes Project.

A glimpse of the way ahead is provided by a recent study of symptomatic and asymptomatic carriers of a specific granulin (*GRN*) mutation (Thr272Ser) responsible for autosomal dominant frontotemporal lobar degeneration (FTLD), a disease whose onset typically occurs in the sixth decade of life (Milanesi et al. 2013). Unsurprisingly, both the symptomatic and asymptomatic *GRN* mutation carriers had lower serum levels of progranulin than non-carriers. However, using whole-genome microarray analysis, the leukocyte expression of the *TMEM40* and *LY6G6F* genes was found to be significantly higher in FTLD patients harbouring *GRN* mutations as compared to asymptomatic carriers. Further, elevated expression of the genes was correlated with increased brain damage and could therefore be directly related to the pathology of the disease (Milanesi et al. 2013).

Epigenetic influences on disease penetrance

As briefly discussed above in the context of the influence of gender upon penetrance, epigenetic modifications may also account for incomplete penetrance. Thus, when monozygotic twins are discordant for disease phenotypes, epigenetic differences should be considered (Wong et al. 2005; Kaminsky et al. 2009; Gordon et al. 2011; 2012). Indeed, monozygotic twins have been reported who differ both in relation to a specific clinical phenotype and in terms of an epigenotype. For example, monozygotic twins discordant for childhood leukaemia have been found to have discordant *BRCA1* methylation status (Galetzka et al. 2012). Similarly, hypermethylation of *SLC6A4*, encoding the serotonin transporter, has been reported in one member of a monozygotic twin pair discordant for bipolar disorder (Sugawara et al. 2011).

Epigenetic differences may also contribute to incomplete penetrance in other conditions such as asthma, where DNA methylation has been reported to modulate the risk of disease conferred by genetic variants at the zona pellucida binding protein 2 (*ZBP2*; Berlivet et al. 2012), forkhead box P3 (*FOXP3*; Runyon et al. 2012), interferon- γ (*IFNG*; Runyon et al. 2012) and interleukin-4 receptor (*IL4R*; Soto-Ramírez et al. 2013) gene loci.

A special case of imprinting is provided by X-inactivation (Dobyns et al. 2004). When a disease gene is X-linked, skewed X-inactivation can cause variable penetrance of pathogenic mutations in female carriers (Van den Veyver 2001). Examples of this phenomenon involve mutations in the *TIMM8A* gene (Xq22.1) in dystonia-deafness syndrome (Plenge et al. 1999), the *EBP* gene (Xp11.23) in X-linked dominant chondrodysplasia punctata (Shirahama et al. 2003), the *FLNA* gene (Xq28) in

otopalatodigital type 1 syndrome (Hidalgo-Bravo et al. 2005), the *ABCD1* gene (Xq28) in a family with X-linked adrenoleukodystrophy (Wang et al. 2013b) and the *ZIC3* gene (Xq26.3) in a family with complex heart defects (Chhin et al. 2007). It should, however, be pointed out that some *ZIC3* mutations are characterized by reduced penetrance in males, a finding that cannot be explained by skewed X-inactivation (Mégarbané et al. 2000).

Gene–environment interactions and penetrance

The environment, in its broadest sense, will often influence clinical penetrance, either ameliorating or exacerbating the impact of heritable genetic variants (Hunter 2005). Indeed, environmental modifiers of disease penetrance (e.g. diet, alcohol intake, drugs, metabolic syndrome) have long been known to influence the penetrance of *HFE* C282Y homozygosity in haemochromatosis (Beutler 2003; Rossi et al. 2008; Deugnier and Mosser 2008).

One way to explore the relative contribution of genes and environment is by studying monozygotic twins harbouring the same pathogenic mutation(s) and sharing the same genetic background. Although the vast majority of such monozygotic twin pairs have been found to be concordant in terms of their clinical phenotypes (e.g. Miesfeldt et al. 1998; Munhoz et al. 2008; McDade et al. 2012), others are quite discordant (Matsuo et al. 2000; Amann et al. 2001; Martin et al. 2003; Holmgren et al. 2004; Lachmann et al. 2004; Czlonkowska et al. 2009; Biegstraaten et al. 2011; Fencel et al. 2012; Iatropoulos et al. 2012), suggesting that the environment can often play an important role in determining both the penetrance and expressivity of pathological mutations. [It should be borne in mind that there are various alternative genetic explanations for discordant phenotypes in monozygotic twins, including de novo post-zygotic mutation (Kentsis et al. 2009; Vogt et al. 2011), compensatory mutations (Mankad et al. 2006) and somatic copy number variation (Bruder et al. 2008) that obviate the need for a major contribution from the environment, as well as acquired epigenetic differences (Galetzka et al. 2012; Bennett et al. 2008)].

An environmental influence on penetrance is perhaps at its most evident in cancer susceptibility (Houlston and Peto 2004; Shen 2009). Indeed, an environmental component is very important in colorectal cancer where inherited genetic variants at a number of different loci interact primarily with dietary variables and overweight to confer risk (Hutter et al. 2012; Siegert et al. 2013). In similar vein, inherited differences in skin pigmentation influence the risk of melanoma, but this risk is further modified both by latitude of habitation and lifestyle choices (van der Velden et al. 2001; Bishop et al. 2002; Begg et al. 2005; Meyle and

Guldberg 2009; Scherer and Kumar 2010). Parity and breast feeding are both known to be modifiers of risk of breast/ovarian cancer in *BRCA1* mutation carriers (McLaughlin et al. 2007; Jernström et al. 2004; Cullinane et al. 2005; Antoniou et al. 2006). Another example of a gene–environment interaction in the context of cancer is provided by cytochrome P450 gene variants that may influence cancer risk by virtue of their roles in xenobiotic metabolism, detoxification of carcinogens, and to a lesser extent the bioactivation of procarcinogens (Rodriguez-Antona et al. 2010). Lung cancer provides an excellent example of the interaction of genes and environment. Three different GWAS, published virtually simultaneously, provided the first convincing evidence for an association between heritable genetic variation at the nicotinic acetylcholine receptor *CHRNA5/CHRNA3/CHRNA4* locus on chromosome 15q25.1 and lung cancer (Amos et al. 2008; Hung et al. 2008; Thorgeirsson et al. 2008). Although allele T of SNP rs1051730, a synonymous variant located within exon 5 of the *CHRNA3* gene, was found to be strongly associated with smoking quantity, the issue of whether the association with lung cancer was direct or indirect (i.e. mediated through cigarette smoking and nicotine dependence) remained unclear. Galvan and Dragan (2009) performed a meta-analysis of reported studies of the 15q25 region and found that this locus was not associated with lung cancer risk in never-smokers. This lack of effect argued for an indirect effect of genetic variation at the 15q25 locus on lung cancer risk via an association between these variants and smoking/nicotine dependence. However, Wang et al. (2010b) subsequently examined the relationship between rs1051730 and lung cancer and concluded that, in addition to its indirect influence on disease risk (through smoking behaviour), this variant also exerted a rather larger (and direct) effect. Kaur-Knudsen et al. (2011) concurred, demonstrating that homozygosity for rs1051730 was associated with a smoking behaviour-adjusted relative risk of lung cancer of 1.6, indicating that rs1051730 is associated with an additional risk of lung cancer over and above that derived from its effect on smoking behaviour. Finally, in a lung cancer case–control study, VanderWeele et al. (2012) employed two 15q25.1 SNPs, rs8034191 and rs1051730, to show that the proportion of increased risk due to smoking was only 3.2 % and that the association of the 15q25 variants with lung cancer operates primarily through pathways other than smoking behaviour. All of the above notwithstanding, the risk of lung cancer conferred directly or indirectly by genetic variants on 15q25 would be small if the individual concerned simply opted not to smoke (Brennan et al. 2011).

The penetrance of genetic variants conferring susceptibility to infectious disease is clearly contingent upon exposure to the specific pathogens concerned (Vannberg et al. 2011; Chapman and Hill 2012). One example is the

CCR5 32-bp (c.554del32) deletion which is associated with a lower rate of HIV infection and a delay in the onset of AIDS (Smith et al. 1997). Sex may also play a role in some conditions; thus, in multiple sclerosis, women appear to be more responsive to the environmental risk factors that cause the disease (Goodin 2012; O’Gorman et al. 2012).

Diet is also an important modifier of clinical penetrance. Thus, an inherited predisposition to obesity (exemplified by the association between dietary fat intake and obesity in carriers of the *PPARG2* Pro12Ala allele; Memisoglu et al. 2003) is in principle modifiable by diet (Walters et al. 2010; Ramachandrapa and Farooqi 2011). Similarly, the impact of genetic variants at the *FTO* locus on risk of obesity can be attenuated by physical activity (Kilpeläinen et al. 2011). Diet is also an important modifier of clinical penetrance in phenylketonuria, as mentioned in the “Introduction” to this review, where the penetrance of the condition can be very substantially reduced by restricting dietary phenylalanine (van Spronsen 2010).

Heavy coffee drinkers have been known for some time to have a reduced risk of developing Parkinson disease. However, the risk of developing Parkinson disease has been found to be reduced even further for heavy coffee drinkers by a specific variant in the *GRIN2A* gene; compared to light coffee drinkers with an rs4998386_CC genotype, heavy coffee drinkers with the same genotype have an 18 % lower risk, whereas heavy coffee drinkers with an rs4998386_TC genotype have a 59 % lower risk (Hamza et al. 2011).

More unusually, altitude has been reported to act as a modifier of the phenotypic severity of hereditary paraganglioma type 1 caused by mutations in the succinate dehydrogenase D (*SDHD*) gene (Astrom et al. 2003). Since chronic hypoxic stimulation at high altitude causes sporadic carotid body paragangliomas, Astrom et al. (2003) proposed that *SDHD* might be involved in oxygen sensing. Thus, whilst *SDHD* mutations could impair oxygen sensing, low altitude may serve to reduce the penetrance of these mutations.

The clinical penetrance of psychological disorders and traits has long been known to be strongly influenced by gene–environment interactions (Dick 2011). For example, a 44-bp deletion/insertion polymorphism in the promoter region of the serotonin transporter gene *SLC6A4* was reported to be associated with depression after stressful life events (Caspi et al. 2003). Recently, Klengel et al. (2013) gave us a glimpse of the likely complexity of the mechanisms underlying gene–environment interactions in the context of psychological disorders. These authors demonstrated that a risk variant for post-traumatic stress disorder and major depression in the FK506-binding protein 5 gene (*FKBP5*) is demethylated in several cell types in children exposed to trauma. This demethylation persists into

adulthood and confers an increased risk of developing disease. In *FKBP5* risk allele carriers, excessive cortisol release during early life stress leads to demethylation within the glucocorticoid-responsive elements of *FKBP5* in intron 7 with the consequence of long-lasting disruption of the ultra-short feedback loop that balances *FKBP5* and glucocorticoid receptor activity, causing dysregulation of the stress hormone system. The *FKBP5* risk allele corresponds to a functional polymorphism located in intron 2 of the *FKBP5* gene that alters the chromatin interaction between the transcriptional start site and long-range enhancers, thereby increasing the transcriptional activity of *FKBP5* over and above that of the wild-type allele. Only the risk allele is able to form a three-dimensional complex which includes RNA polymerase II and a glucocorticoid-responsive element located within intron 7 of *FKBP5*. Enhanced transcription of the risk allele facilitates the PolII-dependent demethylation in intron 7 in response to elevated glucocorticoids under early life stressful conditions. The reduced methylation of intron 7 CpGs leads to increased induction of *FKBP5* by glucocorticoid receptor activation, especially in risk allele carriers, representing an enhancement of the ultra-short feedback loop leading to increased glucocorticoid receptor resistance. If this occurs during developmentally critical periods, then the methylation patterns will remain stable over time (Klengel et al. 2013). Hence, the demethylation in *FKBP5* intron 7 depends upon both childhood trauma and the sequence variant in intron 2, in a tripartite gene–environment interaction (Szyf 2012).

The above examples represent the tip of the iceberg because the clinical penetrance of most monogenic conditions and all complex disease is likely to be influenced by the environment in some way or another. A further glimpse of this complexity is perhaps provided by Kallberg et al. (2007) who reported interactions between *HLA-DRB1* SE alleles, the A allele of the *PTPN22* Arg620Trp (rs2476601)


polymorphism and smoking in conferring risk of rheumatoid arthritis. Gene–environment interactions are also evident in asthma (Custovic et al. 2012; Chang et al. 2012) and eczema (Bisgaard et al. 2008) and will become increasingly apparent in other disorders as new techniques are developed to identify them (Aschard et al. 2012). To this end, mouse models are beginning to come into their own as a means to study the role of gene–environment interactions in the aetiology of human disorders; by these means, short-term gestational hypoxia has been found to increase the penetrance of vertebral defects in congenital scoliosis (Sparrow et al. 2012).

Conclusions

A holy grail of human medical genetics is to be able to deduce the likely clinical phenotype of an individual from their genotype or genomic sequence. It was once perhaps naively assumed that, at least for “monogenic” disorders, genotype–phenotype relationships would be that simple, and also fairly straightforward to discern. However, it has been clear for some time that it is inappropriate to regard such disorders as either simple or monogenic in any strict sense. Further, in many cases, the reality is that we cannot readily draw straight lines of causation from known genotypes to specific clinical phenotypes. This is because instances abound of individuals who harbour a disease-associated mutation/genotype, but who do not express certain features of the disease or who may even be asymptomatic. This phenomenon of reduced penetrance may or may not be the norm, but it is far from being a rare exception. Our appreciation of its full extent is still emerging, although some of the different mechanisms underlying reduced penetrance are now becoming apparent (Fig. 1).

It has become clear from large-scale sequencing studies that many individuals in the general population harbour

Fig. 1 Some of the different mechanisms underlying the phenomenon of reduced penetrance in human inherited disease



large numbers of potentially disadvantageous variants without suffering any obvious ill effects (The 1000 Genomes Project Consortium 2010; MacArthur et al. 2012; Xue et al. 2012; Shen et al. 2013a). Thus, it would appear that many mutations are, on their own, insufficient to cause disease and need to occur in the presence of other genetic variants, either allelic or non-allelic, as well as facultative environmental factor(s), for a disease state to ensue. Indeed, many pathological mutations may only be conditionally pathogenic, exerting a detrimental effect only if and when the genetic and external environments interact to push the phenotype over some notional threshold into pathology.

Penetrance is best thought of as being a genotype-specific rather than a gene-specific or disease-specific phenomenon. Thus, in any given disease gene, some mutations may exhibit complete penetrance, whereas others may show incomplete or even quite low penetrance. Generally speaking, mutations that display low penetrance also tend to exert milder effects on the clinical phenotype and/or protein function, while the more highly penetrant a mutation is, the less frequent it is likely to be in the general population (Coventry et al. 2010; Marth et al. 2011; Gorlov et al. 2011; Tennessen et al. 2012; Nelson et al. 2012; Subramanian 2012; Fu et al. 2013). Whereas highly penetrant mutations may exert their pathogenic effects with relatively little interaction with other genetic or environmental factors, low-penetrance mutations are generally characterized by significant gene–gene and gene–environment interactions (Cordell 2009). Different combinations of such variants may contribute to the variable penetrance characteristic of both monogenic and complex disease.

Whatever the molecular basis may be in the case of a given mutation, reduced penetrance is in general likely to present a serious impediment to the implementation of any scheme designed to classify the pathological significance of human genetic variants (e.g. Plon et al. 2008; Tavtigian et al. 2008). Reduced penetrance is also likely to present problems in identifying pathological mutations in whole-genome/exome sequencing programmes unless it is explicitly built into the disease models being considered (Varga et al. 2013). Despite the complexities it introduces, it also offers hope in the sense that if we are able to identify environmental factors, drugs or other types of intervention that serve to reduce the penetrance of a given pathological variant, or alternatively delay the onset of its pathological sequelae beyond the natural lifespan of its carrier, we shall have a whole new range of therapeutic approaches at our disposal.

Human genetic variation occurs as a continuum ranging from neutral polymorphisms, through functional polymorphisms and disease susceptibility variants to true pathological mutations with high penetrance. However, in addition and as discussed above, it has become increasingly clear that our genomes contain many ‘putatively

disadvantageous variants’ that are probably insufficient on their own to cause disease, but nevertheless still have the potential to contribute to pathogenesis. Since it has also become clear that many genetic disorders are not monogenic as originally supposed, but may instead involve mutations in two or more genes, we speculate that different combinations of pathological mutations with low penetrance, functional polymorphisms, disease susceptibility variants and ‘putatively disadvantageous variants’ may vary quite considerably in terms of their net functional and hence clinical effect. Such combinations are likely to exert an influence on the age of onset and/or clinical severity of the disease in question.

The rationale of genetic studies of complex phenotypes has generally relied upon either the ‘common disease, common variant (CDCV)’ hypothesis or the ‘common disease, rare variant (CDRV)’ hypothesis. The former postulates that complex phenotypes result from the cumulative effects of a number of common variants, each with a modest effect size and relatively low penetrance. The latter proposes that complex phenotypes result from multiple rare variants, each with relatively high penetrance and large effect sizes (Schork et al. 2009). It is highly likely that both rare and common alleles will contribute to complex phenotypes and so effect sizes may be expected to differ quite widely, with rare variants with large effects complemented by a large number of frequent variants with small effects. The clinical phenotypes of complex phenotypes are therefore likely to be due to individual effects of, and interaction between, multiple causative or contributory alleles, as well as non-genetic determinants.

The full relevance of digenic and oligogenic inheritance to the phenomenon of incomplete or variable penetrance remains to be elucidated. If, however, it turns out that digenic and oligogenic conditions are more common than originally anticipated, then many disease contributory variants will have evaded purifying selection, and hence those variants that in combination (but not individually) have significant pathogenic potential will not be as infrequent as might be expected under the CDRV hypothesis. Since both multiple common and rare variants may be involved in conferring disease susceptibility, we are not obliged to favour either the CDCV hypothesis or the CDRV hypothesis. Moreover, in view of the likely complexity of the gene–gene interactions involved, we concur with Lupski et al. (2011) that “for a given individual, what is important to know is not only the number and location of pathogenic variants taken one at a time, but also the unique composition of his or her genome-wide mutational burden”.

Lupski et al. (2011) charted progress on the road to a unified genetic model for human disease and opined that such a model should unite categories of diseases, previously held to be distinct entities, as part of a continuum

which would include chromosomal syndromes, genomic disorders, Mendelian traits and common diseases or complex traits. Concurring with this view, we envisage an integrated concept of genetic aetiology in which different types of mutation (from single base substitutions to copy number variants), different combinations of mutations in multiple genes (whether in homozygosity or heterozygosity), *cis*-acting or *trans*-acting modifiers, common variants, rare variants, de novo variants and even somatic variants, jointly serve to exacerbate or ameliorate a given clinical phenotype. Further, to explain the scale of reduced penetrance, we need to conceptualize clinical phenotypes as being derived, potentially at least, from the expression of different genetic variants in two or more genes. On the basis of the data collated for this review, it seems reasonable to conclude that digenic, oligogenic and polygenic influences are much more frequent than has perhaps hitherto been realized. Unravelling such influences will undoubtedly be key to understanding the molecular basis of reduced penetrance. The impact of disease genotypes may also be modified by epigenetic and environmental factors, allowing both for synergistic and antagonistic interactions resulting in highly individualized contributions to the phenotype (whether deleterious or protective) that will variously perturb the balance of specific biological pathways so as to give rise to disease.

With the advent of next-generation sequencing, very large numbers of genetic variants are being detected in individual genomes and it has been necessary to develop new algorithms to identify those variants which are of key functional/clinical importance. However, if in using these tools, we focus exclusively on single infrequent variants under the assumption that they will invariably exert their effects in splendid isolation, then there is a very real danger that we shall inadvertently exclude from consideration those more frequent variants with modest effects, blithely ignoring their potential for interaction with the rare variants. The irony would then be that, despite having the requisite mutation and polymorphism data available, the molecular basis of genotype–phenotype relationships in many inherited diseases (including, of course, the phenomenon of reduced penetrance) could still remain unintelligible. The alternative, anticipating multigenic influences on the clinical phenotypes associated with disorders traditionally regarded as being monogenic, should not only lead to new insights into the nature of reduced penetrance, but is also likely to improve our understanding of the nature of complex disease.

Acknowledgments The authors are grateful to Peter Stenson for provision of HGMD mutation data. DNC acknowledges receipt of financial support from BIOBASE GmbH through a licence agreement with Cardiff University. CTS is supported by the Wellcome Trust (098051).

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Abifadel M, Rabès JP, Jambart S, Halaby G, Gannagé-Yared MH, Sarkis A, Beaino G, Varret M, Salem N, Corbani S, Aydnian H, Junien C, Munnich A, Boileau C (2009) The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of *LDLR* mutations and role of *PCSK9* as a modifier gene. *Hum Mutat* 30:E682–E691
- Abu-Safieh L, Al-Anazi S, Al-Abdi L, Hashem M, Alkuraya H, Alamr M, Sirelkhatim MO, Al-Hassnan Z, Alkuraya B, Mohamed JY, Al-Salem A, Alrashed M, Faqeh E, Softah A, Al-Hashem A, Wali S, Rahbeeni Z, Alsayed M, Khan AO, Al-Gazali L, Taschner PE, Al-Hazzaa S, Alkuraya FS (2012) In search of triallelism in Bardet–Biedl syndrome. *Eur J Hum Genet* 20:420–427
- Ackermann B, Kröber S, Torres-Benito L, Borgmann A, Peters M, Hosseini Barkooie SM, Tejero R, Jakubik M, Schreml J, Milbradt J, Wunderlich TF, Riessland M, Tabares L, Wirth B (2013) *Plastin 3* ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. *Hum Mol Genet* 22:1328–1347
- Addis M, Meloni C, Tosetto E, Ceol M, Cristofaro R, Melis MA, Vercelloni P, Del Prete D, Marra G, Anglani F (2013) An atypical Dent’s disease phenotype caused by co-inheritance of mutations at *CLCN5* and *OCRL* genes. *Eur J Hum Genet* 21:687–690
- Aganna E, Aksentijevich I, Hitman GA, Kastner DL, Hoepelman AI, Posma FD, Zweers EJ, McDermott MF (2001) Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family: evidence for a *TNFRSF1A* mutation with reduced penetrance. *Eur J Hum Genet* 9:63–66
- Ahluwalia JK, Hariharan M, Bargaje R, Pillai B, Brahmachari V (2009) Incomplete penetrance and variable expressivity: is there a microRNA connection? *BioEssays* 31:981–992
- Akerman BR, Lemass H, Chow LM, Lambert DM, Greenberg C, Bibeau C, Mamer OA, Treacy EP (1999) Trimethylaminuria is caused by mutations of the *FMO3* gene in a North American cohort. *Mol Genet Metab* 68:24–31
- Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, Goldbach-Mansky R, Dean J, Athreya B, Reginato AJ, Henrickson M, Pons-Estel B, O’Shea JJ, Kastner DL (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in *TNFRSF1A*, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. *Am J Hum Genet* 69:301–314
- Alberobello AT, Congedo V, Liu H, Cochran C, Skarulis MC, Forrest D, Celi FS (2011) An intronic SNP in the thyroid hormone receptor β gene is associated with pituitary cell-specific overexpression of a mutant thyroid hormone receptor $\beta 2$ (R338W) in the index case of pituitary-selective resistance to thyroid hormone. *J. Transl. Med.* 9:144
- Albers CA, Paul DS, Schulze H, Freson K, Stephens JC, Smethurst PA, Jolley JD, Cvejic A, Kostadima M, Bertone P, Breuning MH, Debili N, Deloukas P, Favier R, Fiedler J, Hobbs CM, Huang N, Hurler ME, Kiddle G, Krapels I, Nurden P, Ruivenkamp CA, Sambrook JG, Smith K, Stemple DL, Strauss G, Thys C, van Geet C, Newbury-Ecob R, Ouwehand WH, Ghevaert C (2012) Compound inheritance of a low-frequency

- regulatory SNP and a rare null mutation in exon-junction complex subunit *RBM8A* causes TAR syndrome. *Nat Genet* 44:435–439
- Al-Mulla F, Bland JM, Serratt D, Miller J, Chu C, Taylor GT (2009) Age-dependent penetrance of different germline mutations in the *BRCA1* gene. *J Clin Pathol* 62:350–356
- Alonso I, Jardim LB, Artigalás O, Saraiva-Pereira ML, Matsuura T, Ashizawa T, Sequeiros J, Silveira I (2006) Reduced penetrance of intermediate size alleles in spinocerebellar ataxia type 10. *Neurology* 66:1602–1604
- Altès A, Bach V, Ruiz A, Esteve A, Felez J, Remacha AF, Sardà MP, Baiget M (2009) Mutations in *HAMP* and *HJV* genes and their impact on expression of clinical hemochromatosis in a cohort of 100 Spanish patients homozygous for the C282Y mutation of *HFE* gene. *Ann Hematol* 88:951–955
- Alves MM, Sribudiani Y, Brouwer RW, Amiel J, Antiñolo G, Borrego S, Ceccherini I, Chakravarti A, Fernández RM, Garcia-Barcelo MM, Griseri P, Lyonnet S, Tam PK, van Ijcken WF, Eggen BJ, Te Meerman GJ, Hofstra RM (2013) Contribution of rare and common variants determine complex diseases-Hirschsprung disease as a model. *Dev Biol* (in press). doi:10.1016/j.ydbio.2013.05.019
- Amann ST, Gates LK, Aston CE, Pandya A, Whitcomb DC (2001) Expression and penetrance of the hereditary pancreatitis phenotype in monozygotic twins. *Gut* 48:542–547
- Amin AS, Giudicessi JR, Tijssen AJ, Spanjaart AM, Reckman YJ, Klemens CA, Tanck MW, Kapplinger JD, Hofman N, Sinner MF, Müller M, Wijnen WJ, Tan HL, Bezzina CR, Creemers EE, Wilde AA, Ackerman MJ, Pinto YM (2012) Variants in the 3' untranslated region of the *KCNQ1*-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner. *Eur Heart J* 33:714–723
- Ammerlaan AC, Ararou A, Houben BP, Baas F, Tijssen CC, Teepeen JL, Wesseling P, Hulsebos TJ (2008) Long-term survival and transmission of *IN11*-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. *Br J Cancer* 98:474–479
- Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS (2008) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nat Genet* 40:616–622
- Andreasen C, Nielsen JB, Refsgaard L, Holst AG, Christensen AH, Andreasen L, Sajadieh A, Haunsø S, Svendsen JH, Olesen MS (2013) New population-based exome data are questioning the pathogenicity of previously cardiomyopathy-associated genetic variants. *Eur J Hum Genet* (in press)
- Andresen BS, Lund AM, Hougaard DM, Christensen E, Gahrn B, Christensen M, Bross P, Vested A, Simonsen H, Skogstrand K, Olpin S, Brandt NJ, Skovby F, Nørgaard-Pedersen B, Gregersen N (2012) *MCAD* deficiency in Denmark. *Mol Genet Metab* 106:175–188
- Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, Pollak P, Bonaiti B, Bonaiti-Pellié C, Brice A, French Parkinson Disease Genetic Group (2012) Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. *Neurology* 78:417–420
- Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struwing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ; Genetic Modifiers of Cancer Risk in *BRCA1/2* Mutation Carriers Study (GEMO), Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H; Epidemiological Study of *BRCA1* and *BRCA2* Mutation Carriers (EMBRACE), Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H; German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC), Spurdle AB, Chen X, Waddell N, Cloonan N; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Kirchoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowitz F, Raskin L, Andrulis IL, Ilyushik E, Ozelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G; Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) (2007) *RAD51* 135G>C modifies breast cancer risk among *BRCA2* mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet* 81:1186–1200
- Antoniou AC, Chenevix-Trench G (2010) Common genetic variants and cancer risk in Mendelian cancer syndromes. *Curr Opin Genet Dev* 20:299–307
- Antoniou AC, Shenton A, Maher ER, Watson E, Woodward E, Lalloo F, Easton DF, Evans DG (2006) Parity and breast cancer risk among *BRCA1* and *BRCA2* mutation carriers. *Breast Cancer Res* 8:R72
- Apetri AC, Vanik DL, Surewicz WK (2005) Polymorphism at residue 129 modulates the conformational conversion of the D178N variant of human prion protein 90–231. *Biochemistry* 44:15880–15888
- Arbini AA, Bodkin D, Lopaciuk S, Bauer KA (1994) Molecular analysis of Polish patients with factor VII deficiency. *Blood* 84:2214–2220
- Arnold WV, Fertala A (2013) Skeletal diseases caused by mutations that affect collagen structure and function. *Int J Biochem Cell Biol* 45:1556–1567
- Arnold M, Ellwanger DC, Hartsperger ML, Pfeufer A, Stümpflen V (2012) Cis-acting polymorphisms affect complex traits through modifications of microRNA regulation pathways. *PLoS ONE* 7:e36694
- Arzel-Hézode M, Sternberg D, Tabti N, Vicart S, Goizet C, Eymard B, Fontaine B, Fournier E (2010) Homozygosity for dominant mutations increases severity of muscle channelopathies. *Muscle Nerve* 41:470–477
- Asan, Xu Y, Jiang H, Tyler-Smith C, Xue Y, Jiang T, Wang J, Wu M, Liu X, Tian G, Wang J, Wang J, Yang H, Zhang X (2011) Comprehensive comparison of three commercial human whole-exome capture platforms. *Genome Biol* 12:R95
- Aschard H, Lutz S, Maus B, Duell EJ, Fingerlin TE, Chatterjee N, Kraft P, Van Steen K (2012) Challenges and opportunities in genome-wide environmental interaction (GWEI) studies. *Hum Genet* 131:1591–1613
- Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, Dudley JT, Ormond KE, Pavlovic A, Morgan AA, Pushkarev D, Neff NF, Hudgins L, Gong L, Hodges LM, Berlin DS, Thorn CF, Sangkuhl K, Hebert JM, Woon M, Sagreiya H, Whaley R, Knowles JW, Chou MF, Thakuria JV, Rosenbaum AM, Zaranek AW, Church GM, Greely HT, Quake SR, Altman RB (2010) Clinical assessment incorporating a personal genome. *Lancet* 375:1525–1535
- Astrom K, Cohen JE, Willett-Brozick JE, Aston CE, Baysal BE (2003) Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. *Hum Genet* 113:228–237
- Austin ED, Phillips JA, Cogan JD, Hamid R, Yu C, Stanton KC, Phillips CA, Wheeler LA, Robbins IM, Newman JH, Loyd JE (2009a) Truncating and missense *BMPL2* mutations differentially affect the severity of heritable pulmonary arterial hypertension. *Respir Res* 10:87

- Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA 3rd (2009b) Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. *Eur Respir J* 34:1093–1009
- Azaiez H, Chamberlin GP, Fischer SM, Welp CL, Prasad SD, Taggart RT, del Castillo I, Van Camp G, Smith RJ (2004) *GJB2*: the spectrum of deafness-causing allele variants and their phenotype. *Hum Mutat* 24:305–311
- Azmanov DN, Dimitrova S, Florez L, Cherninkova S, Draganov D, Morar B, Saat R, Juan M, Arostegui JI, Ganguly S, Soodyall H, Chakrabarti S, Padh H, López-Nevot MA, Chernodirnska V, Anguelov B, Majumder P, Angelova L, Kaneva R, Mackey DA, Tournev I, Kalaydjieva L (2011) *LTBP2* and *CYP1B1* mutations and associated ocular phenotypes in the Roma/Gypsy founder population. *Eur J Hum Genet* 19:326–333
- Badano JL, Katsanis N (2003) Beyond Mendel: an evolving view of human genetic disease transmission. *Nat Rev Genet* 3:779–789
- Badano JL, Kim JC, Hoskins BE, Lewis RA, Ansley SJ, Cutler DJ, Castellani C, Beales PL, Leroux MR, Katsanis N (2003) Heterozygous mutations in *BBS1*, *BBS2* and *BBS6* have a potential epistatic effect on Bardet–Biedl patients with two mutations at a second BBS locus. *Hum Mol Genet* 12:1651–1659
- Badano JL, Leitch CC, Ansley SJ, May-Simera H, Lawson S, Lewis RA, Beales PL, Dietz HC, Fisher S, Katsanis N (2006) Dissection of epistasis in oligogenic Bardet–Biedl syndrome. *Nature* 439:326–330
- Badenhop RF, Cherian S, Lord RS, Baysal BE, Taschner PE, Schofield PR (2001) Novel mutations in the *SDHD* gene in pedigrees with familial carotid body paraganglioma and sensorineural hearing loss. *Genes Chromosome Cancer* 31:255–263
- Balwani M, Fuerstman L, Kornreich R, Edelmann L, Desnick RJ (2010) Type I Gaucher disease: significant disease manifestations in “asymptomatic” homozygotes. *Arch Intern Med* 170:1463–1469
- Baradaran-Heravi A, Cho KS, Tolhuis B, Sanyal M, Morozova O, Morimoto M, Elizondo LI, Bridgewater D, Lubieniecka J, Beirnes K, Myung C, Leung D, Fam HK, Choi K, Huang Y, Dionis KY, Zonana J, Keller K, Stenzel P, Mayfield C, Lücke T, Bokenkamp A, Marra MA, van Lohuizen M, Lewis DB, Shaw C, Boerkoel CF (2012) Penetrance of biallelic *SMARCAL1* mutations is associated with environmental and genetic disturbances of gene expression. *Hum Mol Genet* 21:2572–2587
- Basel-Vanagaite L, Pelet A, Steiner Z, Munnich A, Rozenbach Y, Shohat M, Lyonnet S (2007) Allele dosage-dependent penetrance of *RET* proto-oncogene in an Israeli–Arab inbred family segregating Hirschsprung disease. *Eur J Hum Genet* 15:242–245
- Baysal BE, McKay SE, Kim YJ, Zhang Z, Alila L, Willett-Brozick JE, Pacak K, Kim TH, Shadel GS (2011) Genomic imprinting at a boundary element flanking the *SDHD* locus. *Hum Mol Genet* 20:4452–4461
- Beales PL, Badano JL, Ross AJ, Ansley SJ, Hoskins BE, Kirsten B, Mein CA, Froguel P, Scambler PJ, Lewis RA, Lupski JR, Katsanis N (2003) Genetic interaction of *BBS1* mutations with alleles at other BBS loci can result in non-Mendelian Bardet–Biedl syndrome. *Am J Hum Genet* 72:1187–1199
- Beckmann JS, Estivill X, Antonarakis SE (2007) Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. *Nat Rev Genet* 8:639–646
- Begg CB, Orlow I, Hummer AJ, Armstrong BK, Krickler A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M, Genes Environment and Melanoma Study Group (2005) Lifetime risk of melanoma in *CDKN2A* mutation carriers in a population-based sample. *J Natl Cancer Inst* 97:1507–1515
- Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, Sheth V, Woodward JE, Peckham HE, Schroth GP, Kim RW, Kingsmore SF (2011) Carrier testing for severe childhood recessive diseases by next-generation sequencing. *Sci Transl Med* 3:65ra
- Benlian P, de Gennes JL, Dairou F, Hermelin B, Ginon I, Villain E, Lagarde JP, Federspiel MC, Bertrand V, Bernard C, Bereziat G (1996) Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100. *Hum Mutat* 7:340–345
- Bennett CM, Boye E, Neufeld EJ (2008) Female monozygotic twins discordant for hemophilia A due to nonrandom X-chromosome inactivation. *Am J Hematol* 83:778–780
- Ben-Shachar S, Lanpher B, German JR, Qasaymeh M, Potocki L, Nagamani SC, Franco LM, Malphrus A, Bottenfield GW, Spence JE, Amato S, Rousseau JA, Moghaddam B, Skinner C, Skinner SA, Bernes S, Armstrong N, Shinawi M, Stankiewicz P, Patel A, Cheung SW, Lupski JR, Beaudet AL, Sahoo T (2009) Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. *J Med Genet* 46:382–388
- Berge KE, Haugaa KH, Früh A, Anfsen OG, Gjesdal K, Siem G, Oyen N, Greve G, Carlsson A, Rognum TO, Hallerud M, Kongsgård E, Amlie JP, Leren TP (2008) Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers. *Scand J Clin Lab Invest* 68:362–368
- Berlivet S, Moussette S, Ouimet M, Verlaan DJ, Koka V, Al Tuwaijri A, Kwan T, Sinnett D, Pastinen T, Naumova AK (2012) Interaction between genetic and epigenetic variation defines gene expression patterns at the asthma-associated locus 17q12-q21 in lymphoblastoid cell lines. *Hum Genet* 131:1161–1171
- Bernardi F, Legnani C, Micheletti F, Lunghi B, Ferraresi P, Palareti G, Biagi R, Marchetti G (1996) A heparin cofactor II mutation (HCII Rimini) combined with factor V Leiden or type I protein C deficiency in two unrelated thrombophilic subjects. *Thromb Haemost* 76:505–509
- Bernardi L, Anfossi M, Gallo M, Geracitano S, Cola R, Puccio G, Curcio SA, Frangipane F, Mirabelli M, Clodomiro A, Di Lorenzo R, Smirne N, Maletta R, Iapaolo D, Bruni AC (2011) *PSEN1* and *PRNP* gene mutations: co-occurrence makes onset very early in a family with FTD phenotype. *J Alzheimers Dis* 24:415–419
- Bertolini S, Pisciotto L, Rabacchi C, Cefalù AB, Noto D, Fasano T, Signori A, Fresa R, Averna M, Calandra S (2013) Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. *Atherosclerosis* 227:342–348
- Beutler E (2003) The *HFE* Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. *Blood* 101:3347–3350
- Bhuiyan ZA, Jongbloed JD, van der Smagt J, Lombardi PM, Wiesfeld AC, Nelen M, Schouten M, Jongbloed R, Cox MG, van Wolferen M, Rodriguez LM, van Gelder IC, Bikker H, Suurmeijer AJ, van den Berg MP, Mannens MM, Hauer RN, Wilde AA, van Tintelen JP (2009) Desmoglein-2 and desmocollin-2 mutations in Dutch arrhythmic right ventricular dysplasia/cardiomyopathy patients: results from a multicenter study. *Circ Cardiovasc Genet* 2:418–427
- Biegstraaten M, van Schaik IN, Aerts JM, Langeveld M, Mannens MM, Bour LJ, Sidransky E, Tayebi N, Fitzgibbon E, Hollak CE (2011) A monozygotic twin pair with highly discordant Gaucher phenotypes. *Blood Cells Mol Dis* 46:39–41
- Bisgaard H, Simpson A, Palmer CN, Bønnelykke K, McLean I, Mukhopadhyay S, Phipper CB, Halkjaer LB, Lipworth B, Hankinson J, Woodcock A, Custovic A (2008) Gene–environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. *PLoS Med* 5:e131

- Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA, Melanoma Genetics Consortium (2002) Geographical variation in the penetrance of *CDKN2A* mutations for melanoma. *J Natl Cancer Inst* 94:894–903
- Blair E, Price SJ, Baty CJ, Ostman-Smith I, Watkins H (2001) Mutations in *cis* can confound genotype-phenotype correlations in hypertrophic cardiomyopathy. *J Med Genet* 38:385–388
- Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria. *Lancet* 376:1417–1427
- Blom AM, Bergström F, Edey M, Diaz-Torres M, Kavanagh D, Lampe A, Goodship JA, Strain L, Moghal N, McHugh M, Inward C, Tomson C, Frémeaux-Bacchi V, Villoutreix BO, Goodship TH (2008) A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. *J Immunol* 180:6385–6391
- Boeve BF, Boylan KB, Graff-Radford NR, DeJesus-Hernandez M, Knopman DS, Pedraza O, Vemuri P, Jones D, Lowe V, Murray ME, Dickson DW, Josephs KA, Rush BK, Machulda MM, Fields JA, Ferman TJ, Baker M, Rutherford NJ, Adamson J, Wszolek ZK, Adeli A, Savica R, Boot B, Kuntz KM, Gavrilo R, Reeves A, Whitwell J, Kantarci K, Jack CR Jr, Parisi JE, Lucas JA, Petersen RC, Rademakers R (2012) Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in *C9ORF72*. *Brain* 135:765–783
- Boinot C, Borgel D, Kitzis A, Guicheteau M, Aiach M, Alhenc-Gelas M (2003) Familial thrombophilia is an oligogenetic disease: involvement of the prothrombin G20210A, *PROC* and *PROS* gene mutations. *Blood Coagul Fibrinolysis* 14:191–196
- Bökenkamp A, deJong M, van Wijk JA, Block D, van Hagen JM, Ludwig M (2005) R561C missense mutation in the *SMARCAL1* gene associated with mild Schimke immuno-osseous dysplasia. *Pediatr Nephrol* 20:1724–1728
- Bolk S, Pelet A, Hofstra RM, Angrist M, Salomon R, Croaker D, Buys CH, Lyonnet S, Chakravarti A (2000) A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the *RET* gene and a new 9q31 locus. *Proc Natl Acad Sci USA* 97:268–273
- Bolszak M, Anttonen AK, Komulainen T, Hinttala R, Pakanen S, Sormunen R, Herva R, Lehesjoki AE, Majamaa K, Rantala H, Uusimaa J (2009) Digenic mutations in severe myoclonic epilepsy of infancy. *Epilepsy Res* 85:300–304
- Borrello MG, Aiello A, Peissel B, Rizzetti MG, Mondellini P, Degl'Innocenti D, Catalano V, Gobbo M, Collini P, Bongarzone I, Pierotti MA, Greco A, Seregini E (2011) Functional characterization of the MTC-associated germline *RET*-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism. *Endocr Relat Cancer* 18:519–527
- Boyko AR, Williamson SH, Indap AR, Degenhardt JD, Hernandez RD, Lohmueller KE, Adams MD, Schmidt S, Sninsky JJ, Sunyaev SR, White TJ, Nielsen R, Clark AG, Bustamante CD (2008) Assessing the evolutionary impact of amino acid mutations in the human genome. *PLoS Genet* 4:e1000083
- Breckpot J, Thienpont B, Arens Y, Tranchevent LC, Vermeesch JR, Moreau Y, Gewillig M, Devriendt K (2011) Challenges of interpreting copy number variation in syndromic and non-syndromic congenital heart defects. *Cytogenet Genome Res* 135:251–259
- Bremner R, Du DC, Connolly-Wilson MJ, Bridge P, Ahmad KF, Mostachfi H, Rushlow D, Dunn JM, Gallie BL (1997) Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma. *Am J Hum Genet* 61:556–570
- Brennan P, Hainaut P, Boffetta P (2011) Genetics of lung-cancer susceptibility. *Lancet Oncol* 12:399–408
- Brenner B, Zivelin A, Lanir N, Greengard JS, Griffin JH, Seligsohn U (1996) Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. *Blood* 88:877–880
- Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party on Complement Genetics in Renal Diseases (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. *J Am Soc Nephrol* 24:475–486
- Bröer S, Bailey CG, Kowalczyk S, Ng C, Vanslambrouck JM, Rodgers H, Auray-Blais C, Cavanaugh JA, Bröer A, Rasko JE (2008) Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters. *J Clin Invest* 118:3881–3892
- Bruder CE, Piotrowski A, Gijbbers AA, Andersson R, Erickson S, Diaz de Ståhl T, Menzel U, Sandgren J, von Tell D, Poplawski A, Crowley M, Crasto C, Partridge EC, Tiwari H, Allison DB, Komorowski J, van Ommen GJ, Boomsma DI, Pedersen NL, den Dunnen JT, Wirdefeldt K, Dumanski JP (2008) Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. *Am J Hum Genet* 82:763–771
- Brugnoni R, Kapetis D, Imbrici P, Pessia M, Canioni E, Colleoni L, de Rosbo NK, Morandi L, Cudia P, Gashemi N, Bernasconi P, Desaphy JF, Conte D, Mantegazza R (2013) A large cohort of myotonia congenita probands: novel mutations and a high-frequency mutation region in exons 4 and 5 of the *CLCN1* gene. *J Hum Genet* (in press). doi:10.1038/jhg.2013.58
- Bullard JE, Noguee LM (2007) Heterozygosity for *ABCA3* mutations modifies the severity of lung disease associated with a surfactant protein C gene (*SFTPC*) mutation. *Pediatr Res* 62:176–179
- Buratti E, Brindisi A, Pagani F, Baralle FE (2004) Nuclear factor TDP-43 binds to the polymorphic TG repeats in *CFTR* intron 8 and causes skipping of exon 9: a functional link with disease penetrance. *Am J Hum Genet* 74:1322–1325
- Burdon KP, Wirth MG, Mackey DA, Russell-Eggitt IM, Craig JE, Elder JE, Dickinson JL, Sale MM (2004) A novel mutation in the Connexin 46 gene causes autosomal dominant congenital cataract with incomplete penetrance. *J Med Genet* 41:e106
- Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie YG (2003) Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. *Blood* 101:3037–3041
- Caciotti A, Bardelli T, Cunningham J, D'Azzo A, Zammarchi E, Morrone A (2003) Modulating action of the new polymorphism L436F detected in the *GLB1* gene of a type-II GM1 gangliosidosis patient. *Hum Genet* 113:44–50
- Cafolla A, D'Andrea G, Baldacci E, Margaglione M, Mazzucconi MG, Foà R (2012) Hereditary protein C deficiency and thrombosis risk: genotype and phenotype relation in a large Italian family. *Eur J Haematol* 88:336–339
- Caglayan AO, Demiryilmaz F, Ozyazgan I, Gumus H. (2010) *MEFV* gene compound heterozygous mutations in familial Mediterranean fever phenotype: a retrospective clinical and molecular study. *Nephrol Dial Transplant* 25:2520–2523
- Caleshu C, Sakhuja R, Nussbaum RL, Schiller NB, Ursell PC, Eng C, De Marco T, McGlothlin D, Burchard EG, Rame JE (2011) Furthering the link between the sarcomere and primary cardiomyopathies: restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated cardiomyopathy. *Am J Med Genet* 155A:2229–2235

- Camus D, Shinar Y, Amar S, Langevitz P, Ben-Zvi I, Livneh A, Lidar M (2012) ‘Silent’ carriage of two familial Mediterranean fever gene mutations in large families with only a single identified patient. *Clin Genet* 82:288–291
- Canto P, Munguía P, Söderlund D, Castro JJ, Méndez JP (2009) Genetic analysis in patients with Kallmann syndrome: coexistence of mutations in prokineticin receptor 2 and *KALI*. *J Androl* 30:41–45
- Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M, International Registry of Recurrent and Familial HUS/TTP (2003) Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. *Hum Mol Genet* 12:3385–3395
- Cardenas-Rodriguez M, Osborn DP, Irigoín F, Graña M, Romero H, Beales PL, Badano JL (2013) Characterization of *CCDC28B* reveals its role in ciliogenesis and provides insight to understand its modifier effect on Bardet–Biedl syndrome. *Hum Genet* 132:91–105
- Carvalho C, Bartnik M, Pehlivan D, Fang P, Shen J, Lupski J (2012) Evidence for disease penetrance relating to CNV size: pelizaeus-Merzbacher disease and manifesting carriers with a familial 11 Mb duplication at Xq22. *Clin Genet* 81:532–541
- Carvill GL, Mefford HC (2013) Microdeletion syndromes. *Curr Opin Genet Develop* 23:1–8
- Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the *5-HTT* gene. *Science* 301:386–389
- Castaman G, Federici AB, Rodeghiero F, Mannucci PM (2003) von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. *Haematologica* 88:94–108
- Castaman G, Bertonecello K, Bernardi M, Eikenboom JC, Budde U, Rodeghiero F (2007) Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2,908 del C) and the missense mutation C2362F: definite evidence for the non-penetrance of the C2362F mutation. *Am J Hematol* 82:376–380
- Castéra L, Sabbagh A, Dehainault C, Michaux D, Mansuet-Lupo A, Patillon B, Lamar E, Aerts I, Lumbroso-Le Rouic L, Couturier J, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C (2010) *MDM2* as a modifier gene in retinoblastoma. *J Natl Cancer Inst* 102:1805–1808
- Cerutti E, Campagnoli MF, Ferretti M, Garelli E, Crescenzo N, Rosolen A, Chiochetti A, Lenardo MJ, Ramenghi U, Dianzani U (2007) Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome. *BMC Immunol* 8:28
- Chang JC, Wang L, Chen RF, Liu CA (2012) Perinatal gene–gene and gene–environment interactions on IgE production and asthma development. *Clin Dev Immunol* 2012:270869
- Chapman SJ, Hill AV (2012) Human genetic susceptibility to infectious disease. *Nat Rev Genet* 13:175–188
- Chaudru V, Lo MT, Lesueur F, Marian C, Mohamdi H, Laud K, Barrois M, Chompret A, Avril MF, Demenais F, Bressac-de Paillerets B (2009) Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of *CDKN2A* mutations, *MC1R* variants and host-related phenotypes. *Fam Cancer* 8:371–377
- Chen S, Parmigiani G (2007) Meta-analysis of *BRCA1* and *BRCA2* penetrance. *J Clin Oncol* 25:1329–1333
- Chen J, Smaoui N, Hammer MB, Jiao X, Riazuddin SA, Harper S, Katsanis N, Riazuddin S, Chaabouni H, Berson EL, Hejtmancik JF (2011) Molecular analysis of Bardet–Biedl syndrome families: report of 21 novel mutations in 10 genes. *Invest Ophthalmol Vis Sci* 52:5317–5324
- Cheng J, Tester DJ, Tan BH, Valdivia CR, Kroboth S, Ye B, January CT, Ackerman MJ, Makielski JC (2011) The common African American polymorphism *SCN5A*-S1103Y interacts with mutation *SCN5A*-R680H to increase late Na current. *Physiol Genomics* 43:461–466
- Cheng WC, Shu WY, Li CY, Tsai ML, Chang CW, Chen CR, Cheng HT, Wang TH, Hsu IC (2012) Intra- and inter-individual variance of gene expression in clinical studies. *PLoS ONE* 7:e38650
- Cheung VG, Spielman RS (2009) Genetics of human gene expression: mapping DNA variants that influence gene expression. *Nat Rev Genet* 10:595–604
- Chhin B, Hatayama M, Bozon D, Ogawa M, Schön P, Tohmonda T, Sassolas F, Aruga J, Valard AG, Chen SC, Bouvagnet P (2007) Elucidation of penetrance variability of a *ZIC3* mutation in a family with complex heart defects and functional analysis of *ZIC3* mutations in the first zinc finger domain. *Hum Mutat* 28:563–570
- Chiang PW, Fulton AB, Spector E, Hisama FM (2008) Synergistic interaction of the *OCA2* and *OCA3* genes in a family. *Am J Med Genet* 146A:2427–2430
- Chiang PW, Spector E, McGregor TL (2009) Evidence suggesting digenic inheritance of Waardenburg syndrome type II with ocular albinism. *Am J Med Genet* 149A:2739–2744
- Chiba-Falek O, Kerem E, Shoshani T, Aviram M, Augarten A, Bentur L, Tal A, Tullis E, Rahat A, Kerem B (1998) The molecular basis of disease variability among cystic fibrosis patients carrying the 3,849 + 10 kb C→T mutation. *Genomics* 53:276–283
- Christodoulou K, Wiskin AE, Gibson J, Tapper W, Willis C, Afzal NA, Upstill-Goddard R, Holloway JW, Simpson MA, Beattie RM, Collins A, Ennis S (2013) Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes. *Gut* 62:977–984
- Chu K, Koller DL, Snyder R, Fishburn T, Lai D, Waguespack SG, Foroud T, Econs MJ (2005) Analysis of variation in expression of autosomal dominant osteopetrosis type 2: searching for modifier genes. *Bone* 37:655–661
- Chung KW, Sunwoo IN, Kim SM, Park KD, Kim WK, Kim TS, Koo H, Cho M, Lee J, Choi BO (2005) Two missense mutations of *EGR2* R359W and *GJB1* V136A in a Charcot-Marie-Tooth disease family. *Neurogenetics* 6:159–163
- Cigni A, Ledda F, Satta AE (2006) A complex case of renal amyloidosis with a rare co-occurrence of 2 mutations in separate hereditary periodic fever syndrome-related genes. *J Nephrol* 19:543–549
- Čiuladaitė Ž, Kasnauskienė J, Cimbalistienė L, Preikšaitienė E, Patsalis PC, Kučinskas V (2011) Mental retardation and autism associated with recurrent 16p11.2 microdeletion: incomplete penetrance and variable expressivity. *J Appl Genet* 52:443–449
- Clain J, Fritsch J, Lehmann-Che J, Bali M, Arous N, Goossens M, Edelman A, Fanen P (2001) Two mild cystic fibrosis-associated mutations result in severe cystic fibrosis when combined in cis and reveal a residue important for cystic fibrosis transmembrane conductance regulator processing and function. *J Biol Chem* 276:9045–9049
- Clementi R, Dagna L, Dianzani U, Dupré L, Dianzani I, Ponzoni M, Cometa A, Chiochetti A, Sabbadini MG, Rugarli C, Ciceri F, Maccario R, Locatelli F, Danesino C, Ferrarini M, Bregni M (2004) Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. *N Engl J Med* 351:1419–1424
- Cogan J, Austin E, Hedges L, Womack B, West J, Loyd J, Hamid R (2012) Role of *BMP2* alternative splicing in heritable

- pulmonary arterial hypertension penetrance. *Circulation* 126:1907–1916
- Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. *Science* 305:869–872
- Cohen W, Castelli C, Alessi MC, Aillaud MF, Bouvet S, Saut N, Brunet D, Barthet MC, Tregouet DA, Lavigne G, Morange PE (2012) ABO blood group and von Willebrand factor levels partially explained the incomplete penetrance of congenital thrombophilia. *Arterioscler Thromb Vasc Biol* 32:2021–2028
- Cole LW, Sidis Y, Zhang C, Quinton R, Plummer L, Pignatelli D, Hughes VA, Dwyer AA, Raivio T, Hayes FJ, Seminara SB, Huot C, Alos N, Speiser P, Takeshita A, Van Vliet G, Pearce S, Crowley WF Jr, Zhou QY, Pitteloud N (2008) Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. *J Clin Endocrinol Metab* 93:3551–3559
- Constantine CC, Anderson GJ, Vulpe CD, McLaren CE, Bahlo M, Yeap HL, Gertig DM, Osborne NJ, Bertalli NA, Beckman KB, Chen V, Matak P, McKie AT, Delatycki MB, Olynyk JK, English DR, Southey MC, Giles GG, Hopper JL, Allen KJ, Gurrin LC (2009) A novel association between a SNP in *CYBRD1* and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis. *Br J Haematol* 147:140–149
- Cooper DN, Chen JM, Ball EV, Howells K, Mort M, Phillips AD, Chuzhanova N, Krawczak M, Kehrer-Sawatzki H, Stenson PD (2010) Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics. *Hum Mutat* 31:631–655
- Cordeiro JM, Perez GJ, Schmitt N, Pfeiffer R, Nesterenko VV, Burashnikov E, Veltmann C, Borggreffe M, Wolpert C, Schimpf R, Antzelevitch C (2010) Overlapping LQT1 and LQT2 phenotype in a patient with long QT syndrome associated with loss-of-function variations in *KCNQ1* and *KCNH2*. *Can J Physiol Pharmacol* 88:1181–1190
- Cordell HJ (2009) Detecting gene–gene interactions that underlie human diseases. *Nat Rev Genet* 10:392–404
- Coventry A, Bull-Otterson LM, Liu X, Clark AG, Maxwell TJ, Crosby J, Hixson JE, Rea TJ, Muzny DM, Lewis LR, Wheeler DA, Sabo A, Lusk A, Lusk K, Weiss KG, Akbar H, Cree A, Hawes AC, Newsham I, Varghese RT, Villasana D, Gross S, Joshi V, Santibanez J, Morgan M, Chang K, Iv WH, Templeton AR, Boerwinkle E, Gibbs R, Sing CF (2010) Deep resequencing reveals excess rare recent variants consistent with explosive population growth. *Nat Commun* 1:131
- Cowley MJ, Cotsapas CJ, Williams RB, Chan EK, Pulvers JN, Liu MY, Luo OJ, Nott DJ, Little PF (2009) Intra- and inter-individual genetic differences in gene expression. *Mamm Genome* 20:281–295
- Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM, Vicentini A, Yang P, Roden DM, George AL Jr, Schwartz PJ (2005) *KCNH2*-K897T is a genetic modifier of latent congenital long-QT syndrome. *Circulation* 112:1251–1258
- Crotti L, Monti MC, Insolia R, Peljto A, Goosen A, Brink PA, Greenberg DA, Schwartz PJ, George AL Jr (2009) *NOS1AP* is a genetic modifier of the long-QT syndrome. *Circulation* 120:1657–1663
- Croxen R, Hatton C, Shelley C, Brydson M, Chauplannaz G, Oosterhuis H, Vincent A, Newsom-Davis J, Colquhoun D, Beeson D (2002) Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. *Neurology* 59:162–168
- Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FL, Mitra RD, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF, Graff-Radford NR, St. Jean P, Lawson M, Ehm MG, Mayeux R, Goate AM, NIA-LOAD/NCRAD Family Study Consortium (2012) Rare variants in *APP*, *PSEN1* and *PSEN2* increase risk for AD in late-onset Alzheimer’s disease families. *PLoS ONE* 7:e31039
- Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, Weber B, Moller P, Offit K, Kim-Sing C, Friedman E, Randall S, Pasini B, Ainsworth P, Gershoni-Baruch R, Foulkes WD, Klijn J, Tung N, Rennert G, Olopade O, Couch F, Wagner T, Olsson H, Sun P, Weitzel JN, Narod SA (2005) Effect of pregnancy as a risk factor for breast cancer in *BRCA1/BRCA2* mutation carriers. *Int J Cancer* 117:988–991
- Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen M, Droogmans G, Reynaert I, Goossens M, Nilius B, Cassiman JJ (1998) Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. *J Clin Invest* 101:487–496
- Custovic A, Marinho S, Simpson A (2012) Gene–environment interactions in the development of asthma and atopy. *Expert Rev Respir Med* 6:301–308
- Członkowska A, Gromadzka G, Chabik G (2009) Monozygotic female twins discordant for phenotype of Wilson’s disease. *Mov Disord* 24:1066–1069
- D’Angelo R, Esposito T, Calabrò M, Rinaldi C, Robledo R, Varriale B, Sidoti A (2013) *FMO3* allelic variants in Sicilian and Sardinian populations: trimethylaminuria and absence of fish-like body odor. *Gene* 515:410–415
- D’Onofrio M, Ambrosini A, Di Mambro A, Arisi I, Santorelli FM, Grieco GS, Nicoletti F, Nappi G, Pierelli F, Schoenen J, Buzzi MG (2009) The interplay of two single nucleotide polymorphisms in the *CACNA1A* gene may contribute to migraine susceptibility. *Neurosci Lett* 453:12–15
- Dabell MP, Rosenfeld JA, Bader P, Escobar LF, El-Khechen D, Vallee SE, Dinulos MB, Curry C, Fisher J, Tervo R, Hannibal MC, Siefkas K, Wyatt PR, Hughes L, Smith R, Ellingwood S, Lacassie Y, Stroud T, Farrell SA, Sanchez-Lara PA, Randolph LM, Niyazov D, Stevens CA, Schoonveld C, Skidmore D, MacKay S, Miles JH, Moodley M, Huillet A, Neill NJ, Ellison JW, Ballif BC, Shaffer LG (2013) Investigation of *NRXN1* deletions: clinical and molecular characterization. *Am J Med Genet A* 161:717–731
- Dächsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM, Huerta C, Ribacoba R, Blazquez M, Alvarez V, Farrer MJ (2006) Digenic parkinsonism: investigation of the synergistic effects of *PRKN* and *LRKK2*. *Neurosci Lett* 410:80–84
- Dalal D, James C, Devanagondi R, Tichnell C, Tucker A, Prakasa K, Spevak PJ, Bluemke DA, Abraham T, Russell SD, Calkins H, Judge DP (2006) Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *J Am Coll Cardiol* 48:1416–1424
- Daw EW, Chen SN, Czernuszewicz G, Lombardi R, Lu Y, Ma J, Roberts R, Shete S, Marian AJ (2007) Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. *Hum Mol Genet* 16:2463–2471
- De Cruz R, Horev L, Green J, Babay S, Sladden M, Zlotogorski A, Sinclair R (2012) A novel monilethrix mutation in coil 2A of *KRT86* causing autosomal dominant monilethrix with incomplete penetrance. *Br J Dermatol* 166(Suppl 2):20–26
- de la Chapelle A (2009) Genetic predisposition to human disease: allele-specific expression and low-penetrance regulatory loci. *Oncogene* 28:3345–3348
- De Luca A, Sarkozy A, Consoli F, Ferese R, Guida V, Dentici ML, Mingarelli R, Bellacchio E, Tuo G, Limongelli G, Digilio MC, Marino B, Dallapiccola B (2010) Familial transposition of the great arteries caused by multiple mutations in laterality genes. *Heart* 96:673–677
- de Pontual L, Pelet A, Clement-Ziza M, Trochet D, Antonarakis SE, Attie-Bitach T, Beales PL, Blouin JL, Dastot-Le Moal F, Dollfus

- H, Goossens M, Katsanis N, Touraine R, Feingold J, Munnich A, Lyonnet S, Amiel J (2007) Epistatic interactions with a common hypomorphic *RET* allele in syndromic Hirschsprung disease. *Hum Mutat* 28:790–796
- de Pontual L, Zaghloul NA, Thomas S, Davis EE, McGaughey DM, Dollfus H, Baumann C, Bessling SL, Babarit C, Pelet A, Gascue C, Beales P, Munnich A, Lyonnet S, Etchevers H, Attie-Bitach T, Badano JL, McCallion AS, Katsanis N, Amiel J (2009) Epistasis between *RET* and *BBS* mutations modulates enteric innervation and causes syndromic Hirschsprung disease. *Proc Natl Acad Sci USA* 106:13921–13926
- Deodoussis GV, Luo Y, Starremans P, Rossetti S, Ramos AJ, Cantiello HF, Katsareli E, Ziroyannis P, Lamnissou K, Harris PC, Zhou J (2008) Co-inheritance of a *PKDI* mutation and homozygous *PKD2* variant: a potential modifier in autosomal dominant polycystic kidney disease. *Eur J Clin Invest* 38:180–190
- Dekel B, Metsuyanin S, Goldstein N, Pode-Shakked N, Kovalski Y, Cohen Y, Davidovits M, Anikster Y (2008) Schimke immunosseous dysplasia: expression of *SMARCA1* in blood and kidney provides novel insight into disease phenotype. *Pediatr Res* 63:398–403
- Delauay J, Nouyrigat V, Proust A, Schischmanoff PO, Cynober T, Yvart J, Gaillard C, Danos O, Tchernia G (2004) Different impacts of alleles α LEPRA and α LELY as assessed versus a novel, virtually null allele of the *SPTA1* gene in *trans*. *Br J Haematol* 127:118–122
- Del-Castillo-Rueda A, Moreno-Carralero MI, Cuadrado-Grande N, Álvarez-Sala-Walther LA, Enríquez-de-Salamanca R, Méndez M, Morán-Jiménez MJ (2012) Mutations in the *HFE*, *TFR2*, and *SLC40A1* genes in patients with hemochromatosis. *Gene* 508:15–20
- Denecke J, Brune T, Feldhaus T, Robenek H, Kranz C, Auchus RJ, Agarwal AK, Marquardt T (2006) A homozygous *ZMPSTE24* null mutation in combination with a heterozygous mutation in the *LMNA* gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS. *Hum Mutat* 27:524–531
- Deugnier Y, Mosser J (2008) Modifying factors of the *HFE* hemochromatosis phenotype. *Expert Rev Gastroenterol Hepatol* 2:531–540
- Di Pierro E, Brancaloni V, Moriondo V, Besana V, Cappellini MD (2007) Co-existence of two functional mutations on the same allele of the human ferrochelatase gene in erythropoietic protoporphyria. *Clin Genet* 71:84–88
- Di WL, Hennekam RC, Callard RE, Harper JJ (2009) A heterozygous null mutation combined with the G1258A polymorphism of *SPINK5* causes impaired LEKTI function and abnormal expression of skin barrier proteins. *Br J Dermatol* 161:404–412
- Dibbens LM, Heron SE, Mulley JC (2007) A polygenic heterogeneity model for common epilepsies with complex genetics. *Genes Brain Behav* 6:593–597
- Dick DM (2011) Gene–environment interaction in psychological traits and disorders. *Annu Rev Clin Psychol* 7:383–409
- Dimas AS, Nica AC, Montgomery SB, Stranger BE, Raj T, Buil A, Giger T, Lappalainen T, Gutierrez-Arcelus M, MuTHER Consortium, McCarthy MI, Dermitzakis ET (2012) Sex-biased genetic effects on gene regulation in humans. *Genome Res* 22:2368–2375
- Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B; SWE-BRCA, Liljegen A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalin M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Cajal TR, Stavropoulou AV, Benítez J, Hamann U; HEBON, Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Gómez García EB, Hoogerbrugge N, Jager A, van der Luijt RB; EMBRACE, Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H; GEMO Study Collaborators, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Léoné M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys S, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tang MK, Gschwanter-Kaulich D, Fink-Retter A, Hansen TV, Ejlersten B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, DeMars LR, DiSilvestro P, Rodriguez G, Toland AE, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Ramus SJ, Sucheston L, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H, Aittomäki K, Simard J; KConFab Investigators, Spurdle AB, Beesley J, Chen X, Tomlinson GE, Weitzel J, Garber JE, Olopade OI, Rubinstein WS, Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor N, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H; OCGN, Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SL; Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). (2012) A nonsynonymous polymorphism in *IRS1* modifies risk of developing breast and ovarian cancers in *BRCA1* and ovarian cancer in *BRCA2* mutation carriers. *Cancer Epidemiol Biomarkers Prev* 21:1362–1370
- Dipple KM, McCabe ERB (2000) Modifier genes convert “simple” Mendelian disorders to complex traits. *Mol Genet Metab* 71:43–50
- Dobyns WB, Filauro A, Tomson BN, Chan AS, Ho AW, Ting NT, Oosterwijk JC, Ober C (2004) Inheritance of most X-linked traits is not dominant or recessive, just X-linked. *Am J Med Genet* 129A:136–143
- Dodé C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, Kottler ML, Lespinasse J, Lienhardt-Roussie A, Mathieu M, Moerman A, Morgan G, Murat A, Toublanc JE, Wolczynski S, Delpech M, Petit C, Young J, Hardelin JP (2006) Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. *PLoS Genet* 2:e175
- Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CH, Stewart PM (2003) Mutations in the genes encoding 11 β -hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. *Nat Genet* 34:434–439
- Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrach RJ, Dorfman R, Sandford AJ, Corey M, Zielinski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR, Gene Modifier Study Group (2005) Genetic modifiers of lung disease in cystic fibrosis. *N Engl J Med* 353:1443–1453
- Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC (2001) A study of Protein S antigen levels in 3,788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. *Br J Haematol* 113:636–641
- Ebermann I, Phillips JB, Liebau MC, Koenekoop RK, Schermer B, Lopez I, Schäfer E, Roux AF, Dafinger C, Bernd A, Zrenner E, Claustres M, Blanco B, Nürnberg G, Nürnberg P, Ruland R, Westerfeld M, Benzing T, Bolz HJ (2010) *PDZD7* is a modifier

- of retinal disease and a contributor to digenic Usher syndrome. *J Clin Invest* 120:1812–1823
- Eichers ER, Lewis RA, Katsanis N, Lupski JR (2004) Triallelic inheritance: a bridge between Mendelian and multifactorial traits. *Ann Med* 36:262–272
- Ekvall S, Hagenäs L, Allanson J, Annerén G, Bondeson ML (2011) Co-occurring *SHOC2* and *PTPN11* mutations in a patient with severe/complex Noonan syndrome-like phenotype. *Am J Med Genet* 155A:1217–1224
- El-Hattab AW, Zhang F, Maxim R, Christensen KM, Ward JC, Hines-Dowell S, Scaglia F, Lupski JR, Cheung SW (2010) Deletion and duplication of 15q24: molecular mechanisms and potential modification by additional copy number variants. *Genet Med* 12:573–586
- Elizondo LI, Cho KS, Zhang W, Yan J, Huang C, Huang Y, Choi K, Sloan EA, Deguchi K, Lou S, Baradaran-Heravi A, Takashima H, Lücke T, Quijcho FA, Boerkoel CF (2009) Schimke immuno-osseous dysplasia: *SMARCAL1* loss-of-function and phenotypic correlation. *J Med Genet* 46:49–59
- Emery AEH (1986) Risk estimation in autosomal dominant disorders with reduced penetrance. *J Med Genet* 23:316–318
- Emison ES, McCallion AS, Kashuk CS, Bush RT, Grice E, Lin S, Portnoy ME, Cutler DJ, Green ED, Chakravarti A (2005) A common sex-dependent mutation in a *RET* enhancer underlies Hirschsprung disease risk. *Nature* 434:857–863
- Emison ES, Garcia-Barcelo M, Grice EA, Lantieri F, Amiel J, Burzynski G, Fernandez RM, Hao L, Kashuk C, West K, Miao X, Tam PK, Griseri P, Ceccherini I, Pelet A, Jannot AS, de Pontual L, Henrion-Caude A, Lyonnet S, Verheij JB, Hofstra RM, Antiñolo G, Borrego S, McCallion AS, Chakravarti A (2010) Differential contributions of rare and common, coding and noncoding *Ret* mutations to multifactorial Hirschsprung disease liability. *Am J Hum Genet* 87:60–74
- Esparza-Gordillo J, Jorge EG, Garrido CA, Carreras L, López-Trascasa M, Sánchez-Corral P, de Córdoba SR (2006) Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. *Mol Immunol* 43:1769–1775
- Esteban Cardeñosa E, de Juan Jiménez I, Palanca Suela S, Chirivella González I, Segura Huerta A, Santaballa Beltran A, Casals El Busto M, Barragán González E, Fuster Lluch O, Bermúdez Edo J, Bolufer Gilabert P (2012) Low penetrance alleles as risk modifiers in familial and sporadic breast cancer. *Fam Cancer* 11:629–636
- Fahim AT, Bowne SJ, Sullivan LS, Webb KD, Williams JT, Wheaton DK, Birch DG, Daiger SP (2011) Allelic heterogeneity and genetic modifier loci contribute to clinical variation in males with X-linked retinitis pigmentosa due to *RPGR* mutations. *PLoS ONE* 6:e23021
- Fahrner JA, Frazier A, Bachir S, Walsh MF, Applegate CD, Thompson R, Halushka MK, Murphy AM, Gunay-Aygun M (2012) A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a *PTPN11* mutation and a novel variant in *SOS1*. *Am J Med Genet* 158A:1414–1421
- Fairley C, Zimran A, Phillips M, Cizmarik M, Yee J, Weinreb N, Packman S (2008) Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. *J Inher Metab Dis* 31:738–744
- Fan X, Yoshida Y, Honda S, Matsumoto M, Sawada Y, Hattori M, Hisanaga S, Hiwa R, Nakamura F, Tomomori M, Miyagawa S, Fujimaru R, Yamada H, Sawai T, Ikeda Y, Iwata N, Uemura O, Matsukuma E, Aizawa Y, Harada H, Wada H, Ishikawa E, Ashida A, Nangaku M, Miyata T, Fujimura Y (2013) Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. *Mol Immunol* 54:238–246
- Fauser S, Munz M, Besch D (2003) Further support for digenic inheritance in Bardet–Biedl syndrome. *J Med Genet* 40:e104
- Fearnhead NS, Wilding JL, Winney B, Tonks S, Bartlett S, Bicknell DC, Tomlinson IP, Mortensen NJ, Bodmer WF (2004) Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas. *Proc Natl Acad Sci USA* 101:15992–15997
- Fechtel K, Osterbur ML, Kehrer-Sawatzki H, Stenson PD, Cooper DN (2011) Delineating the Hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders. *Hum Genet* 130:149–166
- Felderbauer P, Hoffmann P, Einwächter H, Bulut K, Ansorge N, Schmitz F, Schmidt WE (2003) A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous *SPINK1* mutations. *BMC Gastroenterol* 3:34
- Fencel F, Malina M, Stará V, Zieg J, Mixová D, Seeman T, Bláhová K (2012) Discordant expression of a new *WT1* gene mutation in a family with monozygotic twins presenting with congenital nephrotic syndrome. *Eur J Pediatr* 171:121–124
- Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus-Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L, Crook J, Finger E, Hantanpaa KJ, Karydas AM, Sengdy P, Gonzalez J, Seeley WW, Johnson N, Beach TG, Mesulam M, Forloni G, Kertesz A, Knopman DS, Uitti R, White CL 3rd, Caselli R, Lippa C, Bigio EH, Wszolek ZK, Binetti G, Mackenzie IR, Miller BL, Boeve BF, Younkin SG, Dickson DW, Petersen RC, Graff-Radford NR, Geschwind DH, Rademakers R (2011) *TMEM106B* regulates progranulin levels and the penetrance of FTLD in *GRN* mutation carriers. *Neurology* 76:467–474
- Flanagan SE, Xie W, Caswell R, Damhuis A, Vianey-Saban C, Akcay T, Darendeliler F, Bas F, Guven A, Siklar Z, Ocal G, Berberoglu M, Murphy N, O’Sullivan M, Green A, Clayton PE, Banerjee I, Clayton PT, Hussain K, Weedon MN, Ellard S (2013) Next-generation sequencing reveals deep intronic cryptic *ABCC8* and *HADH* splicing founder mutations causing hyperinsulinism by pseudoexon activation. *Am J Hum Genet* 92:131–136
- Floeth M, Bruckner-Tuderman L (1999) Digenic junctional epidermolysis bullosa: mutations in *COL17A1* and *LAMB3* genes. *Am J Hum Genet* 65:1530–1537
- Font-Llitjós M, Jiménez-Vidal M, Bisceglia L, Di Perna M, de Sanctis L, Rousaud F, Zelante L, Palacín M, Nunes V (2005) New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. *J Med Genet* 42:58–68
- Forlani G, Zucchini S, Di Rocco A, Di Luzio R, Scipione M, Marasco E, Romeo G, Marchesini G, Mantovani V (2010) Double heterozygous mutations involving both *HNF1A/MODY3* and *HNF4A/MODY1* genes: a case report. *Diabetes Care* 33:2336–2338
- Formstone CJ, Hallam PJ, Tuddenham EG, Voke J, Layton M, Nicolaides K, Hann IM, Cooper DN (1996) Severe perinatal thrombosis in double and triple heterozygous offspring of a family segregating two independent protein S mutations and a protein C mutation. *Blood* 87:3731–3737
- Franchini M, Mannucci PM (2009) Multiple gene interaction and modulation of hemostatic balance. *Clin Chem Lab Med* 47:1455–1460
- Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SP, Toledo RA, Tavares MR, Alevizaki M, Mian C, Siggelkow H, Hüfner M, Wohlk N, Opocher G, Dvořáková S, Bendlova B, Czetwertynska M, Skasko E, Barontini M, Sanso G, Vorländer C, Maia AL, Patocs A, Links TP, de Groot JW, Kerstens MN, Valk GD, Miehle K, Musholt TJ, Biarnes J, Damjanovic S, Muresan M, Wüster C, Fassnacht M, Peczkowska

- M, Fauth C, Golcher H, Walter MA, Pichl J, Raue F, Eng C, Neumann HP, International RET Exon 10 Consortium (2011) Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline *RET* mutations located in exon 10. *Hum Mutat* 32:51–58
- Friedrich FW, Bausero P, Sun Y, Treszl A, Krämer E, Juhr D, Richard P, Wegscheider K, Schwartz K, Brito D, Arbustini E, Waldenström A, Isnard R, Komajda M, Eschenhagen T, Carrier L, EUROGENE Heart Failure Project (2009) A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. *Eur Heart J* 30:1648–1655
- Friedrich K, Rupp C, Hov JR, Steinebrunner N, Weiss K-H, Stiehl A, Brune M, Schaefer PKY, Schemmer P, Sauer P, Schirmacher P, Runz H, Karlsen TH, Stremmel W, Gotthardt DN (2013) A frequent *PNPLA3* variant is a sex specific disease modifier in PSC patients with bile duct stenosis. *PLoS ONE* 8:e58734
- Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, Gabriel S, Altshuler D, Shendure J, Nickerson DA, Bamshad MJ, NHLBI Exome Sequencing Project, Akey JM (2013) Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. *Nature* 493:216–220
- Fujita-Jimbo E, Yu ZL, Li H, Yamagata T, Mori M, Momoi T, Momoi MY (2012) Mutation in Parkinson disease-associated, G-protein-coupled receptor 37 (*GPR37/PaelR*) is related to Autism spectrum disorder. *PLoS ONE* 7:e51155
- Funayama M, Li Y, Tsoi TH, Lam CW, Ohi T, Yazawa S, Uyama E, Djaldetti R, Melamed E, Yoshino H, Imamichi Y, Takashima H, Nishioka K, Sato K, Tomiyama H, Kubo S, Mizuno Y, Hattori N (2008) Familial Parkinsonism with digenic parkin and *PINK1* mutations. *Mov Disord* 23:1461–1465
- Furukawa Y, Lang AE, Trugman JM, Bird TD, Hunter A, Sadeh M, Tagawa T, St George-Hyslop PH, Guttman M, Morris LW, Hornykiewicz O, Shimadzu M, Kish SJ (1998) Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. *Neurology* 50:1015–1020
- Galassi G, Lamantea E, Invernizzi F, Tavani F, Pisano I, Ferrero I, Palmieri L, Zeviani M (2008) Additive effects of *POLG1* and *ANT1* mutations in a complex encephalomyopathy. *Neuromuscul Disord* 18:465–470
- Galetzka D, Hansmann T, El Hajj N, Weis E, Irmscher B, Ludwig M, Schneider-Rätzke B, Kohlschmidt N, Beyer V, Bartsch O, Zechner U, Spix C, Haaf T (2012) Monozygotic twins discordant for constitutive *BRCA1* promoter methylation, childhood cancer and secondary cancer. *Epigenetics* 7:47–54
- Galvan A, Dragan TA (2009) Nicotine dependence may link the 15q25 locus to lung cancer risk. *Carcinogenesis* 31:331–333
- Gámez-Pozo A, Palacios I, Kontic M, Menéndez I, Camino I, García-Miguel P, Abelairas J, Pestaña A, Alonso J (2007) Pathogenic validation of unique germline intronic variants of *RBI* in retinoblastoma patients using minigenes. *Hum Mutat* 28:1245
- Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M (1995) Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. *Blood* 86:219–224
- Gan-Or Z, Bar-Shira A, Gurevich T, Giladi N, Orr-Urtreger A (2011) Homozygosity for the *MTX1* c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease. *Neurogenetics* 12:325–332
- Garcia-Barcelo MM, Tang CS, Ngan ES, Lui VC, Chen Y, So MT, Leon TY, Miao XP, Shum CK, Liu FQ, Yeung MY, Yuan ZW, Guo WH, Liu L, Sun XB, Huang LM, Tou JF, Song YQ, Chan D, Cheung KM, Wong KK, Cherny SS, Sham PC, Tam PK (2009) Genome-wide association study identifies *NRG1* as a susceptibility locus for Hirschsprung's disease. *Proc Natl Acad Sci USA* 106:2694–2699
- García-García AB, Ivorra C, Martínez-Hervas S, Blesa S, Fuentes MJ, Puig O, Martín-de-Llano JJ, Carmena R, Real JT, Chaves FJ (2011) Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family. *Atherosclerosis* 218:423–430
- Gasparini P, Rabionet R, Barbujani G, Melchionda S, Petersen M, Brøndum-Nielsen K, Metspalu A, Oitmaa E, Pisano M, Fortina P, Zelante L, Estivill X (2000) High carrier frequency of the 35delG deafness mutation in European populations. Genetic Analysis Consortium of *GJB2* 35delG. *Eur J Hum Genet* 8:19–23
- Gau SS, Liao HM, Hong CC, Chien WH, Chen CH (2012) Identification of two inherited copy number variants in a male with autism supports two-hit and compound heterozygosity models of autism. *Am J Med Genet B Neuropsychiatr Genet* 159B:710–717
- Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE (2001) Increased efficiency of mRNA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia. *Nat Genet* 28:389–392
- Genuardi M, Klutz M, Devriendt K, Caruso D, Stirpe M, Lohmann DR (2001) Multiple lipomas linked to an *RBI* gene mutation in a large pedigree with low penetrance retinoblastoma. *Eur J Hum Genet* 9:690–694
- Germeshausen M, Zeidler C, Stuhmann M, Lanciotti M, Ballmaier M, Welte K (2010) Digenic mutations in severe congenital neutropenia. *Haematologica* 95:1207–1210
- Gershoni-Baruch R, Brik R, Shinawi M, Livneh A (2002) The differential contribution of *MEFV* mutant alleles to the clinical profile of familial Mediterranean fever. *Eur J Hum Genet* 10:145–149
- Geyer O, Wolf A, Levinger E, Harari-Shacham A, Walton DS, Shochat C, Korem S, Bercovich D (2011) Genotype/phenotype correlation in primary congenital glaucoma patients from different ethnic groups of the Israeli population. *Am J Ophthalmol* 151:263–271
- Gherasim C, Rosenblatt DS, Banerjee R (2007) Polymorphic background of methionine synthase reductase modulates the phenotype of a disease-causing mutation. *Hum Mutat* 28:1028–1033
- Gianfrancesco F, Rendina D, Di Stefano M, Mingione A, Esposito T, Merlotti D, Gallone S, Magliocca S, Goode A, Formicola D, Morello G, Layfield R, Frattini A, De Filippo G, Nuti R, Searle M, Strazzullo P, Isaia G, Mossetti G, Gennari L (2012) A nonsynonymous *TNFRSF11A* variation increases NFκB activity and the severity of Paget's disease. *J Bone Miner Res* 27:443–452
- Giess R, Holtmann B, Braga M, Grimm T, Müller-Myhsok B, Toyka KV, Sendtner M (2002) Early onset of severe familial amyotrophic lateral sclerosis with a *SOD1* mutation: potential impact of *CNTF* as a candidate modifier gene. *Am J Hum Genet* 70:1277–1286
- Gillespie CF, Almli LM, Smith AK, Bradley B, Kerley K, Crain DF, Mercer KB, Weiss T, Phifer J, Tang Y, Cubells JF, Binder EB, Conneely KN, Ressler KJ (2013) Sex dependent influence of a functional polymorphism in steroid 5- α -reductase type 2 (*SRD5A2*) on post-traumatic stress symptoms. *Am J Med Genet B Neuropsychiatr Genet* 162:283–292
- Ginolhac SM, Gad S, Corbex M, Bressac-De-Paillerets B, Chompret A, Bignon YJ, Peyrat JP, Fournier J, Lasset C, Giraud S, Muller D, Fricker JP, Hardouin A, Berthet P, Maugard C, Nogues C, Lidereau R, Longy M, Olschwang S, Toulas C, Guimbaud R, Yannoukakos D, Szabo C, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch HT, Goldgar D, Stoppa-Lyonnet D, Lenoir

- GM, Sinilnikova OM (2003) *BRCA1* wild-type allele modifies risk of ovarian cancer in carriers of *BRCA1* germ-line mutations. *Cancer Epidemiol Biomarkers Prev* 12:90–95
- Giráldez MD, Balaguer F, Caldés T, Sanchez-de-Abajo A, Gómez-Fernández N, Ruiz-Ponte C, Muñoz J, Garre P, Gonzalo V, Moreira L, Ocaña T, Clofent J, Carracedo A, Andreu M, Jover R, Llor X, Castells A, Castellví-Bel S, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association (2009) Association of *MUTYH* and *MSH6* germline mutations in colorectal cancer patients. *Fam Cancer* 8:525–531
- Girirajan S, Rosenfeld JA, Coe BP, Parikh S, Friedman N, Goldstein A, Filipink RA, McConnell JS, Angle B, Meschino WS, Nezarati MM, Asamoah A, Jackson KE, Gowans GC, Martin JA, Carmany EP, Stockton DW, Schnur RE, Penney LS, Martin DM, Raskin S, Leppig K, Thiess H, Smith R, Aberg E, Niyazov DM, Escobar LF, El-Khechen D, Johnson KD, Lebel RR, Siefkas K, Ball S, Shur N, McGuire M, Brasington CK, Spence JE, Martin LS, Clericuzio C, Ballif BC, Shaffer LG, Eichler EE (2012) Phenotypic heterogeneity of genomic disorders and rare copy-number variants. *N Engl J Med* 367:1321–1331
- Girolami F, Ho CY, Semsarian C, Baldi M, Will ML, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman MJ, Olivetto I (2010) Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. *J Am Coll Cardiol* 55:1444–1453
- Giudicessi JR, Ackerman MJ (2013) Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. *Transl Res* 161:1–14
- Golbus JR, Puckelwartz MJ, Fahrenbach JP, Dellefave-Castillo LM, Wolfgeher D, McNally EM (2012) Population-based variation in cardiomyopathy genes. *Circ Cardiovasc Genet* 5:391–399
- Goldfarb LG, Petersen RB, Tabaton M, Brown P, LeBlanc AC, Montagna P, Cortelli P, Julien J, Vital C, Pendelbury WW (1992) Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. *Science* 258:806–808
- Goode DL, Cooper GM, Schmutz J, Dickson M, Gonzales E, Tsai M, Karra K, Davydov E, Batzoglu S, Myers RM, Sidow A (2010) Evolutionary constraint facilitates interpretation of genetic variation in resequenced human genomes. *Genome Res* 20:301–310
- Goodin DS (2012) The genetic and environmental bases of complex human-disease: extending the utility of twin-studies. *PLoS ONE* 7:e47875
- Gordon L, Joo JH, Andronikos R, Ollikainen M, Wallace EM, Umstad MP, Permezel M, Oshlack A, Morley R, Carlin JB, Saffery R, Smyth GK, Craig JM (2011) Expression discordance of monozygotic twins at birth: effect of intrauterine environment and a possible mechanism for fetal programming. *Epigenetics* 6:579–592
- Gordon L, Joo JE, Powell JE, Ollikainen M, Novakovic B, Li X, Andronikos R, Cruickshank MN, Conneely KN, Smith AK, Alisch RS, Morley R, Visscher PM, Craig JM, Saffery R (2012) Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence. *Genome Res* 22:1395–1406
- Gorlov IP, Gorlova OY, Frazier ML, Spitz MR, Amos CI (2011) Evolutionary evidence of the effect of rare variants on disease etiology. *Clin Genet* 79:199–206
- Gouya L, Puy H, Lamoril J, Da Silva V, Grandchamp B, Nordmann Y, Deybach JC (1999) Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. *Blood* 93:2105–2110
- Gouya L, Puy H, Robreau AM, Bourgeois M, Lamoril J, Da Silva V, Grandchamp B, Deybach JC (2002) The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype *FECH*. *Nat Genet* 30:27–28
- Gouya L, Martin-Schmitt C, Robreau AM, Austerlitz F, Da Silva V, Brun P, Simonin S, Lyoumi S, Grandchamp B, Beaumont C, Puy H, Deybach JC (2006) Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. *Am J Hum Genet* 78:2–14
- Grabowski M, Zimprich A, Lorenz-Depiereux B, Kalscheuer V, Asmus F, Gasser T, Meitinger T, Strom TM (2003) The epsilon-sarcoglycan gene (*SGCE*), mutated in myoclonus-dystonia syndrome, is maternally imprinted. *Eur J Hum Genet* 11:138–144
- Gracia-Aznarez FJ, Fernandez V, Pita G, Peterlongo P, Dominguez O, de la Hoya M, Duran M, Osorio A, Moreno L, Gonzalez-Neira A, Rosa-Rosa JM, Sinilnikova O, Mazoyer S, Hopper J, Lazaro C, Southey M, Odefrey F, Manoukian S, Catucci I, Caldes T, Lynch HT, Hilbers FSM, van Asperen CJ, Vasen HFA, Golgar D, Radice P, Devilee P, Benitez J (2013) Whole exome sequencing suggests much of non-*BRCA1/BRCA2* familial breast cancer is due to moderate and low penetrance susceptibility alleles. *PLoS ONE* 8:e55681
- Granados-Riveron JT, Pope M, Bu'lock FA, Thornborough C, Eason J, Setchfield K, Ketley A, Kirk EP, Fatkin D, Feneley MP, Harvey RP, Brook JD (2012) Combined mutation screening of *NKX2-5*, *GATA4*, and *TBX5* in congenital heart disease: multiple heterozygosity and novel mutations. *Congenit Heart Dis* 7:151–159
- Grocock CJ, Rebours V, Delhaye MN, André-Sandberg A, Weiss FU, Mountford R, Harcus MJ, Niemczyk E, Vitone LJ, Dodd S, Jørgensen MT, Ammann RW, Schaffalitzky de Muckadell O, Butler JV, Burgess P, Kerr B, Charnley R, Sutton R, Raraty MG, Devière J, Whitcomb DC, Neoptolemos JP, Lévy P, Lerch MM, Greenhalf W, European Registry of Hereditary Pancreatitis and Pancreatic Cancer (2010) The variable phenotype of the p.A16 V mutation of cationic trypsinogen (*PRSS1*) in pancreatitis families. *Gut* 59:357–363
- Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Des Georges M, Guittard C, Koudova M, Fallin MD, Nemeth K, Fekete G, Kadasi L, Friedman K, Schwarz M, Bombieri C, Pignatti PF, Kanavakis E, Tzetzis M, Schwartz M, Novelli G, D'Apice MR, Sobczynska-Tomaszewska A, Bal J, Stuhmann M, Macek M Jr, Claustres M, Cutting GR (2004) Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. *Am J Hum Genet* 74:176–179
- Gros-Louis F, Andersen PM, Dupre N, Urushitani M, Dion P, Souchon F, D'Amour M, Camu W, Meininger V, Bouchard JP, Rouleau GA, Julien JP (2009) Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA* 106:21777–21782
- Gruber R, Wilson NJ, Smith FJ, Grabher D, Steinwender L, Fritsch PO, Schmutz M (2009) Increased pachyonychia congenita severity in patients with concurrent keratin and filaggrin mutations. *Br J Dermatol* 161:1391–1395
- Grundberg E, Small KS, Hedman ÅK, Nica AC, Buil A, Keildson S, Bell JT, Yang TP, Meduri E, Barrett A, Nisbett J, Sekowska M, Wilk A, Shin SY, Glass D, Travers M, Min JL, Ring S, Ho K, Thorleifsson G, Kong A, Thorsteindottir U, Ainali C, Dimas AS, Hassanali N, Ingle C, Knowles D, Krestyaninova M, Lowe CE, Di Meglio P, Montgomery SB, Parts L, Potter S, Surdulescu G, Tsaprouni L, Tsoka S, Bataille V, Durbin R, Nestle FO, O'Rahilly S, Soranzo N, Lindgren CM, Zondervan KT, Ahmadi KR, Schadt EE, Stefansson K, Smith GD, McCarthy MI, Deloukas P, Dermitzakis ET, Spector TD, Multiple Tissue Human Expression Resource (MuTHER) Consortium (2012) Mapping *cis*- and *trans*-regulatory effects across multiple tissues in twins. *Nat Genet* 44:1084–1089

- Grundy CB, Melissari E, Lindo V, Scully MF, Kakkar VV, Cooper DN (1991) Late-onset homozygous protein C deficiency. *Lancet* 338:575–576
- Guerrero R, Vernia S, Sanz R, Abreu-Rodríguez I, Almaraz C, García-Hoyos M, Michelucci R, Tassinari CA, Riguzzi P, Nobile C, Sanz P, Serratos JM, Gómez-Garre P (2011) A PTG variant contributes to a milder phenotype in Lafora disease. *PLoS ONE* 6:e21294
- Gui J, Wang T, Trump D, Zimmer T, Lei M (2010) Mutation-specific effects of polymorphism H558R in *SCN5A*-related sick sinus syndrome. *J Cardiovasc Electrophysiol* 21:564–573
- Hamid R, Cogan JD, Hedges LK, Austin E, Phillips JA 3rd, Newman JH, Loyd JE (2009a) Penetrance of pulmonary arterial hypertension is modulated by the expression of normal *BMPR2* allele. *Hum Mutat* 30:649–654
- Hamid R, Phillips JA 3rd, Holladay C, Cogan JD, Austin ED, Backeljauw PF, Travers SH, Patton JG (2009b) A molecular basis for variation in clinical severity of isolated growth hormone deficiency type II. *J Clin Endocrinol Metab* 94:4728–4734
- Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM, Tenesa A, Kusel VI, Sheehan P, Eaaswarkhanth M, Yearout D, Samii A, Roberts JW, Agarwal P, Bordelon Y, Park Y, Wang L, Gao J, Vance JM, Kendler KS, Bacanu SA, Scott WK, Ritz B, Nutt J, Factor SA, Zabetian CP, Payami H (2011) Genome-wide gene–environment study identifies glutamate receptor gene *GRIN2A* as a Parkinson's disease modifier gene via interaction with coffee. *PLoS Genet* 7:e1002237
- Harada Y, Sutomo R, Sadewa AH, Akutsu T, Takeshima Y, Wada H, Matsuo M, Nishio H (2002) Correlation between *SMN2* copy number and clinical phenotype of spinal muscular atrophy: three *SMN2* copies fail to rescue some patients from the disease severity. *J Neurol* 249:1211–1219
- Harbour JW (2001) Molecular basis of low-penetrance retinoblastoma. *Arch Ophthalmol* 119:1699–1704
- Harlid S, Ivarsson MI, Butt S, Grzybowska E, Eyfjörd JE, Lenner P, Försti A, Hemminki K, Manjer J, Dillner J, Carlson J (2012) Combined effect of low-penetrant SNPs on breast cancer risk. *Br J Cancer* 106:389–396
- Harries LW, Locke JM, Shields B, Hanley NA, Hanley KP, Steele A, Njølstad PR, Ellard S, Hattersley AT (2008) The diabetic phenotype in *HNF4A* mutation carriers is moderated by the expression of *HNF4A* isoforms from the P1 promoter during fetal development. *Diabetes* 57:1745–1752
- Hayashida M, Yamada H, Yamazaki S, Nomura H, Yoshimura K, Kitahara O, Momose K, Kubo K, Kurihara M, Hamasaki N (2003) Combined protein C and protein S deficiency in a family with repetitive thromboembolism and segregated gene mutations. *Intern Med* 42:268–272
- Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW, International LRRK2 Consortium (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol* 7:583–590
- Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, Niederacher D, Goecke TO, Doelken SC, Dikow N, Jonat W, Morlot S, Schmutzler RC, Arnold NK (2012) Double heterozygosity for mutations in *BRCA1* and *BRCA2* in German breast cancer patients: implications on test strategies and clinical management. *Breast Cancer Res Treat* 134:1229–1239
- Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V (2008) Heterogeneity of penetrance in familial amyloid polyneuropathy. *ATTR Val30Met*, in the Swedish population. *Amyloid* 15:181–186
- Hensen EF, Jansen JC, Siemers MD, Oosterwijk JC, Vriends AH, Corssmit EP, Bayley JP, van der Mey AG, Cornelisse CJ, Devilee P (2010) The Dutch founder mutation *SDHD.D92Y* shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. *Eur J Hum Genet* 18:62–66
- Hes FJ, Weiss MM, Woortman SA, de Miranda NF, van Bunderen PA, Bonsing BA, Stokkel MP, Morreau H, Romijn JA, Jansen JC, Vriends AH, Bayley JP, Corssmit EP (2010) Low penetrance of a *SDHB* mutation in a large Dutch paraganglioma family. *BMC Med Genet* 11:92
- Hidalgo-Bravo A, Pompa-Mera EN, Kofman-Alfaro S, Gonzalez-Bonilla CR, Zenteno JC (2005) A novel filamin A D203Y mutation in a female patient with otopalatodigital type I syndrome and extremely skewed X chromosome inactivation. *Am J Med Genet A* 136:190–193
- Hirose Y, Chiba K, Karasugi T, Nakajima M, Kawaguchi Y, Mikami Y, Furuichi T, Mio F, Miyake A, Miyamoto T, Ozaki K, Takahashi A, Mizuta H, Kubo T, Kimura T, Tanaka T, Toyama Y, Ikegawa S (2008) A functional polymorphism in *THBS2* that affects alternative splicing and MMP binding is associated with lumbar-disc herniation. *Am J Hum Genet* 82:1122–1129
- Hmani-Aifa M, Benzina Z, Zulfiqar F, Dhoub H, Shahzadi A, Ghorbel A, Rebaï A, Söderkvist P, Riazuddin S, Kimberling WJ, Ayadi H (2009) Identification of two new mutations in the *GPR98* and the *PDE6B* genes segregating in a Tunisian family. *Eur J Hum Genet* 17:474–482
- Ho YY, Ionita-Laza I, Ottman R (2012) Domain-dependent clustering and genotype-phenotype analysis of *LGII* mutations in AD-PEAF. *Neurology* 78:563–568
- Hodapp JA, Carter GT, Lipe HP, Michelson SJ, Kraft GH, Bird TD (2006) Double trouble in hereditary neuropathy: concomitant mutations in the *PMP-22* gene and another gene produce novel phenotypes. *Arch Neurol* 63:112–117
- Hoefele J, Wolf MT, O'Toole JF, Otto EA, Schultheiss U, Dêschenes G, Attanasio M, Utsch B, Antignac C, Hildebrandt F (2007) Evidence of oligogenic inheritance in nephronophthisis. *J Am Soc Nephrol* 18:2789–2795
- Hoffmann F, Lohse P, Stojanov S, Shin YS, Renner ED, Kéry A, Zellerer S, Belohradsky BH (2005) Identification of a novel mevalonate kinase gene mutation in combination with the common *MVK V377I* substitution and the low-penetrance *TNFRSF1A R92Q* mutation. *Eur J Hum Genet* 13:510–512
- Holmgren G, Wikström L, Lundgren HE, Suhr OB (2004) Discordant penetrance of the trait for familial amyloidotic polyneuropathy in two pairs of monozygotic twins. *J Intern Med* 256:453–456
- Horowitz M, Pasmanik-Chor M, Borochoy Z, Falik-Zaccai T, Heldmann K, Carmi R, Parvari R, Beit-Or H, Goldman B, Peleg L, Levy-Lahad E, Renbaum P, Legum S, Shomrat R, Yeger H, Benbenisti D, Navon R, Dror V, Shohat M, Magal N, Navot N, Eyal N (1998) Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. *Hum Mutat* 12:240–244
- Hosak L, Silhan P, Hosakova J (2012) Genomic copy number variations: a breakthrough in our knowledge on schizophrenia etiology? *Neuro Endocrinol Lett* 33:183–190
- Houlston RS, Peto J (2004) The search for low-penetrance cancer susceptibility alleles. *Oncogene* 23:6471–6476
- Hsiao TL, Vitkup D (2008) Role of duplicate genes in robustness against deleterious human mutations. *PLoS Genet* 4:e1000014
- Hu Z, Jin F, Wang L, Chen F, Wang X, Shen H (2007) *MDM2* promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. *Cancer Epidemiol Biomarkers Prev* 16:2717–2723

- Hu RM, Tan BH, Orland KM, Valdivia CR, Peterson A, Pu J, Makielski JC (2013) Digenic inheritance novel mutations in *SCN5A* and *SNTA1* increase late INa contributing to LQT syndrome. *Am J Physiol Heart Circ Physiol* 304:H994–H1001
- Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA (1997) The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. *Arterioscler Thromb Vasc Biol* 17:2825–2829
- Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpén F, Elvestad MB, Hveem K, Vatten L, Linseisen J, Clavel-Chapelon F, Vineis P, Bueno-de-Mesquita HB, Lund E, Martínez C, Bingham S, Rasmuson T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Lagiou P, Trichopoulos D, Holcátová I, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway DI, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature* 452:633–637
- Hung CC, Lin SY, Lee CN, Chen CP, Lin SP, Chao MC, Chiou SS, Su YN (2011) Low penetrance of retinoblastoma for p.V654L mutation of the *RBI* gene. *BMC Med Genet* 12:76
- Hunter DJ (2005) Gene–environment interactions in human diseases. *Nat Rev Genet* 6:287–298
- Huntington Study Group COHORT Investigators (2012) Characterization of a large group of individuals with Huntington disease and their relatives enrolled in the COHORT study. *PLoS ONE* 7:e29522
- Hutchinson S, Furger A, Halliday D, Judge DP, Jefferson A, Dietz HC, Firth H, Handford PA (2003) Allelic variation in normal human *FBNI* expression in a family with Marfan syndrome: a potential modifier of phenotype? *Hum Mol Genet* 12:2269–2276
- Hutter CM, Chang-Claude J, Slattery ML, Pflugeisen BM, Lin Y, Duggan D, Nan H, Lemire M, Rangrej J, Figueiredo JC, Jiao S, Harrison TA, Liu Y, Chen LS, Stelling DL, Warnick GS, Hoffmeister M, Küry S, Fuchs CS, Giovannucci E, Hazra A, Kraft P, Hunter DJ, Gallinger S, Zanke BW, Brenner H, Frank B, Ma J, Ulrich CM, White E, Newcomb PA, Kooperberg C, LaCroix AZ, Prentice RL, Jackson RD, Schoen RE, Chanock SJ, Berndt SI, Hayes RB, Caan BJ, Potter JD, Hsu L, Bézieau S, Chan AT, Hudson TJ, Peters U (2012) Characterization of gene–environment interactions for colorectal cancer susceptibility loci. *Cancer Res* 72:2036–2044
- Iatropoulos P, Daina E, Mele C, Maranta R, Remuzzi G, Noris M (2012) Discordant phenotype in monozygotic twins with renal coloboma syndrome and a *PAX2* mutation. *Pediatr Nephrol* 27:1989–1993
- Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C (2005) Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. *J Med Genet* 42:e59
- Island ML, Jouanolle AM, Mosser A, Deugnier Y, David V, Brissot P, Loréal O (2009) A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in *HFE*-related hemochromatosis. *Haematologica* 94:720–724
- Itoh H, Shimizu W, Hayashi K, Yamagata K, Sakaguchi T, Ohno S, Makiyama T, Akao M, Ai T, Noda T, Miyazaki A, Miyamoto Y, Yamagishi M, Kamakura S, Horie M (2010) Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multicenter study. *Heart Rhythm* 7:1411–1418
- Jackson CE, Fischer RE, Hsu AP, Anderson SM, Choi Y, Wang J, Dale JK, Fleisher TA, Middleton LA, Sneller MC, Lenardo MJ, Straus SE, Puck JM (1999) Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. *Am J Hum Genet* 64:1002–1014
- Jacquemont S, Hagerman RJ, Leehey MA, Hall DA, Levine RA, Brunberg JA, Zhang L, Jardini T, Gane LW, Harris SW, Herman K, Grigsby J, Greco CM, Berry-Kravis E, Tassone F, Hagerman PJ (2004) Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. *JAMA* 291:460–469
- Jacot S, Le Gac G, Scotet V, Quere I, Mura C, Férec C (2004) *HAMP* as a modifier gene that increases the phenotypic expression of the *HFE* pC282Y homozygous genotype. *Blood* 103:2835–2840
- Jan de Beur S, Ding C, Germain-Lee E, Cho J, Maret A, Levine MA (2003) Discordance between genetic and epigenetic defects in pseudohypoparathyroidism type 1b revealed by inconsistent loss of maternal imprinting at *GNAS1*. *Am J Hum Genet* 73:314–322
- Jendrzewski J, He H, Radomska HS, Li W, Tomsic J, Liyanaratchi S, Davuluri RV, Nagy R, de la Chapelle A (2012) The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. *Proc Natl Acad Sci USA* 109:8646–8651
- Jensen MK, Havndrup O, Christiansen M, Andersen PS, Diness B, Axelsson A, Skovby F, Køber L, Bundgaard H (2013) Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. *Circulation* 127:48–54
- Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA (2004) Breast-feeding and the risk of breast cancer in *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst* 96:1094–1098
- Jiang Q, Ho YY, Hao L, Nichols Berrios C, Chakravarti A (2011) Copy number variants in candidate genes are genetic modifiers of Hirschsprung disease. *PLoS ONE* 6:e21219
- Jin ZB, Mandai M, Yokota T, Higuchi K, Ohmori K, Ohtsuki F, Takakura S, Itabashi T, Wada Y, Akimoto M, Ooto S, Suzuki T, Hirami Y, Ikeda H, Kawagoe N, Oishi A, Ichiyama S, Takahashi M, Yoshimura N, Kosugi S (2008) Identifying pathogenic genetic background of simplex or multiplex retinitis pigmentosa patients: a large scale mutation screening study. *J Med Genet* 45:465–472
- Joergensen MT, Brusgaard K, Crüger DG, Gerdes AM, Schaffalitzky de Muckadell OB (2010) Genetic, epidemiological, and clinical aspects of hereditary pancreatitis: a population-based cohort study in Denmark. *Am J Gastroenterol* 105:1876–1883
- Johansen CT, Hegele RA (2012) Allelic and phenotypic spectrum of plasma triglycerides. *Biochim Biophys Acta* 1821:833–842
- Johansen CT, Wang J, McIntyre AD, Martins RA, Ban MR, Lanktree MB, Huff MW, Péterfy M, Mehrabian M, Lusic AJ, Kathiresan S, Anand SS, Yusuf S, Lee AH, Glimcher LH, Cao H, Hegele RA (2012) Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. *Circ Cardiovasc Genet* 5:66–72
- Kajiwara K, Berson EL, Dryja TP (1994) Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/*RDS* and *ROM1* loci. *Science* 264:1604–1608
- Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, Toes RE, Huizinga TW, Klareskog L, Alfredsson L, Epidemiological Investigation of Rheumatoid Arthritis study group (2007) Gene–gene and gene–environment interactions involving *HLA-DRB1*, *PTPN22*, and smoking in two subsets of rheumatoid arthritis. *Am J Hum Genet* 80:867–875

- Kaminsky ZA, Tang T, Wang SC, Ptak C, Oh GH, Wong AH, Feldcamp LA, Virtanen C, Halfvarson J, Tysk C, McRae AF, Visscher PM, Montgomery GW, Gottesman II, Martin NG, Petronis A (2009) DNA methylation profiles in monozygotic and dizygotic twins. *Nat Genet* 41:240–245
- Kaneko H, Kawamoto N, Asano T, Mabuchi Y, Horikoshi H, Teramoto T, Matsui E, Kondo M, Fukao T, Kasahara K, Kondo N (2005) Leaky phenotype of X-linked agammaglobulinemia in a Japanese family. *Clin Exp Immunol* 140:520–523
- Karges B, Bergmann C, Scholl K, Heinze E, Rasche FM, Zerres K, Debatin KM, Wabitsch M, Karges W (2007) Digenic inheritance of hepatocyte nuclear factor-1 α and -1 β with maturity-onset diabetes of the young, polycystic thyroid, and urogenital malformations. *Diabetes Care* 30:1613–1614
- Kaski DN, Pennington C, Beck J, Poulter M, Uphill J, Bishop MT, Linehan JM, O'Malley C, Wadsworth JD, Joiner S, Knight RS, Ironside JW, Brandner S, Collinge J, Mead S (2011) Inherited prion disease with 4-octapeptide repeat insertion: disease requires the interaction of multiple genetic risk factors. *Brain* 134:1829–1838
- Katsanis N, Ansley SJ, Badano JL, Eichers ER, Lewis RA, Hoskins BE, Scambler PJ, Davidson WS, Beales PL, Lupski JR (2001) Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. *Science* 293:2256–2259
- Kaur-Knudsen D, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG (2011) Nicotinic acetylcholine receptor polymorphism, smoking behavior, and tobacco-related cancer and lung and cardiovascular diseases: a cohort study. *J Clin Oncol* 29:2875–2882
- Kauwe JS, Bertelsen S, Mayo K, Cruchaga C, Abraham R, Hollingworth P, Harold D, Owen MJ, Williams J, Lovestone S, Morris JC, Goate AM, Alzheimer's Disease Neuroimaging Initiative (2010) Suggestive synergy between genetic variants in *TF* and *HFE* as risk factors for Alzheimer's disease. *Am J Med Genet B Neuropsychiatr Genet* 153B:955–959
- Kawamura S, Ikeda Y, Tomita K, Watanabe N, Seki K (2004) A family of hypokalemic periodic paralysis with *CACNA1S* gene mutation showing incomplete penetrance in women. *Intern Med* 43:218–222
- Ke Q, Luo B, Qi M, Du Y, Wu W (2013) Gender differences in penetrance and phenotype in hypokalemic periodic paralysis. *Muscle Nerve* 47:41–45
- Keenan BT, Shulman JM, Chibnik LB, Raj T, Tran D, Sabuncu MR, Alzheimer's Disease Neuroimaging Initiative, Allen AN, Corneveaux JJ, Hardy JA, Huentelman MJ, Lemere CA, Myers AJ, Nicholson-Weller A, Reiman EM, Evans DA, Bennett DA, De Jager PL (2012) A coding variant in *CR1* interacts with APOE- ϵ 4 to influence cognitive decline. *Hum Mol Genet* 21:2377–2388
- Kelberman D, Islam L, Holder SE, Jacques TS, Calvas P, Hennekam RC, Nischal KK, Sowden JC (2011) Digenic inheritance of mutations in *FOXC1* and *PITX2*: correlating transcription factor function and Axenfeld-Rieger disease severity. *Hum Mutat* 32:1144–1152
- Kellermayer R, Keller M, Ratajczak P, Richardson E, Harangi F, Mérei E, Melegh B, Kosztolányi G, Richard G (2005) Bigenic connexin mutations in a patient with hidrotic ectodermal dysplasia. *Eur J Dermatol* 15:75–79
- Kenna KP, McLaughlin RL, Hardiman O, Bradley DG (2013) Using reference databases of genetic variation to evaluate the potential pathogenicity of candidate disease variants. *Hum Mutat* 34:836–841
- Kentsis A, Anewalt R, Ganguly A, Allen JB, Neufeld EJ (2009) Discordant haemophilia A in male siblings due to a de novo mutation on a familial missense mutant allele. *Haemophilia* 15:971–972
- Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. *Blood* 102:3085–3092
- Khalid A, Finkelstein S, Thompson B, Kelly L, Hanck C, Godfrey TE, Whitcomb DC (2006) A 93 year old man with the *PRSS1* R122H mutation, low *SPINK1* expression, and no pancreatitis: insights into phenotypic non-penetrance. *Gut* 55:728–731
- Khanna H, Davis EE, Murga-Zamalloa CA, Estrada-Cuzcano A, Lopez I, den Hollander AI, Zonneveld MN, Othman MI, Waseem N, Chakarova CF, Maubaret C, Diaz-Font A, MacDonald I, Muzny DM, Wheeler DA, Morgan M, Lewis LR, Logan CV, Tan PL, Beer MA, Inglehearn CF, Lewis RA, Jacobson SG, Bergmann C, Beales PL, Attié-Bitach T, Johnson CA, Otto EA, Bhattacharya SS, Hildebrandt F, Gibbs RA, Koeneke RK, Swaroop A, Katsanis N (2009) A common allele in *RPGRIP1L* is a modifier of retinal degeneration in ciliopathies. *Nat Genet* 41:739–745
- Khayat M, Hardouf H, Zlotogora J, Shalev SA (2010) High carriers frequency of an apparently ancient founder mutation p.Tyr322X in the *ERCC8* gene responsible for Cockayne syndrome among Christian Arabs in Northern Israel. *Am J Med Genet* 152A:3091–3094
- Kiesewetter S, Macek M Jr, Davis C, Curristin SM, Chu CS, Graham C, Shrimpton AE, Cashman SM, Tsui LC, Mickle J, Amos J, Highsmith WE, Shuber A, Witt DR, Crystal RG, Cutting GR (1993) A mutation in *CFTR* produces different phenotypes depending on chromosomal background. *Nat Genet* 5:274–278
- Kilpeläinen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, Ahmad T, Mora S, Kaakinen M, Sandholt CH, Holzapfel C, Autenrieth CS, Hyppönen E, Cauchi S, He M, Kutalik Z, Kumari M, Stančáková A, Meidtner K, Balkau B, Tan JT, Mangino M, Timpson NJ, Song Y, Zillikens MC, Jablonski KA, Garcia ME, Johansson S, Bragg-Gresham JL, Wu Y, van Vliet-Ostaptchouk JV, Onland-Moret NC, Zimmermann E, Rivera NV, Tanaka T, Stringham HM, Silbernagel G, Kanoni S, Feitosa MF, Snitker S, Ruiz JR, Metter J, Larrad MT, Atalay M, Hakanen M, Amin N, Cavalcanti-Proença C, Grøntved A, Hallmans G, Jansson JO, Kuusisto J, Kähönen M, Lutsey PL, Nolan JJ, Palla L, Pedersen O, Pérusse L, Renström F, Scott RA, Shungin D, Sovio U, Tammelin TH, Rönnemaa T, Lakka TA, Uusitupa M, Rios MS, Ferrucci L, Bouchard C, Meirhaeghe A, Fu M, Walker M, Borecki IB, Dedoussis GV, Fritsche A, Ohlsson C, Boehnke M, Bandinelli S, van Duijn CM, Ebrahim S, Lawlor DA, Gudnason V, Harris TB, Sørensen TI, Mohlke KL, Hofman A, Uitterlinden AG, Tuomilehto J, Lehtimäki T, Raitakari O, Isomaa B, Njølstad PR, Florez JC, Liu S, Ness A, Spector TD, Tai ES, Froguel P, Boeing H, Laakso M, Marmot M, Bergmann S, Power C, Khaw KT, Chasman D, Ridker P, Hansen T, Monda KL, Illig T, Järvelin MR, Wareham NJ, Hu FB, Groop LC, Orho-Melander M, Ekelund U, Franks PW, Loos RJ (2011) Physical activity attenuates the influence of *FTO* variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. *PLoS Med* 8:e1001116
- Klassen T, Davis C, Goldman A, Burgess D, Chen T, Wheeler D, McPherson J, Bourquin T, Lewis L, Villasana D, Morgan M, Muzny D, Gibbs R, Noebels J (2011) Exome sequencing of ion channel genes reveals complex confounding personal risk assessment in epilepsy. *Cell* 145:1036–1048
- Klei L, Sanders SJ, Murtha MT, Hus V, Lowe JK, Willsey AJ, Moreno-De-Luca D, Yu TW, Fombonne E, Geschwind D, Grice DE, Ledbetter DH, Lord C, Mane SM, Lese Martin C, Martin DM, Morrow EM, Walsh CA, Melhem NM, Chaste P, Sutcliffe JS, State MW, Cook EH Jr, Roeder K, Devlin B (2012) Common genetic variants, acting additively, are a major source of risk for autism. *Mol Autism* 3:9
- Kleinle S, Lang R, Fischer GF, Vierhapper H, Waldhauser F, Födinger M, Baumgartner-Parzer SM (2009) Duplications of the

- functional *CYP21A2* gene are primarily restricted to Q318X alleles: evidence for a founder effect. *J Clin Endocrinol Metab* 94:3954–3958
- Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, Pace TW, Mercer KB, Mayberg HS, Bradley B, Nemeroff CB, Holsboer F, Heim CM, Ressler KJ, Rein T, Binder EB (2013) Allele-specific *FKBP5* DNA demethylation mediates gene-childhood trauma interactions. *Nat Neurosci* 16:33–41
- Klopocki E, Lohan S, Doelken SC, Stricker S, Ockeloen CW, Thiele Soares, de Aguiar R, Lezirovitz K, Mingroni Netto RC, Jamsheer A, Shah H, Kurth I, Habenicht R, Warman M, Devriendt K, Kordass U, Hempel M, Rajab A, Mäkitie O, Naveed M, Radhakrishna U, Antonarakis SE, Horn D, Mundlos S (2012) Duplications of *BHLHA9* are associated with ectrodactyly and tibia hemimelia inherited in non-Mendelian fashion. *J Med Genet* 49:119–125
- Klutzb M, Brockmann D, Lohmann DR (2002) A parent-of-origin effect in two families with retinoblastoma is associated with a distinct splice mutation in the *RBI* gene. *Am J Hum Genet* 71:174–179
- Knoll B, Hach-Wunderle V, Rieger S, Häring D, Mannhalter C (2001) Combined occurrence of a heterozygous missense mutation in the protein C gene and allelic exclusion of one protein S allele leading to severe venous thrombosis. *Thromb Res* 103:3–8
- Kock N, Naismith TV, Boston HE, Ozelius LJ, Corey DP, Breakefield XO, Hanson PI (2006) Effects of genetic variations in the dystonia protein torsin A: identification of polymorphism at residue 216 as protein modifier. *Hum Mol Genet* 15:1355–1364
- Koeijvoets KC, Mooijaart SP, Dallinga-Thie GM, Defesche JC, Steyerberg EW, Westendorp RG, Kastelein JJ, van Hagen PM, Sijbrands EJ (2009) Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia. *Eur Heart J* 30:618–623
- Koeleman BP, Reitsma PH, Allaart CF, Bertina RM (1994) Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. *Blood* 84:1031–1035
- Koeleman BP, van Rumpft D, Hamulyák K, Reitsma PH, Bertina RM (1995) Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? *Thromb Haemost* 74:580–583
- Kontorovich T, Levy A, Korostishevsky M, Nir U, Friedman E (2010) Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. *Int J Cancer* 127:589–597
- Koren-Michowitz M, Friedman E, Gershoni-Baruch R, Brok-Simoni F, Patael Y, Rechavi G, Amariglio N (2005) Coinheritance of *BRCA1* and *BRCA2* mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development. *Am J Hematol* 78:203–206
- Kowalewski C, Hamada T, Wozniak K, Kawano Y, Szczecinska W, Yasumoto S, Schwartz RA, Hashimoto T (2007) A novel autosomal partially dominant mutation designated G476D in the keratin 5 gene causing epidermolysis bullosa simplex Weber-Cockayne type: a family study with a genetic twist. *Int J Mol Med* 20:75–78
- Kratzke RA, Otterson GA, Hogg A, Coxon AB, Geradts J, Cowell JK, Kaye FJ (1994) Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. *Oncogene* 9:1321–1326
- Krayenbuehl PA, Hersberger M, Truninger K, Müllhaupt B, Maly FE, Bargetzi M, Schulthess G (2010) Toll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis. *Eur J Gastroenterol Hepatol* 22:835–841
- Krüger S, Silber AS, Engel C, Görgens H, Mangold E, Pagenstecher C, Holinski-Feder E, von Knebel Doeberitz M, Moeslein G, Dietmaier W, Stemmler S, Friedl W, Rüschoff J, Schackert HK, German Hereditary Non-Polyposis Colorectal Cancer Consortium (2005) Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study. *Lancet Oncol* 6:566–572
- Krüger S, Engel C, Bier A, Silber AS, Görgens H, Mangold E, Pagenstecher C, Holinski-Feder E, von Knebel Doeberitz M, Royer-Pokora B, Dechant S, Pox C, Rahner N, Müller A, Schackert HK, German HNPCC Consortium (2007) The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. *Cancer Lett* 252:55–64
- Kryukov GV, Pennacchio LA, Sunyaev SR (2007) Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. *Am J Hum Genet* 80:727–739
- Kubo T, Kitaoka H, Okawa M, Baba Y, Hirota T, Hayato K, Yamasaki N, Matsumura Y, Otsuka H, Arimura T, Kimura A, Doi YL (2011) Genetic screening and double mutation in Japanese patients with hypertrophic cardiomyopathy. *Circ J* 75:2654–2659
- Kujovich JL (2011) Factor V Leiden thrombophilia. *Genet Med* 13:1–16
- Kumar V, Westra HJ, Karjalainen J, Zhernakova DV, Esko T, Hrdlickova B, Almeida R, Zhernakova A, Reinmaa E, Vösa U, Hofker MH, Fehrmann RS, Fu J, Withoff S, Metspalu A, Franke L, Wijmenga C (2013) Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. *PLoS Genet* 9:e1003201
- Küry S, Buecher B, Robiou-du-Pont S, Scouf C, Colman H, Le Neel T, Le Houérou C, Faroux R, Ollivry J, Lafraise B, Chupin LD, Sébille V, Bézieau S (2008) Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. *BMC Cancer* 8:326
- Kwok JB, Raskin S, Morgan G, Antoniuk SA, Bruk I, Schofield PR (2001) Mutations in the glycine receptor alpha1 subunit (*GLRA1*) gene in hereditary hyperekplexia pedigrees: evidence for non-penetrance of mutation Y279C. *J Med Genet* 38:E17
- Kwong AK, Fung CW, Chan SY, Wong VC (2012) Identification of *SCN1A* and *PCDH19* mutations in Chinese children with Dravet syndrome. *PLoS ONE* 7:e41802
- Lachmann RH, Grant IR, Halsall D, Cox TM (2004) Twin pairs showing discordance of phenotype in adult Gaucher's disease. *QJM* 97:199–204
- Lahtinen AM, Lehtonen A, Kaartinen M, Toivonen L, Swan H, Widén E, Lehtonen E, Lehto VP, Kontula K (2008) Plakophilin-2 missense mutations in arrhythmogenic right ventricular cardiomyopathy. *Int J Cardiol* 126:92–100
- Lahtinen AM, Marjamaa A, Swan H, Kontula K (2011) *KCNE1* D85N polymorphism—a sex-specific modifier in type 1 long QT syndrome? *BMC Med Genet* 12:11
- Lappalainen T, Montgomery SB, Nica AC, Dermitzakis ET (2011) Epistatic selection between coding and regulatory variation in human evolution and disease. *Am J Hum Genet* 89:459–463
- LaRusch J, Barmada MM, Solomon S, Whitcomb DC (2012) Whole exome sequencing identifies multiple, complex etiologies in an idiopathic hereditary pancreatitis kindred. *JOP* 13:258–262
- Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT,

- Cambi F, Gusella JF, Myers RH (2008) The Gly2019Ser mutation in *LRRK2* is not fully penetrant in familial Parkinson's disease: the GenePD study. *BMC Med* 6:32
- Lavie O, Narod S, Lejbkowitz F, Dishon S, Goldberg Y, Gerner O, Rennert G (2011) Double heterozygosity in the *BRCA1* and *BRCA2* genes in the Jewish population. *Ann Oncol* 22:964–966
- Law MJ, Lower KM, Voon HP, Hughes JR, Garrick D, Viprakasit V, Mitson M, De Gobbi M, Marra M, Morris A, Abbott A, Wilder SP, Taylor S, Santos GM, Cross J, Ayyub H, Jones S, Ragoussis J, Rhodes D, Dunham I, Higgs DR, Gibbons RJ (2010) ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. *Cell* 143:367–378
- Lazarin GA, Haque IS, Nazareth S, Iori K, Patterson AS, Jacobson JL, Marshall JR, Seltzer WK, Patrizio P, Evans EA, Srinivasan BS (2013) An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. *Genet Med* 15:178–186
- Le Ber I, Camuzat A, Guillot-Noel L, Hannequin D, Lacomblez L, Golfier V, Puel M, Martinaud O, Deramecourt V, Rivaud-Pechoux S, Millecamps S, Vercelletto M, Couratier P, Sellal F, Pasquier F, Salachas F, Thomas-Antérion C, Didic M, Pariente J, Seilhean D, Ruberg M, Wargon I, Blanc F, Camu W, Michel BF, Berger E, Sauvée M, Thauvin-Robinet C, Mondon K, Tournier-Lasserre E, Goizet C, Fleury M, Viennet G, Verpillat P, Meininger V, Duyckaerts C, Dubois B, Brice A (2013) *C9ORF72* repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. *J Alzheimers Dis* 34:485–499
- Lebo RV, Grody WW (2007) Variable penetrance and expressivity of the splice altering 5T sequence in the cystic fibrosis gene. *Genet Test* 11:32–44
- Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS, PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF, COHORT study of the HSG (2012a) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. *Neurology* 78:690–695
- Lee Y, Gamazon ER, Rebman E, Lee Y, Lee S, Dolan ME, Cox NJ, Lussier YA (2012) Variants affecting exon skipping contribute to complex traits. *PLoS Genet* 8:e1002998
- Leege B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, Leenders EP, Wesseling J, de Hullu J, Hoogerbrugge N, Ligtenberg MJ, Ardern-Jones A, Bancroft E, Salmon A, Barwell J, Eeles R, Oosterwijk JC (2005) Phenotypic expression of double heterozygosity for *BRCA1* and *BRCA2* germline mutations. *J Med Genet* 42:e20
- Lefèvre SH, Chauveinc L, Stoppa-Lyonnet D, Michon J, Lumbroso L, Berthet P, Frappaz D, Dutrillaux B, Chevillard S, Malfoy B (2002) A T to C mutation in the polypyrimidine tract of the exon 9 splicing site of the *RBI* gene responsible for low penetrance hereditary retinoblastoma. *J Med Genet* 39:E21
- Leistriz DF, Pepin MG, Schwarze U, Byers PH (2011) *COL3A1* haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy. *Genet Med* 13:717–722
- Lekarev O, Tafuri K, Lane AH, Zhu G, Nakamoto JM, Buller-Burckle AM, Wilson TA, New MI (2013) Erroneous prenatal diagnosis of congenital adrenal hyperplasia owing to a duplication of the *CYP21A2* gene. *J Perinatol* 33:76–78
- Lerch MM, Mayerle J, Aghdassi AA, Budde C, Nitsche C, Sauter G, Persike M, Günther A, Simon P, Weiss FU (2010) Advances in the etiology of chronic pancreatitis. *Dig Dis* 28:324–329
- Li FF, Li QQ, Tan ZX, Zhang SY, Liu J, Zhao EY, Yu GC, Zhou J, Zhang LM, Liu SL (2012) A novel mutation in *CACNA1S* gene associated with hypokalemic periodic paralysis which has a gender difference in the penetrance. *J Mol Neurosci* 46:378–383
- Li-Chang HH, Driman DK, Levin H, Siu VM, Scanlan NL, Buckley K, Cairney AE, Ainsworth PJ (2013) Colorectal cancer in a 9-year-old due to combined *EPCAM* and *MSH2* germline mutations: case report of a unique genotype and immunophenotype. *J Clin Pathol* (in press)
- Lim KP, Yip SP, Cheung SC, Leung KW, Lam ST, To CH (2009) Novel *PRPF31* and *PRPH2* mutations and co-occurrence of *PRPF31* and *RHO* mutations in Chinese patients with retinitis pigmentosa. *Arch Ophthalmol* 127:784–790
- Liu JY, Dai X, Sheng J, Cui X, Wang X, Jiang X, Tu X, Tang Z, Bai Y, Liu M, Wang QK (2008) Identification and functional characterization of a novel splicing mutation in RP gene *PRPF31*. *Biochem Biophys Res Commun* 367:420–426
- Liu XZ, Yuan Y, Yan D, Ding EH, Ouyang XM, Fei Y, Tang W, Yuan H, Chang Q, Du LL, Zhang X, Wang G, Ahmad S, Kang DY, Lin X, Dai P (2009) Digenic inheritance of non-syndromic deafness caused by mutations at the gap junction proteins *Cx26* and *Cx31*. *Hum Genet* 125:53–62
- Lo HS, Wang Z, Hu Y, Yang HH, Gere S, Buetow KH, Lee MP (2003) Allelic variation in gene expression is common in the human genome. *Genome Res* 13:1855–1862
- Loewen CJ, Moritz OL, Molday RS (2001) Molecular characterization of peripherin-2 and rom-1 mutants responsible for digenic retinitis pigmentosa. *J Biol Chem* 276:22388–22396
- Lohmueller KE, Indap AR, Schmidt S, Boyko AR, Hernandez RD, Hubisz MJ, Sninsky JJ, White TJ, Sunyaev SR, Nielsen R, Clark AG, Bustamante CD (2008) Proportionally more deleterious genetic variation in European than in African populations. *Nature* 451:994–997
- Lopes LR, Zekavati A, Syrris P, Hubank M, Giambartolomei C, Dalageorgou C, Jenkins S, McKenna W, UK10K Consortium, Pagnol V, Elliott PM (2013) Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. *J Med Genet* 50:228–239
- Lorenzon A, Beggagna G, Baucé B, De Bortoli M, Li Mura IE, Calore M, Dazzo E, Basso C, Nava A, Thiene G, Rampazzo A (2013) Desmin mutations and arrhythmogenic right ventricular cardiomyopathy. *Am J Cardiol* 111:400–405
- Löwik M, Levchenko E, Westra D, Groenen P, Steenbergen E, Weening J, Lilien M, Monnens L, van den Heuvel L (2008) Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 23:3146–3151
- Lupski JR, Belmont JW, Boerwinkle E, Gibbs RA (2011) Clan genomics and the complex architecture of human disease. *Cell* 147:32–43
- MacArthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, Walter K, Jostins L, Habegger L, Pickrell JK, Montgomery SB, Albers CA, Zhang ZD, Conrad DF, Lunter G, Zheng H, Ayub Q, DePristo MA, Banks E, Hu M, Handsaker RE, Rosenfeld JA, Fromer M, Jin M, Mu XJ, Khurana E, Ye K, Kay M, Saunders GI, Suner MM, Hunt T, Barnes IH, Amid C, Carvalho-Silva DR, Bignell AH, Snow C, Yngvadottir B, Bumpstead S, Cooper DN, Xue Y, Romero IG, 1000 Genomes Project Consortium, Wang J, Li Y, Gibbs RA, McCarroll SA, Dermitzakis ET, Pritchard JK, Barrett JC, Harrow J, Hurler ME, Gerstein MB, Tyler-Smith C

- (2012) A systematic survey of loss-of-function variants in human protein-coding genes. *Science* 335:823–828
- Machens A, Schaaf L, Karges W, Frank-Raue K, Bartsch DK, Rothmund M, Schneyer U, Goretzki P, Raue F, Dralle H (2007) Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. *Clin Endocrinol* 67:613–622
- Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chiò A, Restagno G, Nicolaou N, Simon-Sanchez J, van Swieten JC, Abramzon Y, Johnson JO, Sendtner M, Pampillet R, Orrell RW, Mead S, Sidle KC, Houlden H, Rohrer JD, Morrison KE, Pall H, Talbot K, Ansorge O; Chromosome 9-ALS/FTD Consortium; French research network on FTL/FTLD/ALS; ITALSGEN Consortium, Hernandez DG, Arepalli S, Sabatelli M, Mora G, Corbo M, Giannini F, Calvo A, Englund E, Borghero G, Floris GL, Remes AM, Laaksovirta H, McCluskey L, Trojanowski JQ, Van Deerlin VM, Schellenberg GD, Nalls MA, Drory VE, Lu CS, Yeh TH, Ishiura H, Takahashi Y, Tsuji S, Le Ber I, Brice A, Drepper C, Williams N, Kirby J, Shaw P, Hardy J, Tienari PJ, Heutink P, Morris HR, Pickering-Brown S, Traynor BJ (2011) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. *Lancet Neurol* 11:323–330
- Maller J, George S, Purcell S, Fagerness J, Altshuler D, Daly MJ, Seddon JM (2006) Common variation in three genes, including a noncoding variant in *CFH*, strongly influences risk of age-related macular degeneration. *Nat Genet* 38:1055–1059
- Maloney JP, Stearman RS, Bull TM, Calabrese DW, Tripp-Addison ML, Wick MJ, Broeckel U, Robbins IM, Wheeler LA, Cogan JD, Loyd JE (2012) Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol* 302:L541–L554
- Mankad A, Taniguchi T, Cox B, Akkari Y, Rathbun RK, Lucas L, Bagby G, Olson S, D'Andrea A, Grompe M (2006) Natural gene therapy in monozygotic twins with Fanconi anemia. *Blood* 107:3084–3090
- Marchani EE, Bird TD, Steinbart EJ, Rosenthal E, Yu CE, Schellenberg GD, Wijsman EM (2010) Evidence for three loci modifying age-at-onset of Alzheimer's disease in early onset *PSEN2* families. *Am J Med Genet B Neuropsychiatr Genet* 153B:1031–1041
- Margolin DH, Kousi M, Chan YM, Lim ET, Schmahmann JD, Hadjivassiliou M, Hall JE, Adam I, Dwyer A, Plummer L, Aldrin SV, O'Rourke J, Kirby A, Lage K, Milunsky A, Milunsky JM, Chan J, Hedley-Whyte ET, Daly MJ, Katsanis N, Seminara SB (2013) Ataxia, dementia, and hypogonadotropism caused by disordered ubiquitination. *N Engl J Med* 368:1992–2003
- Marras C, Klein C, Lang AE, Wakutani Y, Moreno D, Sato C, Yip E, Munhoz RP, Lohmann K, Djarmati A, Bi A, Rogaeva E (2010) *LRRK2* and *Parkin* mutations in a family with parkinsonism—lack of genotype-phenotype correlation. *Neurobiol Aging* 31:721–722
- Marth GT, Yu F, Indap AR, Garimella K, Gravel S, Leong WF, Tyler-Smith C, Bainbridge M, Blackwell T, Zheng-Bradley X, Chen Y, Challis D, Clarke L, Ball EV, Cibulskis K, Cooper DN, Fulton B, Hartl C, Koboldt D, Muzny D, Smith R, Sougnez C, Stewart C, Ward A, Yu J, Xue Y, Altshuler D, Bustamante CD, Clark AG, Daly M, DePristo M, Flicek P, Gabriel S, Mardis E, Palotie A, Gibbs R, 1000 Genomes Project (2011) The functional spectrum of low-frequency coding variation. *Genome Biol* 12:R84
- Martin N, Zügge K, Brandt R, Friebe D, Janssen B, Zimmerhackl LB (2003) Discordant clinical manifestations in monozygotic twins with the identical mutation in the *TSC2* gene. *Clin Genet* 63:427–430
- Martinelli N, Trabetti E, Pinotti M, Olivieri O, Sandri M, Friso S, Pizzolo F, Bozzini C, Caruso PP, Cavallari U, Cheng S, Pignatti PF, Bernardi F, Corrocher R, Girelli D (2008) Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis. *PLoS ONE* 3:e1523
- Martinez SL, Kolodner RD (2010) Functional analysis of human mismatch repair gene mutations identifies weak alleles and polymorphisms capable of polygenic interactions. *Proc Natl Acad Sci USA* 107:5070–5075
- Martino D, Gajos A, Gallo V, Cif L, Coubes P, Tinazzi M, Schneider SA, Fiorio M, Zorzi G, Nardocci N, Ben-Shlomo Y, Edwards MJ, Bhatia KP (2013) Extragenetic factors and clinical penetrance of *DYT1* dystonia: an exploratory study. *J Neurol* 260:1081–1086
- Masson E, Le Maréchal C, Levy P, Chuzhanova N, Ruzsiewicz P, Cooper DN, Chen JM, Férec C (2007) Co-inheritance of a novel deletion of the entire *SPINK1* gene with a *CFTR* missense mutation (L997F) in a family with chronic pancreatitis. *Mol Genet Metab* 92:168–175
- Mathias A, Moss AJ, Lopes CM, Barsheshet A, McNitt S, Zareba W, Robinson JL, Locati EH, Ackerman MJ, Benhorin J, Kaufman ES, Platonov PG, Qi M, Shimizu W, Towbin JA, Vincent GM, Wilde AA, Zhang L, Goldenberg I (2013) Prognostic implications of mutation-specific QTc standard deviation in congenital long QT syndrome. *Heart Rhythm* 10:720–725
- Matsuo T, Okamoto S, Izumi Y, Hosokawa A, Takegawa T, Fukui H, Tun Z, Honda K, Matoba R, Tatsumi K, Amino N (2000) A novel mutation of the *KALI* gene in monozygotic twins with Kallmann syndrome. *Eur J Endocrinol* 143:783–787
- Matsuzaki H, Wang PH, Hu J, Rava R, Fu GK (2009) High resolution discovery and confirmation of copy number variants in 90 Yoruba Nigerians. *Genome Biol* 10:R125
- Maubaret CG, Vaclavik V, Mukhopadhyay R, Waseem NH, Churchill A, Holder GE, Moore AT, Bhattacharya SS, Webster AR (2011) Autosomal dominant retinitis pigmentosa with intrafamilial variability and incomplete penetrance in two families carrying mutations in *PRPF8*. *Invest Ophthalmol Vis Sci* 52:9304–9309
- Maugeri A, Flotthmann K, Hemmrich N, Ingvast S, Jorge P, Paloma E, Patel R, Rozet JM, Tammur J, Testa F, Balcells S, Bird AC, Brunner HG, Hoyng CB, Metspalu A, Simonelli F, Allikmets R, Bhattacharya SS, D'Urso M, González-Duarte R, Kaplan J, te Meerman GJ, Santos R, Schwartz M, Van Camp G, Wadelius C, Weber BH, Cremers FP (2002) The *ABCA4* 2588G>C Stargardt mutation: single origin and increasing frequency from South-West to North-East Europe. *Eur J Hum Genet* 10:197–203
- Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF, on behalf of EMBRACE (2013) Cancer risks for *BRCA1* and *BRCA2* mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst* 105:812–822
- Mayeux R, Stern Y, Ottman R, Tatemichi TK, Tang MX, Maestre G, Ngai C, Tycko B, Ginsberg H (1993) The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. *Ann Neurol* 34:752–754
- McCull M, Tait RC, Walker ID, Perry DJ, McCall F, Conkie JA (1996) Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation. *Blood Coagul Fibrinolysis* 7:689–694
- McCune CA, Ravine D, Carter K, Jackson HA, Hutton D, Hedderich J, Krawczak M, Worwood M (2006) Iron loading and morbidity

- among relatives of *HFE* C282Y homozygotes identified either by population genetic testing or presenting as patients. *Gut* 55:554–562
- McDade E, Boeve BF, Burrus TM, Boot BP, Kantarci K, Fields J, Lowe VJ, Peller P, Knopman D, Baker M, Finch N, Rademakers R, Petersen R (2012) Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin. *Neurology* 78:1245–1249
- McGee TL, Devoto M, Ott J, Berson EL, Dryja TP (1997) Evidence that the penetrance of mutations at the *RP11* locus causing dominant retinitis pigmentosa is influenced by a gene linked to the homologous *RP11* allele. *Am J Hum Genet* 61:1059–1066
- McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group (2007) Reproductive risk factors for ovarian cancer in carriers of *BRCA1* or *BRCA2* mutations: a case-control study. *Lancet Oncol* 8:26–34
- McNeil SM, Novelletto A, Srinidhi J, Barnes G, Kombluth I, Altherr MR, Wasmuth JJ, Gusella JF, MacDonald ME, Myers RH (1997) Reduced penetrance of the Huntington's disease mutation. *Hum Mol Genet* 6:775–779
- Medeiros F, Lindor NM, Couch FJ, Highsmith WE Jr (2012) The germline *MLH1* K618A variant and susceptibility to Lynch syndrome-associated tumors. *J Mol Diagn* 14:264–273
- Mégarbané A, Salem N, Stephan E, Ashoush R, Lenoir D, Delague V, Kassab R, Loiselet J, Bouvagnet P (2000) X-linked transposition of the great arteries and incomplete penetrance among males with a nonsense mutation in *ZIC3*. *Eur J Hum Genet* 8:704–708
- Meggouh F, de Visser M, Arts WF, De Coo RI, van Schaik IN, Baas F (2005) Early onset neuropathy in a compound form of Charcot-Marie-Tooth disease. *Ann Neurol* 57:589–591
- Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC, Hunter DJ (2003) Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. *Hum Mol Genet* 12:2923–2929
- Mereuta OM, Baldovino S, Errichiello E, Binello GB, Restagno G, Battaglia GG, Mazzucco G, Roccatello D (2013) Systemic AA amyloidosis as a unique manifestation of a combined mutation of *TNFRSF1A* and *MEFV* genes. *Amyloid* 20:122–126
- Merryweather-Clarke AT, Cadet E, Bomford A, Capron D, Viprakasit V, Miller A, McHugh PJ, Chapman RW, Pointon JJ, Wimhurst VL, Livesey KJ, Tanphaichit V, Rochette J, Robson KJ (2003) Digenic inheritance of mutations in *HAMP* and *HFE* results in different types of haemochromatosis. *Hum Mol Genet* 12:2241–2247
- Metzger S, Rong J, Nguyen HP, Cape A, Tomiuk J, Soehn AS, Propping P, Freudenberg-Hua Y, Freudenberg J, Tong L, Li SH, Li XJ, Riess O (2008) Huntington-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. *Hum Mol Genet* 17:1137–1146
- Meyle KD, Guldberg P (2009) Genetic risk factors for melanoma. *Hum Genet* 126:499–510
- Michels M, Soliman OI, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, Dooijes D, Majoor-Krakauer D, Ten Cate FJ (2009) Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. *Eur Heart J* 30:2593–2598
- Miesfeldt S, Turner BL, Lovell MA, Cooper MR, Lescallett J, Jones SM (1998) A novel *BRCA1* mutation in an identical twin pair with similar clinical histories. *Cancer Genet Cytogenet* 100:43–48
- Migita K, Agematsu K, Masumoto J, Ida H, Honda S, Jiuchi Y, Izumi Y, Maeda Y, Uehara R, Nakamura Y, Koga T, Kawakami A, Nakashima M, Fujeida Y, Nonaka F, Eguchi K, Furukawa H, Nakamura T, Nakamura M, Yasunami M (2013) The contribution of *SAAI* polymorphisms to familial Mediterranean fever susceptibility in the Japanese population. *PLoS ONE* 8:e55227
- Milanesi E, Bonvicini C, Alberici A, Pilotto A, Cattane N, Premi E, Gazzina S, Archetti S, Gasparotti R, Cancelli V, Gennarelli M, Padovani A, Borroni B (2013) Molecular signature of disease onset in granulin mutation carriers: a gene expression analysis study. *Neurobiol Aging* 34:1837–1845
- Milet J, Dehais V, Bourgain C, Jouanolle AM, Mosser A, Perrin M, Morcet J, Brissot P, David V, Deugnier Y, Mosser J (2007) Common variants in the *BMP2*, *BMP4*, and *HJV* genes of the hepcidin regulation pathway modulate *HFE* hemochromatosis penetrance. *Am J Hum Genet* 81:799–807
- Millar DS, Kembal-Cook G, McVey JH, Tuddenham EG, Mumford AD, Attock GB, Reverter JC, Lanir N, Parapia LA, Reynaud J, Meili E, von Felton A, Martinowitz U, Prangnell DR, Krawczak M, Cooper DN (2000) Molecular analysis of the genotype-phenotype relationship in factor VII deficiency. *Hum Genet* 107:327–342
- Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A, Prieur F, Bresson JL, Faivre L, Eicher JC, Chassaing N, Crehalet H, Porcher R, Rodriguez-Lafrasse C, Rousson R (2010) Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. *Eur J Med Genet* 53:261–267
- Milos IN, Frank-Raue K, Wohlk N, Maia AL, Pusiol E, Patocs A, Robledo M, Biarnes J, Barontini M, Links TP, de Groot JW, Dvorakova S, Peczkowska M, Rybicki LA, Sullivan M, Raue F, Zosin I, Eng C, Neumann HP (2008) Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line *RET* Cys634Trp (TGC > TGG) mutation. *Endocr Relat Cancer* 15:1035–1041
- Mitne-Neto M, Kok F, Beetz C, Pessoa A, Bueno C, Graciani Z, Martyn M, Monteiro CB, Mitne G, Hubert P, Nygren AO, Valadares M, Cerqueira AM, Starling A, Deufel T, Zatz M (2007) A multi-exonic *SPG4* duplication underlies sex-dependent penetrance of hereditary spastic paraplegia in a large Brazilian pedigree. *Eur J Hum Genet* 15:1276–1279
- Mondal K, Ramachandran D, Patel VC, Hagen KR, Bose P, Cutler DJ, Zwick ME (2012) Excess variants in *AFF2* detected by massively parallel sequencing of males with autism spectrum disorder. *Hum Mol Genet* 21:4356–4364
- Morak M, Massdorf T, Sykora H, Kerscher M, Holinski-Feder E (2011) First evidence for digenic inheritance in hereditary colorectal cancer by mutations in the base excision repair genes. *Eur J Cancer* 47:1046–1055
- Morell R, Spritz RA, Ho L, Pierpont J, Guo W, Friedman TB, Asher JH Jr (1997) Apparent digenic inheritance of Waardenburg syndrome type 2 (WS2) and autosomal recessive ocular albinism (AROA). *Hum Mol Genet* 6:659–664
- Morgan NV, Hartley JL, Setchell KD, Simpson MA, Brown R, Tee L, Kirkham S, Pasha S, Trembath RC, Maher ER, Gissen P, Kelly DA (2013) A combination of mutations in *AKR1D1* and *SKIV2L* in a family with severe infantile liver disease. *Orphanet J Rare Dis* 8:74
- Müller B, Hedrich K, Kock N, Dragasevic N, Svetel M, Garrels J, Landt O, Nitschke M, Pramstaller PP, Reik W, Schwinger E, Sperner J, Ozelius L, Kostic V, Klein C (2002) Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. *Am J Hum Genet* 71:1303–1311
- Mulley JC, Scheffer IE, Desai T, Bayly MA, Grinton BE, Vears DF, Berkovic SF, Dibbens LM (2011) Investigation of the 15q13.3 CNV as a genetic modifier for familial epilepsies with variable phenotypes. *Epilepsia* 52:e139–e142

- Munhoz RP, Wakutani Y, Marras C, Teive HA, Raskin S, Werneck LC, Moreno D, Sato C, Lang AE, Rogaeva E (2008) The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. *Mov Disord* 23:290–294
- Muntoni F, Bonne G, Goldfarb LG, Mercuri E, Piercy RJ, Burke M, Yaou RB, Richard P, Récan D, Shatunov A, Sewry CA, Brown SC (2006) Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. *Brain* 129:1260–1268
- Nadeau JH (2003) Modifier genes and protective alleles in humans and mice. *Curr Opin Genet Dev* 13:290–295
- Nahas F, Garbern J, Feely S, Feldman GL (2009) An intergenerational contraction of a fully penetrant Huntington disease allele to a reduced penetrance allele: interpretation of results and significance for risk assessment and genetic counseling. *Am J Med Genet* 149A:732–736
- Nakajima T, Kaneko Y, Irie T, Takahashi R, Kato T, Iijima T, Iso T, Kurabayashi M (2012) Compound and digenic heterozygosity in desmosome genes as a cause of arrhythmogenic right ventricular cardiomyopathy in Japanese patients. *Circ J* 76:737–743
- Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A, Lin CF, Stevens C, Wang LS, Makarov V, Polak P, Yoon S, Maguire J, Crawford EL, Campbell NG, Geller ET, Valladares O, Schafer C, Liu H, Zhao T, Cai G, Lihm J, Dannenfelser R, Jabado O, Peralta Z, Nagaswamy U, Muzny D, Reid JG, Newsham I, Wu Y, Lewis L, Han Y, Voight BF, Lim E, Rossin E, Kirby A, Flannick J, Fromer M, Shakir K, Fennell T, Garimella K, Banks E, Poplin R, Gabriel S, DePristo M, Wimbish JR, Boone BE, Levy SE, Betancur C, Sunyaev S, Boerwinkle E, Buxbaum JD, Cook EH Jr, Devlin B, Gibbs RA, Roeder K, Schellenberg GD, Sutcliffe JS, Daly MJ (2012) Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature* 485:242–245
- Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, Shen J, Tang Z, Bacanu SA, Fraser D, Warren L, Aponte J, Zawistowski M, Liu X, Zhang H, Zhang Y, Li J, Li Y, Li L, Woollard P, Topp S, Hall MD, Nangle K, Wang J, Abecasis G, Cardon LR, Zöllner S, Whittaker JC, Chisoe SL, Novembre J, Mooser V (2012) An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. *Science* 337:100–104
- Ng PC, Levy S, Huang J, Stockwell TB, Walenz BP, Li K, Axelrod N, Busam DA, Strausberg RL, Venter JC (2008) Genetic variation in an individual human exome. *PLoS Genet* 4:e1000160
- Niksic M, Romano M, Buratti E, Pagani F, Baralle FE (1999) Functional analysis of cis-acting elements regulating the alternative splicing of human *CFTR* exon 9. *Hum Mol Genet* 8:2339–2349
- Nishiguchi KM, Rivolta C (2012) Genes associated with retinitis pigmentosa and allied diseases are frequently mutated in the general population. *PLoS ONE* 7:e41902
- Nishio Y, Makiyama T, Itoh H, Sakaguchi T, Ohno S, Gong YZ, Yamamoto S, Ozawa T, Ding WG, Toyoda F, Kawamura M, Akao M, Matsuura H, Kimura T, Kita T, Horie M (2009) D85N, a *KCNE1* polymorphism, is a disease-causing gene variant in long QT syndrome. *J Am Coll Cardiol* 54:812–819
- Nissim-Rafinia M, Kerem B (2005) The splicing machinery is a genetic modifier of disease severity. *Trends Genet* 21:480–483
- Niu DM, Hwang B, Hwang HW, Wang NH, Wu JY, Lee PC, Chien JC, Shieh RC, Chen YT (2006) A common *SCN5A* polymorphism attenuates a severe cardiac phenotype caused by a nonsense *SCN5A* mutation in a Chinese family with an inherited cardiac conduction defect. *J Med Genet* 43:817–821
- Noguchi T, Katsuda S, Kawashiri MA, Tada H, Nohara A, Inazu A, Yamagishi M, Kobayashi J, Mabuchi H (2010) The E32K variant of *PCSK9* exacerbates the phenotype of familial hypercholesterolaemia by increasing *PCSK9* function and concentration in the circulation. *Atherosclerosis* 210:166–172
- Nolte D, Sobanski E, Wissen A, Regula JU, Lichy C, Müller U (2010) Spinocerebellar ataxia type 17 associated with an expansion of 42 glutamine residues in TATA-box binding protein gene. *J Neurol Neurosurg Psychiatry* 81:1396–1399
- Nossent AY, VAN Marion V, VAN Tilburg NH, Rosendaal FR, Bertina RM, VAN Mourik JA, Eikenboom HC (2006) von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. *J Thromb Haemost* 4:2556–2562
- Nozu K, Inagaki T, Fu XJ, Nozu Y, Kaito H, Kanda K, Sekine T, Igarashi T, Nakanishi K, Yoshikawa N, Iijima K, Matsuo M (2008) Molecular analysis of digenic inheritance in Barter syndrome with sensorineural deafness. *J Med Genet* 45:182–186
- Núñez L, Barana A, Amorós I, de la Fuente MG, Dolz-Gaitón P, Gómez R, Rodríguez-García I, Mosquera I, Monserrat L, Delpón E, Caballero R, Castro-Beiras A, Tamargo J (2013) p.D1690N Nav1.5 rescues p.G1748D mutation gating defects in a compound heterozygous Brugada syndrome patient. *Heart Rhythm* 10:264–272
- Núñez-Torres R, Fernández RM, Acosta MJ, Enguix-Riego Mdel V, Marbá M, Carlos de Agustín J, Castaño L, Antiñolo G, Borrego S (2011) Comprehensive analysis of *RET* common and rare variants in a series of Spanish Hirschsprung patients confirms a synergistic effect of both kinds of events. *BMC Med Genet* 12:138
- Nuytemans K, Bademci G, Inchausti V, Dressen A, Kinnamon DD, Mehta A, Wang L, Züchner S, Beecham GW, Martin ER, Scott WK, Vance JM (2013) Whole exome sequencing of rare variants in *EIF4G1* and *VPS35* in Parkinson disease. *Neurology* 80:982–989
- O'Gorman C, Lucas R, Taylor B (2012) Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. *Int J Mol Sci* 13:11718–11752
- Ober C, Loisel DA, Gilad Y (2008) Sex-specific genetic architecture of human disease. *Nat Rev Genet* 9:911–922
- Oda M, Maruyama H, Komure O, Morino H, Terasawa H, Izumi Y, Imamura T, Yasuda M, Ichikawa K, Ogawa M, Matsumoto M, Kawakami H (2004) Possible reduced penetrance of expansion of 44 to 47 CAG/CAA repeats in the TATA-binding protein gene in spinocerebellar ataxia type 17. *Arch Neurol* 61:209–212
- Ogaki K, Li Y, Atsuta N, Tomiyama H, Funayama M, Watanabe H, Nakamura R, Yoshino H, Yato S, Tamura A, Naito Y, Taniguchi A, Fujita K, Izumi Y, Kaji R, Hattori N, Sobue G, Japanese Consortium for Amyotrophic Lateral Sclerosis research (JaCALS) (2012) Analysis of *C9orf72* repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. *Neurobiol Aging* 33:2527
- Ohmori I, Ouchida M, Miki T, Mimaki N, Kiyonaka S, Nishiki T, Tomizawa K, Mori Y, Matsui H (2008) A *CACNB4* mutation shows that altered Ca_v2.1 function may be a genetic modifier of severe myoclonic epilepsy in infancy. *Neurobiol Dis* 32:349–354
- Ohmori I, Ouchida M, Kobayashi K, Jitsumori Y, Mori A, Michiue H, Nishiki T, Ohtsuka Y, Matsui H (2013) *CACNA1A* variants may modify the epileptic phenotype of Dravet syndrome. *Neurobiol Dis* 50:209–217
- Okkels H, Sunde L, Lindorff-Larsen K, Thorlacius-Ussing O, Gandrup P, Lindebjerg J, Stubbeteglbjaerg P, Oestergaard JR, Nielsen FC, Krarup HB (2006) Polyposis and early cancer in a patient with low penetrant mutations in *MSH6* and *APC*: hereditary colorectal cancer as a polygenic trait. *Int J Colorectal Dis* 21:847–850
- Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, Hermida-Prieto M, Sabater M, García-Molina E, Ortiz M, Rodríguez-García MI,

- Núñez L, Gimeno JR, Castro-Beiras A, Valdés M (2010) Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in *MYBPC3*. *Heart* 96:1980–1984
- Onadim Z, Hogg A, Baird PN, Cowell JK (1992) Oncogenic point mutations in exon 20 of the *RBI* gene in families showing incomplete penetrance and mild expression of the retinoblastoma phenotype. *Proc Natl Acad Sci USA* 89:6177–6181
- Oprea GE, Kröber S, McWhorter ML, Rossoll W, Müller S, Krawczak M, Bassell GJ, Beattie CE, Wirth B (2008) Platin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. *Science* 320:524–527
- Ostrer H, Skorecki K (2013) The population genetics of the Jewish people. *Hum Genet* 132:119–127
- Otterson GA, Wd Chen, Coxon AB, Khleif SN, Kaye FJ (1997) Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function. *Proc Natl Acad Sci USA* 94:12036–12040
- Otterson GA, Modi S, Nguyen K, Coxon AB, Kaye FJ (1999) Temperature-sensitive RB mutations linked to incomplete penetrance of familial retinoblastoma in 12 families. *Am J Hum Genet* 65:1040–1046
- Otto PA, Maestrelli SR (2000) Heterozygosity probabilities for normal relatives of isolated cases affected by incompletely penetrant conditions and the calculation of recurrence risks for their offspring. I. Autosomal dominant genes. *Am J Med Genet* 95:43–48
- Paavonen KJ, Swan H, Piippo K, Laitinen P, Fodstad H, Sarna S, Toivonen L, Kontula K, Viitasalo M (2007) Beta1-adrenergic receptor polymorphisms, QTc interval and occurrence of symptoms in type I of long QT syndrome. *Int J Cardiol* 118:197–202
- Padalon-Brauch G, Amitai DB, Vodo D, Harel A, Sarig O, Sprecher E, Mashiah J (2012) Digenic inheritance in epidermolysis bullosa simplex. *J Invest Dermatol* 132:2852–2854
- Page SP, Kounas S, Syrris P, Christiansen M, Frank-Hansen R, Andersen PS, Elliott PM, McKenna WJ (2012) Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. *Circ Cardiovasc Genet* 5:156–166
- Palacios R, Gazave E, Gofí J, Piedrafita G, Fernando O, Navarro A, Villoslada P (2009) Allele-specific gene expression is widespread across the genome and biological processes. *PLoS ONE* 4:e4150
- Panegyres PK, Goh JG (2011) The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene. *J Neurol Sci* 301:14–20
- Pantakani DV, Zechner U, Arygriou L, Pauli S, Sauter SM, Mannan AU (2008) Compound heterozygosity in the *SPG4* gene causes hereditary spastic paraplegia. *Clin Genet* 73:268–272
- Park Y, Kubo A, Komiya T, Coxon A, Beebe K, Neckers L, Meltzer PS, Kaye FJ (2008) Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras. *Cell Cycle* 7:2384–2391
- Pedroni M, Di Gregorio C, Cortesi L, Reggiani Bonetti L, Magnani G, Simone ML, Medici V, Priore Oliva C, Marino M, Ponz de Leon M (2013) Double heterozygosity for *BRCA1* and *hMLH1* gene mutations in a 46-year-old woman with five primary tumors. *Tech Coloproctol* (in press)
- Pei Y, Paterson AD, Wang KR, He N, Hefferton D, Watnick T, Germino GG, Parfrey P, Somlo S, St George-Hyslop P (2001) Bilineal disease and *trans*-heterozygotes in autosomal dominant polycystic kidney disease. *Am J Hum Genet* 68:355–363
- Pelucchi S, Mariani R, Calza S, Fracanzani AL, Modignani GL, Bertola F, Busti F, Trombini P, Fraquelli M, Forni GL, Girelli D, Fargion S, Specchia C, Piperno A (2012) *CYBRD1* as a modifier gene that modulates iron phenotype in *HFE* p.C282Y homozygous patients. *Haematologica* 97:1818–1825
- Pereira TV, Mingroni-Netto RC, Yamada Y (2011) *ADRB2* and *LEPR* gene polymorphisms: synergistic effects on the risk of obesity in Japanese. *Obesity* 19:1523–1527
- Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW, Dörk T (2012) Mutation analysis of *BRCA1*, *BRCA2*, *PALB2* and *BRD7* in a hospital-based series of German patients with triple-negative breast cancer. *PLoS ONE* 7:e47993
- Phillips JA 3rd, Poling JS, Phillips CA, Stanton KC, Austin ED, Cogan JD, Wheeler L, Yu C, Newman JH, Dietz HC, Loyd JE (2008) Synergistic heterozygosity for TGFbeta1 SNPs and *BMP2* mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension. *Genet Med* 10:359–365
- Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, Conroy J, Magalhaes TR, Correia C, Abrahams BS, Almeida J, Bacchelli E, Bader GD, Bailey AJ, Baird G, Battaglia A, Berney T, Bolshakova N, Bölte S, Bolton PF, Bourgeron T, Brennan S, Brian J, Bryson SE, Carson AR, Casallo G, Casey J, Chung BH, Cochrane L, Corsello C, Crawford EL, Crossett A, Cytrynbaum C, Dawson G, de Jonge M, Delorme R, Drmic I, Duketis E, Duque F, Estes A, Farrar P, Fernandez BA, Folstein SE, Fombonne E, Freitag CM, Gilbert J, Gillberg C, Glessner JT, Goldberg J, Green A, Green J, Guter SJ, Hakonarson H, Heron EA, Hill M, Holt R, Howe JL, Hughes G, Hus V, Iglizoi R, Kim C, Klauck SM, Kolevzon A, Korvatska O, Kustanovich V, Lajonchere CM, Lamb JA, Laskawiec M, Leboyer M, Le Couteur A, Leventhal BL, Lionel AC, Liu XQ, Lord C, Lotspeich L, Lund SC, Maestrini E, Mahoney W, Mantoulan C, Marshall CR, McConachie H, McDougle CJ, McGrath J, McMahon WM, Merikangas A, Migita O, Minschew NJ, Mirza GK, Munson J, Nelson SF, Noakes C, Noor A, Nygren G, Oliveira G, Papanikolaou K, Parr JR, Parrini B, Paton T, Pickles A, Pilorge M, Piven J, Ponting CP, Posey DJ, Poustka A, Poustka F, Prasad A, Ragoussis J, Renshaw K, Rickaby J, Roberts W, Roeder K, Roge B, Rutter ML, Bierut LJ, Rice JP, Salt J, Sansom K, Sato D, Segurado R, Sequeira AF, Senman L, Shah N, Sheffield VC, Soorya L, Sousa I, Stein O, Sykes N, Stoppioni V, Strawbridge C, Tancredi R, Tansley K, Thiruvahindrapuram B, Thompson AP, Thomson S, Tryfon A, Tsiantis J, Van Engeland H, Vincent JB, Volkmar F, Wallace S, Wang K, Wang Z, Wassink TH, Webber C, Weksberg R, Wing K, Wittemeyer K, Wood S, Wu J, Yaspan BL, Zurawiecki D, Zwaigenbaum L, Buxbaum JD, Cantor RM, Cook EH, Coon H, Cuccaro ML, Devlin B, Ennis S, Gallagher L, Geschwind DH, Gill M, Haines JL, Hallmayer J, Miller J, Monaco AP, Nurnberger II Jr, Paterson AD, Pericak-Vance MA, Schellenberg GD, Szatmari P, Vicente AM, Vieland VJ, Wijsman EM, Scherer SW, Sutcliffe JS, Betancur C (2010) Functional impact of global rare copy number variation in autism spectrum disorders. *Nature* 466:368–372
- Pisciotta L, Priore Oliva C, Cefalù AB, Noto D, Bellocchio A, Fresa R, Cantafora A, Patel D, Averna M, Tarugi P, Calandra S, Bertolini S (2006) Additive effect of mutations in *LDLR* and *PCSK9* genes on the phenotype of familial hypercholesterolemia. *Atherosclerosis* 186:433–440
- Pitteloud N, Quinton R, Pearce S, Raivio T, Acierno J, Dwyer A, Plummer L, Hughes V, Seminara S, Cheng YZ, Li WP, Maccoll G, Eliseenkova AV, Olsen SK, Ibrahimi OA, Hayes FJ, Boepple P, Hall JE, Bouloux P, Mohammadi M, Crowley W (2007) Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. *J Clin Invest* 117:457–463
- Plassart-Schiess E, Gervais A, Eymard B, Lagueny A, Pouget J, Warter JM, Fardeau M, Jentsch TJ, Fontaine B (1998) Novel muscle chloride channel (*CLCN1*) mutations in myotonia congenita with various modes of inheritance including incomplete dominance and penetrance. *Neurology* 50:1176–1179

- Plenge RM, Tranebjaerg L, Jensen PK, Schwartz C, Willard HF (1999) Evidence that mutations in the X-linked DDP gene cause incompletely penetrant and variable skewed X inactivation. *Am J Hum Genet* 64:759–767
- Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV, IARC Unclassified Genetic Variants Working Group (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. *Hum Mutat* 29:1282–1291
- Plon SE, Wheeler DA, Strong LC, Tomlinson GE, Pirics M, Meng Q, Cheung HC, Begin PR, Muzny DM, Lewis L, Biegel JA, Gibbs RA (2011) Identification of genetic susceptibility to childhood cancer through analysis of genes in parallel. *Cancer Genet* 204:19–25
- Podder S, Ghosh TC (2011) Insights into the molecular correlates modulating functional compensation between monogenic and polygenic disease gene duplicates in human. *Genomics* 97:200–204
- Preda L, Dinca O, Bucur A, Dragomir C, Severin E (2010) Identical mutation in *SH3BP2* gene causes clinical phenotypes with different severity in mother and daughter—case report. *Mol Syndromol* 1:87–90
- Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, Burghes AH, Kissel JT (2009) A positive modifier of spinal muscular atrophy in the *SMN2* gene. *Am J Hum Genet* 85:408–413
- Qiu LX, Wang Y, Xia ZG, Xi B, Mao C, Wang JL, Wang BY, Lv FF, Wu XH, Hu LQ (2011) miR-196a2 C allele is a low-penetrant risk factor for cancer development. *Cytokine* 56:589–592
- Quarrell OW, Rigby AS, Barron L, Crow Y, Dalton A, Dennis N, Fryer AE, Heydon F, Kinning E, Lashwood A, Losekoot M, Margerison L, McDonnell S, Morrison PJ, Norman A, Peterson M, Raymond FL, Simpson S, Thompson E, Warner J (2007) Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study. *J Med Genet* 44:e68
- Quaynor SD, Kim HG, Cappello EM, Williams T, Chorich LP, Bick DP, Sherins RJ, Layman LC (2011) The prevalence of digenic mutations in patients with normosmic hypogonadotropic hypogonadism and Kallmann syndrome. *Fertil Steril* 96:1424–1430
- Raef H, Baitei EY, Zou M, Shi Y (2008) Genotype-phenotype correlation in a family with primary cortisol resistance: possible modulating effect of the ER22/23EK polymorphism. *Eur J Endocrinol* 158:577–582
- Raivio T, Sidis Y, Plummer L, Chen H, Ma J, Mukherjee A, Jacobson-Dickman E, Quinton R, Van Vliet G, Lavoie H, Hughes VA, Dwyer A, Hayes FJ, Xu S, Sparks S, Kaiser UB, Mohammadi M, Pitteloud N (2009) Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab* 94:4380–4390
- Ramachandrapa S, Farooqi IS (2011) Genetic approaches to understanding human obesity. *J Clin Invest* 121:2080–2086
- Rana HQ, Balwani M, Bier L, Alcalay RN (2013) Age-specific Parkinson disease risk in *GBA* mutation carriers: information for genetic counseling. *Genet Med* 15:146–149
- Rankin J, Auer-Grumbach M, Bagg W, Colclough K, Nguyen TD, Fenton-May J, Hattersley A, Hudson J, Jardine P, Josifova D, Longman C, McWilliam R, Owen K, Walker M, Wehnert M, Ellard S (2008) Extreme phenotypic diversity and nonpenetrance in families with the *LMNA* gene mutation R644C. *Am J Med Genet* 146A:1530–1542
- Rasmussen TB, Palmfeldt J, Nissen PH, Magnoni R, Dalager S, Jensen UB, Kim WY, Heickendorff L, Mølgaard H, Jensen HK, Baandrup UT, Bross P, Mogensen J (2013) Mutated desmoglein-2 proteins are incorporated into desmosomes and exhibit dominant-negative effects in arrhythmogenic right ventricular cardiomyopathy. *Hum Mutat* 34:697–705
- Rave-Harel N, Kerem E, Nissim-Rafinia M, Madjar I, Goshen R, Augarten A, Rahat A, Hurwitz A, Darvasi A, Kerem B (1997) The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. *Am J Hum Genet* 60:87–94
- Refsgaard L, Holst AG, Sadjadih G, Haunsø S, Nielsen JB, Olesen MS (2012) High prevalence of genetic variants previously associated with LQT syndrome in new exome data. *Eur J Hum Genet* 20:905–908
- Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burbanc M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M, EUROGENE Heart Failure Project (2003) Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. *Circulation* 107:2227–2232
- Rigaud S, Lopez-Granados E, Sibérlil S, Gloire G, Lambert N, Lenoir C, Synaeve C, Stacey M, Fugger L, Stephan JL, Fischer A, Picard C, Durandy A, Chapel H, Latour S (2011) Human X-linked variable immunodeficiency caused by a hypomorphic mutation in *XIAP* in association with a rare polymorphism in *CD40LG*. *Blood* 118:252–261
- Rio Frio T, Civic N, Ransijn A, Beckmann JS, Rivolta C (2008) Two *trans*-acting eQTLs modulate the penetrance of *PRPF31* mutations. *Hum Mol Genet* 17:3154–3165
- Rio Frio T, McGee TL, Wade NM, Iseli C, Beckmann JS, Berson EL, Rivolta C (2009) A single-base substitution within an intronic repetitive element causes dominant retinitis pigmentosa with reduced penetrance. *Hum Mutat* 30:1340–1347
- Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA (2001) Prevalence and penetrance of germline *BRCA1* and *BRCA2* mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 68:700–710
- Risch NJ, Bressman SB, Senthil G, Ozelius LJ (2007) Intragenic *cis* and *trans* modification of genetic susceptibility in *DYT1* torsion dystonia. *Am J Hum Genet* 80:1188–1193
- Rivolta C, McGee TL, Rio Frio T, Jensen RV, Berson EL, Dryja TP (2006) Variation in retinitis pigmentosa-11 (*PRPF31* or *RP11*) gene expression between symptomatic and asymptomatic patients with dominant *RP11* mutations. *Hum Mutat* 27:644–653
- Robson KJ, Lehmann DJ, Wilmhurst VL, Livesey KJ, Combrinck M, Merryweather-Clarke AT, Warden DR, Smith AD (2004) Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (*HFE*) as risk factors for developing Alzheimer's disease. *J Med Genet* 41:261–265
- Rochette J, Le Gac G, Lassoued K, Férec C, Robson KJ (2010) Factors influencing disease phenotype and penetrance in *HFE* haemochromatosis. *Hum Genet* 128:233–248
- Rodeghiero F, Castaman G, Dini E (1987) Epidemiological investigation of the prevalence of von Willebrand's disease. *Blood* 69:454–459
- Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M (2010) Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. *Hum Genet* 127:1–17
- Rohlf s EM, Zhou Z, Heim RA, Nagan N, Rosenblum LS, Flynn K, Scholl T, Akmaev VR, Sirko-Osadsa DA, Allitto BA, Sugarman EA (2011) Cystic fibrosis carrier testing in an ethnically diverse US population. *Clin Chem* 57:841–848
- Roncarati R, Viviani Anselmi C, Krawitz P, Lattanzi G, von Kodolitsch Y, Perrot A, di Pasquale E, Papa L, Portararo P, Columbaro M, Forni A, Faggian G, Condorelli G, Robinson PN (2013) Doubly heterozygous *LMNA* and *TTN* mutations revealed

- by exome sequencing in a severe form of dilated cardiomyopathy. *Eur J Hum Genet* (in press)
- Rosendahl J, Landt O, Bernadova J, Kovacs P, Teich N, Bodeker H, Keim V, Ruffert C, Mossner J, Kage A, Stumvoll M, Groneberg D, Kruger R, Luck W, Treiber M, Becker M, Witt H (2013) *CFTR*, *SPINK1*, *CTRC* and *PRSS1* variants in chronic pancreatitis: is the role of mutated *CFTR* overestimated? *Gut* 62:582–592
- Rosenfeld JA, Coe BP, Eichler EE, Cuckle H, Shaffer LG (2013) Estimates of penetrance for recurrent pathogenic copy-number variations. *Genet Med* 15:478–481
- Rossetti S, Kubly VI, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet P, Torres VE, Harris PC (2009) Incompletely penetrant *PKDI* alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. *Kidney Int* 75:848–855
- Rossi E, Olynyk JK, Jeffrey GP (2008) Clinical penetrance of C282Y homozygous *HFE* hemochromatosis. *Expert Rev Hematol* 1:205–216
- Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, Bigot S, Hue C, Satchell SC, Mathieson PW, Mousson C, Noel C, Sautes-Fridman C, Halbwachs-Mecarelli L, Atkinson JP, Lionet A, Fremeaux-Bacchi V (2012) A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. *Blood* 119:4182–4191
- Roxburgh RH, Marquis-Nicholson R, Ashton F, George AM, Lea RA, Eccles D, Mossman S, Bird T, van Gassen KL, Kamsteeg EJ, Love DR (2013) The p.Ala510Val mutation in the *SPG7* (paraplegin) gene is the most common mutation causing adult onset neurogenetic disease in patients of British ancestry. *J Neurol* 260:1286–1294
- Ruiz-Martínez J, Gorostidi A, Ibañez B, Alzualde A, Otaegui D, Moreno F, López de Munain A, Bergareche A, Gómez-Esteban JC, Martí Massó JF (2010) Penetrance in Parkinson's disease related to the *LRKK2* R1441G mutation in the Basque country (Spain). *Mov Disord* 25:2340–2345
- Runyon RS, Cachola LM, Rajeshuni N, Hunter T, Garcia M, Ahn R, Lurmann F, Krasnow R, Jack LM, Miller RL, Swan GE, Kohli A, Jacobson AC, Nadeau KC (2012) Asthma discordance in twins is linked to epigenetic modifications of T cells. *PLoS ONE* 7:e48796
- Ryan JG, Masters SL, Booty MG, Habal N, Alexander JD, Barham BK, Remmers EF, Barron KS, Kastner DL, Aksentijevich I (2010) Clinical features and functional significance of the P369S/R408Q variant in pyrin, the familial Mediterranean fever protein. *Ann Rheum Dis* 69:1383–1388
- Sagong B, Baek J-I, Oh S-K, Na KJ, Bae JW, Choi SY, Jeong JY, Choi JY, Lee S-H, Lee K-Y, Kim U-K (2013) A rapid method for simultaneous screening of multi-gene mutations associated with hearing loss in the Korean population. *PLoS ONE* 8:e57237
- Saini S, Robinson PN, Singh JR, Vanita V (2012) A novel 7 bp deletion in *PRPF31* associated with autosomal dominant retinitis pigmentosa with incomplete penetrance in an Indian family. *Exp Eye Res* 104:82–88
- Sampieri K, Hadjistilianou T, Mari F, Speciale C, Mencarelli MA, Cetta F, Manoukian S, Peissel B, Giachino D, Pasini B, Acquaviva A, Caporossi A, Frezzotti R, Renieri A, Bruttini M (2006) Mutational screening of the *RBI* gene in Italian patients with retinoblastoma reveals 11 novel mutations. *J Hum Genet* 51:209–216
- San Millán JL, Botella-Carretero JJ, Alvarez-Blasco F, Luque-Ramírez M, Sancho J, Moghetti P, Escobar-Morreale HF (2005) A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. *J Clin Endocrinol Metab* 90:4157–4162
- Sánchez-Mejías A, Fernández RM, López-Alonso M, Antiñolo G, Borrego S (2009) Contribution of *RET*, *NTRK3* and *EDN3* to the expression of Hirschsprung disease in a multiplex family. *J Med Genet* 46:862–864
- Sánchez-Sánchez F, Kruetzfeldt M, Nájera C, Mittnacht S (2005) A novel constitutional mutation affecting splicing of retinoblastoma tumor suppressor gene intron 23 causes partial loss of pRB activity. *Hum Mutat* 25:223
- Sánchez-Sánchez F, Ramírez-Castillejo C, Weekes DB, Beneyto M, Prieto F, Nájera C, Mittnacht S (2007) Attenuation of disease phenotype through alternative translation initiation in low-penetrance retinoblastoma. *Hum Mutat* 28:159–167
- Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO (2008) *APOE* epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. *BMC Neurol* 8:9
- Santana A, Salido E, Torres A, Shapiro LJ (2003) Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. *Proc Natl Acad Sci USA* 100:7277–7282
- Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, Garcia-Piñero A, Wolczynski S, Brailly-Tabard S, Bidet M, Ramos-Arroyo M, Mathieu M, Lienhardt-Roussie A, Morgan G, Turki Z, Bremont C, Lespinasse J, Du Boullay H, Chabbert-Buffet N, Jacquemont S, Reach G, De Talence N, Tonella P, Conrad B, Despert F, Delobel B, Brue T, Bouvattier C, Cabrol S, Pugeat M, Murat A, Bouchard P, Hardelin JP, Dodé C, Young J (2010) A comparative phenotypic study of Kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. *J Clin Endocrinol Metab* 95:659–669
- Sato K, Emi M, Ezura Y, Fujita Y, Takada D, Ishigami T, Umemura S, Xin Y, Wu LL, Larrinaga-Shum S, Stephenson SH, Hunt SC, Hopkins PN (2004) Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. *J Hum Genet* 49:29–34
- Sato D, Lionel AC, Leblond CS, Prasad A, Pinto D, Walker S, O'Connor I, Russell C, Drmic IE, Hamdan FF, Michaud JL, Endris V, Roeth R, Delorme R, Huguet G, Leboyer M, Rastam M, Gillberg C, Lathrop M, Stavropoulos DJ, Anagnostou E, Weksberg R, Fombonne E, Zwaigenbaum L, Fernandez BA, Roberts W, Rappold GA, Marshall CR, Bourgeron T, Szatmari P, Scherer SW (2012) *SHANK1* deletions in males with autism spectrum disorder. *Am J Hum Genet* 90:879–887
- Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ (2002) Digenic inheritance of severe insulin resistance in a human pedigree. *Nat Genet* 31:379–384
- Schaaf CP, Blazo M, Lewis RA, Tonini RE, Takei H, Wang J, Wong LJ, Scaglia F (2011a) Early-onset severe neuromuscular phenotype associated with compound heterozygosity for *OPA1* mutations. *Mol Genet Metab* 103:383–387
- Schaaf CP, Sabo A, Sakai Y, Crosby J, Muzny D, Hawes A, Lewis L, Akbar H, Varghese R, Boerwinkle E, Gibbs RA, Zoghbi HY (2011b) Oligogenic heterozygosity in individuals with high-functioning autism spectrum disorders. *Hum Mol Genet* 20:3366–3375
- Scheffer H, Van Der Vlies P, Burton M, Verlind E, Moll AC, Imhof SM, Buys CH (2000) Two novel germline mutations of the retinoblastoma gene (*RBI*) that show incomplete penetrance, one splice site and one missense. *J Med Genet* 37:E6
- Scherer D, Kumar R (2010) Genetics of pigmentation in skin cancer—a review. *Mutat Res* 705:141–153

- Schild R, Knüppel T, Konrad M, Bergmann C, Trautmann A, Kemper MJ, Wu K, Yaklichkin S, Wang J, Pestell R, Müller-Wiefel DE, Schaefer F, Weber S (2013) Double homozygous missense mutations in *DACH1* and *BMP4* in a patient with bilateral cystic renal dysplasia. *Nephrol Dial Transplant* 28:227–232
- Schneider A, Larusch J, Sun X, Aloe A, Lamb J, Hawes R, Cotton P, Brand RE, Anderson MA, Money ME, Banks PA, Lewis MD, Baillie J, Sherman S, Disario J, Burton FR, Gardner TB, Amann ST, Gelrud A, George R, Rockacy MJ, Kassabian S, Martinson J, Slivka A, Yadav D, Oruc N, Barmada MM, Frizzell R, Whitcomb DC (2011) Combined bicarbonate conductance-impairing variants in *CFTR* and *SPINK1* variants are associated with chronic pancreatitis in patients without cystic fibrosis. *Gastroenterology* 140:162–171
- Schork NJ, Murray SS, Frazer KA, Topol EJ (2009) Common vs. rare allele hypotheses for complex diseases. *Curr Opin Genet Dev* 19:212–219
- Schubert EL, Strong LC, Hansen MF (1997) A splicing mutation in *RB1* in low penetrance retinoblastoma. *Hum Genet* 100:557–563
- Schwartz PJ, Priori SG, Napolitano C (2003) How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. *J Cardiovasc Electrophysiol* 14:1120–1121
- Sequeiros J, Ramos EM, Cerqueira J, Costa MC, Sousa A, Pinto-Basto J, Alonso I (2010) Large normal and reduced penetrance alleles in Huntington disease: instability in families and frequency at the laboratory, at the clinic and in the population. *Clin Genet* 78:381–387
- Serrano-Fernández P, Debniak T, Górski B, Bogdanova N, Dörk T, Cybulski C, Huzarski T, Byrski T, Gronwald J, Wokolorczyk D, Narod SA, Lubiński J (2009) Synergistic interaction of variants in *CHEK2* and *BRCA2* on breast cancer risk. *Breast Cancer Res Treat* 117:161–165
- Sévin M, Kutalik Z, Bergman S, Vercelletto M, Renou P, Lamy E, Vingerhoets FJ, Di Virgilio G, Boisseau P, Bezieau S, Pasquier L, Rival JM, Beckmann JS, Damier P, Jacquemont S (2009) Penetrance of marked cognitive impairment in older male carriers of the *FMRI* gene premutation. *J Med Genet* 46:818–824
- Shalata A, Furman H, Adir V, Adir N, Hujeirat Y, Shalev SA, Borochowitz ZU (2010) Myotonia congenita in a large consanguineous Arab family: insight into the clinical spectrum of carriers and double heterozygotes of a novel mutation in the chloride channel *CLCN1* gene. *Muscle Nerve* 41:464–469
- Shankar RK, Ellard S, Standiford D, Pihoker C, Gilliam LK, Hattersley A, Dolan LM (2013) Digenic heterozygous *HNF1A* and *HNF4A* mutations in two siblings with childhood-onset diabetes. *Pediatr Diabetes* (in press)
- Shaw ND, Seminara SB, Welt CK, Au MG, Plummer L, Hughes VA, Dwyer AA, Martin KA, Quinton R, Mericq V, Merino PM, Gusella JF, Crowley WF Jr, Pitteloud N, Hall JE (2011) Expanding the phenotype and genotype of female GnRH deficiency. *J Clin Endocrinol Metab* 96:E566–E576
- Shen J (2009) Evaluation of environmental and personal susceptibility characteristics that modify genetic risks. *Methods Mol Biol* 471:163–177
- Shen H, Li J, Zhang J, Xu C, Jiang Y, Wu Z, Zhao F, Liao L, Chen J, Lin Y, Tian Q, Papiasian CJ, Deng H-W (2013a) Comprehensive characterization of human genome variation by high coverage whole-genome sequencing of forty four Caucasians. *PLoS ONE* 8:e59494
- Shen W, Gu Y, Zhu R, Zhang L, Zhang J, Ying C (2013b) Copy number variations of the *F8* gene are associated with venous thromboembolism. *Blood Cells Mol Dis* 50:259–262
- Shinlapawittayatorn K, Du XX, Liu H, Ficker E, Kaufman ES, Deschênes I (2011) A common *SCN5A* polymorphism modulates the biophysical defects of *SCN5A* mutations. *Heart Rhythm* 8:455–462
- Shirahama S, Miyahara A, Kitoh H, Honda A, Kawase A, Yamada K, Mabuchi A, Kura H, Yokoyama Y, Tsutsumi M, Ikeda T, Tanaka N, Nishimura G, Ohashi H, Ikegawa S (2003) Skewed X-chromosome inactivation causes intra-familial phenotypic variation of an *EBP* mutation in a family with X-linked dominant chondrodysplasia punctata. *Hum Genet* 112:78–83
- Shohat M, Halpern GJ (2011) Familial Mediterranean fever—a review. *Genet Med* 13:487–498
- Sibille A, Eng CM, Kim SJ, Pastores G, Grabowski GA (1993) Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications. *Am J Hum Genet* 52:1094–1101
- Sidransky E (2006) Heterozygosity for a Mendelian disorder as a risk factor for complex disease. *Clin Genet* 70:275–282
- Siegert S, Hampe J, Schafmayer C, von Schönfels W, Egberts JH, Försti A, Chen B, Lascorz J, Hemminki K, Franke A, Nothnagel M, Nöthlings U, Krawczak M (2013) Genome-wide investigation of gene–environment interactions in colorectal cancer. *Hum Genet* 132:219–231
- Sierra M, González-Aramburu I, Sánchez-Juan P, Sánchez-Quintana C, Polo JM, Berciano J, Combarros O, Infante J (2011) High frequency and reduced penetrance of *LRRK2* G2019S mutation among Parkinson’s disease patients in Cantabria (Spain). *Mov Disord* 26:2343–2346
- Silva E, Dharmaraj S, Li YY, Pina AL, Carter RC, Loyer M, Traboulsi E, Theodossiadis G, Koenekoop R, Sundin O, Maumenee I (2004) A missense mutation in *GUCY2D* acts as a genetic modifier in *RPE65*-related Leber Congenital Amaurosis. *Ophthalmic Genet* 25:205–217
- Simi L, Sestini R, Ferruzzi P, Gaglianò MS, Gensini F, Mascialchi M, Guerrini L, Pratesi C, Pinzani P, Nesi G, Ercolino T, Genuardi M, Mannelli M (2005) Phenotype variability of neural crest derived tumours in six Italian families segregating the same founder *SDHD* mutation Q109X. *J Med Genet* 42:e52
- Singh NA, Pappas C, Dahle EJ, Claes LR, Pruess TH, De Jonghe P, Thompson J, Dixon M, Gurnett C, Peiffer A, White HS, Filloux F, Leppert MF (2009) A role of *SCN9A* in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. *PLoS Genet* 5:e1000649
- Skelly DA, Ronald J, Akey JM (2009) Inherited variation in gene expression. *Annu Rev Genomics Hum Genet* 10:313–332
- Sleegers K, Bettens K, Brouwers N, Engelborghs S, van Mieghroet H, De Deyn PP, Van Broeckhoven C (2009) Common variation in *GRB*-associated binding protein 2 (*GAB2*) and increased risk for Alzheimer dementia. *Hum Mutat* 30:E338–E344
- Smaoui N, Chaabouni M, Sergeev YV, Kallel H, Li S, Mahfoudh N, Maazoul F, Kammoun H, Gandoura N, Bouaziz A, Nouiri E, M’Rad R, Chaabouni H, Hejtmancik JF (2006) Screening of the eight BBS genes in Tunisian families: no evidence of triallelism. *Invest Ophthalmol Vis Sci* 47(8):3487–3495
- Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O’Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW, O’Brien SJ (1997) Contrasting genetic influence of *CCR2* and *CCR5* variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multi-center AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. *Science* 277:959–965
- Snozok CL, Lagerstedt SA, Khoo TK, Rubenfire M, Isley WL, Train LJ, Baudhuin LM (2009) *LDLR* promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance. *Eur J Hum Genet* 17:85–90

- Soares ML, Coelho T, Sousa A, Batalov S, Conceição I, Sales-Luís ML, Ritchie MD, Williams SM, Nievergelt CM, Schork NJ, Saraiva MJ, Buxbaum JN (2005) Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. *Hum Mol Genet* 14:543–553
- Song MJ, Lee ST, Lee MK, Ji Y, Kim JW, Ki CS (2012) Estimation of carrier frequencies of six autosomal-recessive Mendelian disorders in the Korean population. *J Hum Genet* 57:139–144
- Soriano A, Manna R (2012) Familial Mediterranean fever: new phenotypes. *Autoimmun Rev* 12:31–37
- Soto-Ramírez N, Arshad SH, Holloway JW, Zhang H, Schaubberger E, Ewart S, Patil V, Karmaus W (2013) The interaction of genetic variants and DNA methylation of the interleukin-4 receptor gene increase the risk of asthma at age 18 years. *Clin Epigenetics* 5:1
- Sparrow DB, Chapman G, Smith AJ, Mattar MZ, Major JA, O'Reilly VC, Saga Y, Zackai EH, Dormans JP, Alman BA, McGregor L, Kageyama R, Kusumi K, Dunwoodie SL (2012) A mechanism for gene–environment interaction in the etiology of congenital scoliosis. *Cell* 149:295–306
- Spurdle AB, Whaley PJ, Thompson B, Feng B, Healey S, Brown MA, Pettigrew C; kConFab, Van Asperen CJ, Ausems MG, Kattentidt-Mouravieva AA, van den Ouweland AM; Dutch Belgium UV Consortium, Lindblom A, Pigg MH, Schmutzler RK, Engel C, Meindl A; German Consortium of Hereditary Breast and Ovarian Cancer, Caputo S, Sinilnikova OM, Lidereau R; French COVAR group collaborators, Couch FJ, Guidugli L, Hansen Tv, Thomassen M, Eccles DM, Tucker K, Benitez J, Domchek SM, Toland AE, Van Rensburg EJ, Wappenschmidt B, Borg Å, Vreeswijk MP, Goldgar DE; ENIGMA Consortium (2012) *BRCA1* R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. *J Med Genet* 49:525–532
- Staropoli JF, Xin W, Barone R, Cotman SL, Sims KB (2012) An atypical case of neuronal ceroid lipofuscinosis with co-inheritance of a variably penetrant *POLG1* mutation. *BMC Med Genet* 13:50
- Steinberg MH, Sebastiani P (2012) Genetic modifiers of sickle cell disease. *Am J Hematol* 87:795–803
- Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN (2009) The human gene mutation database: 2008 update. *Genome Med* 1:13
- Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, Montgomery S, Tavaré S, Deloukas P, Dermitzakis ET (2007) Population genomics of human gene expression. *Nat Genet* 39:1217–1224
- Striano P, Weber YG, Toliat MR, Schubert J, Leu C, Chaimana R, Baulac S, Guerrero R, LeGuern E, Lehesjoki AE, Polvi A, Robbiano A, Serratos JM, Guerrini R, Nürnberg P, Sander T, Zara F, Lerche H, Marini C, EPICURE Consortium (2012) *GLUT1* mutations are a rare cause of familial idiopathic generalized epilepsy. *Neurology* 78:557–562
- Strom SP, Gorin MB (2013) Evaluation of autosomal dominant retinal dystrophy genes in an unaffected cohort suggests rare or private missense variants may often be benign. *Mol Vis* 19:980–985
- Stutzmann F, Tan K, Vatin V, Dina C, Jouret B, Tichet J, Balkau B, Potoczna N, Horber F, O'Rahilly S, Farooqi IS, Froguel P, Meyre D (2008) Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. *Diabetes* 57:2511–2518
- Subramanian S (2012) Quantifying harmful mutations in human populations. *Eur J Hum Genet* 20:1320–1322
- Sugawara H, Iwamoto K, Bundo M, Ueda J, Miyauchi T, Komori A, Kazuno A, Adati N, Kusumi I, Okazaki Y, Ishigooka J, Kojima T, Kato T (2011) Hypermethylation of serotonin transporter gene in bipolar disorder detected by epigenome analysis of discordant monozygotic twins. *Transl Psychiatry* 1:e24
- Sullivan LS, Bowne SJ, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Lewis RA, Garcia CA, Ruiz RS, Blanton SH, Northrup H, Gire AI, Seaman R, Duzkale H, Spellacy CJ, Zhu J, Shankar SP, Daiger SP (2006) Prevalence of disease-causing mutations in families with autosomal dominant retinitis pigmentosa: a screen of known genes in 200 families. *Invest Ophthalmol Vis Sci* 47:3052–3064
- Sullivan M, Rybicki LA, Winter A, Hoffmann MM, Reiermann S, Linke H, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Bock A, Wiech T, Gaspert A, Fehr T, Woznowski M, Berisha G, Malinoc A, Goek ON, Eng C, Neumann HP (2011) Age-related penetrance of hereditary atypical hemolytic uremic syndrome. *Ann Hum Genet* 75:639–647
- Svenson IK, Ashley-Koch AE, Gaskell PC, Riney TJ, Cumming WJ, Kingston HM, Hogan EL, Boustany RM, Vance JM, Nance MA, Pericak-Vance MA, Marchuk DA (2001) Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia. *Am J Hum Genet* 68:1077–1085
- Sykotiis GP, Plummer L, Hughes VA, Au M, Durrani S, Nayak-Young S, Dwyer AA, Quinton R, Hall JE, Gusella JF, Seminara SB, Crowley WF Jr, Pitteloud N (2010) Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. *Proc Natl Acad Sci USA* 107:15140–15144
- Synofzik M, Ronchi D, Keskin I, Basak AN, Wilhelm C, Gobbi C, Birve A, Biskup S, Zecca C, Fernández-Santiago R, Kaugesaar T, Schöls L, Marklund SL, Andersen PM (2012) Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS. *Hum Mol Genet* 21:3568–3574
- Szabó A, Sahin-Tóth M (2012) Increased activation of hereditary pancreatitis-associated human cationic trypsinogen mutants in presence of chymotrypsin C. *J Biol Chem* 287:20701–20710
- Szyf M (2012) How do environments talk to genes? *Nat Neurosci* 16:2–4
- Szymanski M, Wang R, Bassett SS, Avramopoulos D (2011) Alzheimer's risk variants in the clusterin gene are associated with alternative splicing. *Transl Psychiatry* 1:e18
- Tada H, Kawashiri MA, Ohtani R, Noguchi T, Nakanishi C, Konno T, Hayashi K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M (2011) A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. *Atherosclerosis* 219:663–666
- Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. *Am J Hematol* 84:208–214
- Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW (1994) Prevalence of antithrombin deficiency in the healthy population. *Br J Haematol* 87:106–112
- Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM (1995) Prevalence of protein C deficiency in the healthy population. *Thromb Haemost* 73:87–93
- Takada D, Ezura Y, Ono S, Iino Y, Katayama Y, Xin Y, Wu LL, Larringa-Shum S, Stephenson SH, Hunt SC, Hopkins PN, Emi M (2003a) Apolipoprotein H variant modifies plasma triglyceride phenotype in familial hypercholesterolemia: a molecular study in an eight-generation hyperlipidemic family. *J Atheroscler Thromb* 10:79–84
- Takada D, Ezura Y, Ono S, Iino Y, Katayama Y, Xin Y, Wu LL, Larringa-Shum S, Stephenson SH, Hunt SC, Hopkins PN, Emi M (2003b) Growth hormone receptor variant (L526I) modifies plasma HDL cholesterol phenotype in familial hypercholesterolemia: intra-familial association study in an eight-generation hyperlipidemic kindred. *Am J Med Genet* 121A:136–140

- Talmud PJ (2007) Rare *APOA5* mutations—clinical consequences, metabolic and functional effects: an ENID review. *Atherosclerosis* 194:287–292
- Tamanaha R, Camacho CP, Pereira AC, da Silva AM, Maciel RM, Cerutti JM (2009) Evaluation of *RET* polymorphisms in a six-generation family with G533C *RET* mutation: specific *RET* variants may modulate age at onset and clinical presentation. *Clin Endocrinol* 71:56–64
- Tang B, Xiong H, Sun P, Zhang Y, Wang D, Hu Z, Zhu Z, Ma H, Pan Q, Xia JH, Xia K, Zhang Z (2006) Association of *PINK1* and *DJ-1* confers digenic inheritance of early onset Parkinson's disease. *Hum Mol Genet* 15:1816–1825
- Tang CS, Sribudiani Y, Miao XP, de Vries AR, Burzynski G, So MT, Leon YY, Yip BH, Osinga J, Hui KJ, Verheij JB, Cherny SS, Tam PK, Sham PC, Hofstra RM, Garcia-Barceló MM (2010) Fine mapping of the 9q31 Hirschsprung's disease locus. *Hum Genet* 127:675–683
- Tang CS, Tang WK, So MT, Miao XP, Leung BM, Yip BH, Leon TY, Ngan ES, Lui VC, Chen Y, Chan IH, Chung PH, Liu XL, Wu XZ, Wong KK, Sham PC, Cherny SS, Tam PK, Garcia-Barceló MM (2011) Fine mapping of the *NRG1* Hirschsprung's disease locus. *PLoS ONE* 6:e16181
- Tang CS, Ngan ES, Tang WK, So MT, Cheng G, Miao XP, Leon TY, Leung BM, Hui KJ, Lui VH, Chen Y, Chan IH, Chung PH, Liu XL, Wong KK, Sham PC, Cherny SS, Tam PK, Garcia-Barceló MM (2012a) Mutations in the *NRG1* gene are associated with Hirschsprung disease. *Hum Genet* 131:67–76
- Tang CS, Cheng G, So MT, Yip BH, Miao XP, Wong EH, Ngan ES, Lui VC, Song YQ, Chan D, Cheung K, Yuan ZW, Lei L, Chung PH, Liu XL, Wong KK, Marshall CR, Scherer SW, Cherny SS, Sham PC, Tam PK, Garcia-Barceló MM (2012b) Genome-wide copy number analysis uncovers a new HSCR gene: *NRG3*. *PLoS Genet* 8:e1002687
- Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB, IARC Unclassified Genetic Variants Working Group (2008) In silico analysis of missense substitutions using sequence-alignment based methods. *Hum Mutat* 29:1327–1336
- Taylor M, Dehainault C, Desjardins L, Doz F, Levy C, Sastre X, Couturier J, Stoppa-Lyonnet D, Houdayer C, Gauthier-Villars M (2007) Genotype-phenotype correlations in hereditary familial retinoblastoma. *Hum Mutat* 28:284–293
- Taylor A, Bayly G, Patel K, Yarram L, Williams M, Hamilton-Shield J, Humphries SE, Norbury G (2010) A double heterozygote for familial hypercholesterolemia and familial defective apolipoprotein B-100. *Ann Clin Biochem* 47:487–490
- Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, McGee S, Do R, Liu X, Jun G, Kang HM, Jordan D, Leal SM, Gabriel S, Rieder MJ, Abecasis G, Altshuler D, Nickerson DA, Boerwinkle E, Sunyaev S, Bustamante CD, Bamshad MJ, Akey JM, Broad GO, Seattle GO, on behalf of the NHLBI Exome Sequencing Project (2012) Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science* 337:64–69
- Tester DJ, Will ML, Haglund CM, Ackerman MJ (2005) Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. *Heart Rhythm* 2:507–517
- Thauvin-Robinet C, Munck A, Huet F, Génin E, Bellis G, Gautier E, Audrézet MP, Férec C, Lalau G, Georges MD, Claustres M, Bienvenu T, Gérard B, Boisseau P, Cabet-Bey F, Feldmann D, Clavel C, Bieth E, Iron A, Simon-Bouy B, Costa C, Medina R, Leclerc J, Hubert D, Nové-Josserand R, Sermet-Gaudelus I, Rault G, Flori J, Leroy S, Wizla N, Bellon G, Haloun A, Perez-Martin S, d'Acremont G, Corvol H, Clément A, Houssin E, Binquet C, Bonithon-Kopp C, Alberti-Boulmé C, Morris MA, Faivre L, Goossens M, Roussey M, Collaborating Working Group on R117H, Girodon E (2009) The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. *J Med Genet* 46:752–758
- The 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. *Nature* 467:1061–1073
- Thiadens AA, Roosing S, Collin RW, van Moll-Ramirez N, van Lith-Verhoeven JJ, van Schooneveld MJ, den Hollander AI, van den Born LI, Hoyng CB, Cremers FP, Klaver CC (2010) Comprehensive analysis of the achromatopsia genes *CNGA3* and *CNGB3* in progressive cone dystrophy. *Ophthalmology* 117:825–830
- Thiel C, Kessler K, Giessler A, Dimmler A, Shalev SA, von der Haar S, Zenker M, Zahnleiter D, Stöss H, Beinder E, Abou Jamra R, Etki AB, Schröder-Kress N, Aigner T, Kirchner T, Reis A, Brandstätter JH, Rauch A (2011) *NEK1* mutations cause short-rib polydactyly syndrome type Majewski. *Am J Hum Genet* 88:106–114
- Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, Sulem P, Rafnar T, Esko T, Walter S, Gieger C, Rawal R, Mangino M, Prokopenko I, Mägi R, Keskitalo K, Gudjonsson IH, Gretarsdottir S, Stefansson H, Thompson JR, Aulchenko YS, Nelis M, Aben KK, den Heijer M, Dirksen A, Ashraf H, Soranzo N, Valdes AM, Steves C, Uitterlinden AG, Hofman A, Tönjes A, Kovacs P, Hottenga JJ, Willemsen G, Vogelzangs N, Döring A, Dahmen N, Nitz B, Pergadia ML, Saez B, De Diego V, Lezcano V, Garcia-Prats MD, Ripatti S, Perola M, Kettunen J, Hartikainen AL, Pouta A, Laitinen J, Isohanni M, Huei-Yi S, Allen M, Krestyaninova M, Hall AS, Jones GT, van Rij AM, Mueller T, Dieplinger B, Haltmayer M, Jonsson S, Matthiasson SE, Oskarsson H, Tyrfingsson T, Kiemeny LA, Mayordomo JI, Lindholt JS, Pedersen JH, Franklin WA, Wolf H, Montgomery GW, Heath AC, Martin NG, Madden PA, Giegling I, Rujescu D, Järvelin MR, Salomaa V, Stumvoll M, Spector TD, Wichmann HE, Metspalu A, Samani NJ, Penninx BW, Oostra BA, Boomsma DI, Tiemeier H, van Duijn CM, Kaprio J, Gulcher JR, ENGAGE Consortium, McCarthy MI, Peltonen L, Thorsteinsdottir U, Stefansson K (2008) Sequence variants at *CHRNA3-CHRNA6* and *CYP2A6* affect smoking behavior. *Nat Genet* 42:448–453
- Tirado I, Mateo J, Soria JM, Oliver A, Borrell M, Coll I, Vallvé C, Souto JC, Martínez-Sánchez E, Fontcuberta J (2001) Contribution of prothrombin 20210A allele and factor V Leiden mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies. *Haematologica* 86:1200–1208
- Tirado I, Mateo J, Soria JM, Oliver A, Martínez-Sánchez E, Vallvé C, Borrell M, Urrutia T, Fontcuberta J (2005) The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. *Thromb Haemost* 93:468–474
- Titeux M, Pendaries V, Tonasso L, Décha A, Bodemer C, Hovnanian A (2008) A frequent functional SNP in the *MMP1* promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa. *Hum Mutat* 29:267–276
- To-Figueras J, Ducamp S, Clayton J, Badenas C, Delaby C, Ged C, Lyoumi S, Gouya L, de Verneuil H, Beaumont C, Ferreira GC, Deybach JC, Herrero C, Puy H (2011) *ALAS2* acts as a modifier gene in patients with congenital erythropoietic porphyria. *Blood* 118:1443–1451
- Toledo RA, Wagner SM, Coutinho FL, Lourenço DM Jr, Azevedo JA, Longuini VC, Reis MT, Siqueira SA, Lucon AM, Tavares MR, Fragoso MC, Pereira AA, Dahia PL, Mulligan LM, Toledo SP (2010) High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the *RET* protooncogene. *J Clin Endocrinol Metab* 95:1318–1327
- Tonooka N, Tomura H, Takahashi Y, Onigata K, Kikuchi N, Horikawa Y, Mori M, Takeda J (2002) High frequency of

- mutations in the HNF-1 α gene in non-obese patients with diabetes of youth in Japanese and identification of a case of digenic inheritance. *Diabetologia* 45:1709–1712
- Tory K, Lacoste T, Burglen L, Morinière V, Boddart N, Macher MA, Llanas B, Nivet H, Bensman A, Niaudet P, Antignac C, Salomon R, Saunier S (2007) High *NPHP1* and *NPHP6* mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of *NPHP6* and *AH11* mutations in patients with *NPHP1* mutations. *J Am Soc Nephrol* 18:1566–1575
- Toutou I, Perez C, Dumont B, Federici L, Jorgensen C (2006) Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations. *Ann Rheum Dis* 65:1530–1531
- Tropeano M, Ahn JW, Dobson RJ, Breen G, Rucker J, Dixit A, Pal DK, McGuffin P, Farmer A, White PS, Andrieux J, Vassos E, Ogilvie CM, Curran S, Collier DA (2013) Male-biased autosomal effect of 16p13.11 copy number variation in neurodevelopmental disorders. *PLoS ONE* 8:e61365
- Tzetis M, Kaliakatsos M, Fotoulaki M, Papatheodorou A, Doudounakis S, Tsezou A, Makrythanasis P, Kanavakis E, Nousia-Arvanitakis S (2007) Contribution of the *CFTR* gene, the pancreatic secretory trypsin inhibitor gene (*SPINK1*) and the cationic trypsinogen gene (*PRSS1*) to the etiology of recurrent pancreatitis. *Clin Genet* 71:451–457
- Uhrhammer N, Bignon YJ (2008) Report of a family segregating mutations in both the *APC* and *MSH2* genes: juvenile onset of colorectal cancer in a double heterozygote. *Int J Colorectal Dis* 23:1131–1135
- Utz VM, Beight CD, Marino MJ, Hagstrom SA, Traboulsi EI. (2013) Autosomal dominant retinitis pigmentosa secondary to pre-mRNA splicing-factor gene *PRPF31* (RP11): review of disease mechanism and report of a family with a novel 3-base pair insertion. *Ophthalmic Genet* (in press)
- Vaags AK, Lionel AC, Sato D, Goodenberger M, Stein QP, Curran S, Ogilvie C, Ahn JW, Drmic I, Senman L, Chrysler C, Thompson A, Russell C, Prasad A, Walker S, Pinto D, Marshall CR, Stavropoulos DJ, Zwaigenbaum L, Fernandez BA, Fombonne E, Bolton PF, Collier DA, Hodge JC, Roberts W, Szatmari P, Scherer SW (2012) Rare deletions at the neurexin 3 locus in autism spectrum disorder. *Am J Hum Genet* 90:133–141
- Valenti L, Fracanzani AL, Rametta R, Fraquelli M, Soverini G, Pelusi S, Dongiovanni P, Conte D, Fargion S (2012) Effect of the A736V *TMPRSS6* polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. *J Hepatol* 57:1319–1325
- Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, Li Z, Zeng Q, Zhang HT, Pennison MJ, Sadim M, Pasche B, Tanner SM, de la Chapelle A (2008) Germline allele-specific expression of *TGFBR1* confers an increased risk of colorectal cancer. *Science* 321:1361–1365
- Valverde JR, Alonso J, Palacios I, Pestaña A (2005) *RBI* gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database. *BMC Genet* 6:53
- van Blitterswijk M, van Es MA, Hennekam EA, Dooijes D, van Rheenen W, Medic J, Bourque PR, Schelhaas HJ, van der Kooi AJ, de Visser M, de Bakker PI, Veldink JH, van den Berg LH (2012a) Evidence for an oligogenic basis of amyotrophic lateral sclerosis. *Hum Mol Genet* 21:3776–3784
- van Blitterswijk M, van Es MA, Koppers M, van Rheenen W, Medic J, Schelhaas HJ, van der Kooi AJ, de Visser M, Veldink JH, van den Berg LH (2012b) *VAPB* and *C9orf72* mutations in 1 familial amyotrophic lateral sclerosis patient. *Neurobiol Aging* 33:2950.e1–4
- van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA (1996) Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. *Thromb Haemost* 75:417–421
- van den Veyver IB (2001) Skewed X inactivation in X-linked disorders. *Semin Reprod Med* 19:183–191
- van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in *BRCA1* and *BRCA2* families: high cancer incidence at older age. *Breast Cancer Res Treat* 124:643–651
- van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, Gruis NA (2001) Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. *Am J Hum Genet* 69:774–779
- van der Werf C, Nederend I, Hofman N, van Geloven N, Ebink C, Frohn-Mulder IM, Alings AM, Bosker HA, Bracke FA, van den Heuvel F, Waalewijn RA, Bikker H, van Tintelen JP, Bhuiyan ZA, van den Berg MP, Wilde AA (2012) Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. *Circ Arrhythm Electrophysiol* 5:748–756
- Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ (2004) Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 44:1903–1910
- Van Goethem G, Löfgren A, Dermaut B, Ceuterick C, Martin JJ, Van Broeckhoven C (2003) Digenic progressive external ophthalmoplegia in a sporadic patient: recessive mutations in *POLG* and *C10orf2/Twinkle*. *Hum Mutat* 22:175–176
- van Mens TE, Levi M, Middeldorp S (2013) Evolution of Factor V Leiden. *Thromb Haemost* (in press). doi:10.1160/TH13-02-0115
- van Puijnenbroek M, Nielsen M, Reinards TH, Weiss MM, Wagner A, Hendriks YM, Vasen HF, Tops CM, Wijnen J, van Wezel T, Hes FJ, Morreau H (2007) The natural history of a combined defect in *MSH6* and *MUTYH* in a HNPCC family. *Fam Cancer* 6:43–51
- van Rijsingen IA, Nannenberg EA, Arbustini E, Elliott PM, Mogensen J, Ast JF, van der Kooi AJ, van Tintelen JP, van den Berg MP, Grasso M, Serio A, Jenkins S, Rowland C, Richard P, Wilde AA, Perrot A, Pankuweit S, Zwiderman AH, Charron P, Christiaans I, Pinto YM (2013) Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. *Eur J Heart Fail* 15:376–384
- van Spronsen FJ (2010) Phenylketonuria: a 21st century perspective. *Nat. Rev. Endocrinol.* 6:509–514
- van Tuyl van Serooskerken AM, de Rooij FW, Edixhoven A, Bladergroen RS, Baron JM, Jousens S, Merk HF, Steijlen PM, Poblete-Gutiérrez P, te Velde K, Wilson JH, Koole RH, van Geel M, Frank J (2011) Digenic inheritance of mutations in the coproporphyrinogen oxidase and protoporphyrinogen oxidase genes in a unique type of porphyria. *J Invest Dermatol* 131:2249–2254
- VanderWeele TJ, Asomaning K, Tchetgen Tchetgen EJ, Han Y, Spitz MR, Shete S, Wu X, Gaborieau V, Wang Y, McLaughlin J, Hung RJ, Brennan P, Amos CI, Christiani DC, Lin X (2012) Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. *Am J Epidemiol* 175:1013–1020
- Vannberg FO, Chapman SJ, Hill AVS (2011) Human genetic susceptibility to intracellular pathogens. *Immunol Rev* 240:105–116
- Varga RE, Schüle R, Fadel H, Valenzuela I, Speziani F, Gonzalez M, Rudenskaia G, Nürnberg G, Thiele H, Altmüller J, Alvarez V, Gamez J, Garbern JY, Nürnberg P, Zuchner S, Beetz C (2013) Don't trust the pedigree: reduced and sex-dependent penetrance at a novel mutation hotspot in *ATL1* blurs autosomal dominant inheritance of spastic paraplegia. *Hum Mutat* 34:860–863

- Vassos E, Collier DA, Holden S, Patch C, Rujescu D, St Clair D, Lewis CM (2010) Penetrance for copy number variants associated with schizophrenia. *Hum Mol Genet* 19:3477–3481
- Venturini G, Rose AM, Shah AZ, Bhattacharya SS, Rivolta C (2012) *CNOT3* is a modifier of *PRPF31* mutations in retinitis pigmentosa with incomplete penetrance. *PLoS Genet* 8:e1003040
- Vincent AL, Billingsley G, Buys Y, Levin AV, Priston M, Trope G, Williams-Lyn D, Héon E (2002) Digenic inheritance of early onset glaucoma: *CYP11B1*, a potential modifier gene. *Am J Hum Genet* 70:448–460
- Vital A, Latour P, Sole G, Ferrer X, Rouanet M, Tison F, Vital C, Goizet C (2012) A French family with Charcot–Marie–Tooth disease related to simultaneous heterozygous *MFN2* and *GDAP1* mutations. *Neuromuscul Disord* 22:735–741
- Vitali T, Sossi V, Tiziano F, Zappata S, Giuli A, Paravatou-Petsotas M, Neri G, Brahe C (1999) Detection of the survival motor neuron (SMN) genes by FISH: further evidence for a role for *SMN2* in the modulation of disease severity in SMA patients. *Hum Mol Genet* 8:2525–2532
- Vithana EN, Abu-Safieh L, Pelosini L, Winchester E, Hornan D, Bird AC, Hunt DM, Bustin SA, Bhattacharya SS (2003) Expression of *PRPF31* mRNA in patients with autosomal dominant retinitis pigmentosa: a molecular clue for incomplete penetrance? *Invest Ophthalmol Vis Sci* 44:4204–4209
- Vitko I, Chen Y, Arias JM, Shen Y, Wu XR, Perez-Reyes E (2005) Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of *CACNA1H*, a T-type calcium channel. *J Neurosci* 25:4844–4855
- Vockley J, Rinaldo P, Bennett MJ, Matern D, Vladutiu GD (2000) Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. *Mol Genet Metab* 71:10–18
- Vogel F, Motulsky AG (1997) Human genetics. Problems and approaches. 3rd edn., Springer, Berlin
- Vogt J, Kohlhasse J, Morlot S, Kluwe L, Mautner VF, Cooper DN, Kehrer-Sawatzki H (2011) Monozygotic twins discordant for neurofibromatosis type 1 due to a postzygotic *NF1* gene mutation. *Hum Mutat* 32:E2134–E2147
- Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, Rudenhe B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC (2010) Incompletely penetrant *PKD1* alleles mimic the renal manifestations of ARPKD. *J Am Soc Nephrol* 21:1097–1102
- Vytopil M, Ricci E, Dello Russo A, Hanisch F, Neudecker S, Zierz S, Ricotti R, Demay L, Richard P, Wehnert M, Bonne G, Merlini L, Toniolo D (2002) Frequent low penetrance mutations in the lamin A/C gene, causing Emery Dreifuss muscular dystrophy. *Neuromuscul Disord* 12:958–963
- Waaen J, Beutler E (2009) Genetic screening for low-penetrance variants in protein-coding genes. *Annu Rev Genomics Hum Genet* 10:431–450
- Walker LC, Fredericksen ZS, Wang X, Tarrell R, Pankratz VS, Lindor NM, Beesley J, Healey S, Chen X; KConFab investigators, Stoppa-Lyonnet D, Tirapo C, Giraud S, Mazoyer S, Muller D, Fricker JP, Delnatte C; GEMO Study Collaborators, Schmutzler RK, Wappenschmidt B, Engel C, Schönbuchner I, Deissler H, Meindl A, Hogervorst FB, Verheus M, Hoening MJ, van den Ouweland AM, Nelen MR, Ausems MG, Aalfs CM, van Asperen CJ, Devilee P, Gerrits MM, Waisfisz Q; HEBON, Szabo CI; ModSQuaD, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Harrington P, Evans DG, Laloo F, Eeles R, Izatt L, Chu C, Davidson R, Eccles D, Ong KR, Cook J; EMBRACE, Rebbeck T, Nathanson KL, Domchek SM, Singer CF, Gschwantler-Kaulich D, Dressler AC, Pfeiler G, Godwin AK, Heikkinen T, Nevanlinna H, Agnarsson BA, Caligo MA, Olsson H, Kristofersson U, Liljegren A, Arver B, Karlsson P, Melin B; SWE-BRCA, Sinilnikova OM, McGuffog L, Antoniou AC, Chenevix-Trench G, Spurdle AB, Couch FJ (2010) Evidence for *SMAD3* as a modifier of breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Res* 12:R102
- Walsh DM, Shalev SA, Simpson MA, Morgan NV, Gelman-Kohan Z, Chemke J, Trembath RC, Maher ER (2013) Acrocallosal syndrome: identification of a novel *KIF7* mutation and evidence for oligogenic inheritance. *Eur J Med Genet* 56:39–42
- Walters RG, Jacquemont S, Valsesia A, de Smith AJ, Martinet D, Andersson J, Falchi M, Chen F, Andrieux J, Lobbens S, Delobel B, Stutzmann F, El-Sayed Moustafa JS, Chèvre JC, Lecoeur C, Vatin V, Bouquillon S, Buxton JL, Boute O, Holder-Espinasse M, Cuisset JM, Lemaitre MP, Ambresin AE, Brioschi A, Gaillard M, Giusti V, Fellmann F, Ferrarini A, Hadjikhani N, Campion D, Guilmatre A, Goldenberg A, Calmels N, Mandel JL, Le Caignec C, David A, Isidor B, Cordier MP, Dupuis-Girod S, Labalme A, Sanlaville D, Béri-Dexheimer M, Jonveaux P, Leheup B, Ounap K, Bochukova EG, Henning E, Keogh J, Ellis RJ, Macdermot KD, van Haelst MM, Vincent-Delorme C, Plessis G, Touraine R, Philippe A, Malan V, Mathieu-Dramard M, Chiesa J, Blaumeiser B, Kooy RF, Caiazzo R, Pigeyre M, Balkau B, Sladek R, Bergmann S, Mooser V, Waterworth D, Reymond A, Vollenweider P, Waeber G, Kurg A, Palta P, Esko T, Metspalu A, Nelis M, Elliott P, Hartikainen AL, McCarthy MI, Peltonen L, Carlsson L, Jacobson P, Sjöström L, Huang N, Hurles ME, O’Rahilly S, Farooqi IS, Männik K, Jarvelin MR, Pattou F, Meyre D, Walley AJ, Coin LJ, Blakemore AI, Froguel P, Beckmann JS (2010) A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. *Nature* 463:671–675
- Wang J, Ban MR, Zou GY, Cao H, Lin T, Kennedy BA, Anand S, Yusuf S, Huff MW, Pollex RL, Hegele RA (2008) Polygenic determinants of severe hypertriglyceridemia. *Hum Mol Genet* 17:2894–2899
- Wang X, Pankratz VS, Fredericksen Z, Tarrell R, Karaus M, McGuffog L, Pharaoh PD, Ponder BA, Dunning AM, Peock S, Cook M, Oliver C, Frost D, EMBRACE, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Houdayer C; GEMO, Hogervorst FB, Hoening MJ, Ligtenberg MJ, HEBON, Spurdle A, Chenevix-Trench G; kConFab, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Domchek SM, Nathanson KL, Rebbeck TR, Singer CF, Gschwantler-Kaulich D, Dressler C, Fink A, Szabo CI, Zikan M, Foretova L, Claes K, Thomas G, Hoover RN, Hunter DJ, Chanock SJ, Easton DF, Antoniou AC, Couch FJ (2010a) Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Hum Mol Genet* 19:2886–2897
- Wang J, Spitz MR, Amos CI, Wilkinson AV, Wu X, Shete S (2010b) Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the *CHRNA5-A3* genetic locus and lung cancer risk. *Cancer* 116:3458–3462
- Wang C, Cai Y, Zheng Z, Tang BS, Xu Y, Wang T, Ma J, Chen SD, Langston JW, Tanner CM, Chan P, Chinese Parkinson Study Group (CPSG) (2012) Penetrance of *LRRK2* G2385R and R1628P is modified by common PD-associated genetic variants. *Parkinsonism Relat Disord* 18:958–963
- Wang QY, Song J, Gibbs RA, Boerwinkle E, Dong JF, Yu FL (2013a) Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1,000 Genomes. *J Thromb Haemost* 11:261–269
- Wang Z, Yan A, Lin Y, Xie H, Zhou C, Lan F (2013b) Familial skewed x chromosome inactivation in adrenoleukodystrophy manifesting heterozygotes from a chinese pedigree. *PLoS ONE* 8:e57977
- Wasielewski M, Riaz M, Vermeulen J, van den Ouweland A, Labrijn-Marks I, Olmer R, van der Spaa L, Klijn JG, Meijers-Heijboer H, Dooijes D, Schutte M (2010) Association of rare *MSH6* variants

- with familial breast cancer. *Breast Cancer Res Treat* 123:315–320
- Wei AH, Yang XM, Lian S, Li W (2013) Genetic analyses of Chinese patients with digenic oculocutaneous albinism. *Chin Med J* 126:226–230
- Weischenfeldt J, Symmons O, Spitz F, Korbel JO (2013) Phenotypic impact of genomic structural variation: insights from and for human disease. *Nat Rev Genet* 14:125–138
- Weiss G (2010) Genetic mechanisms and modifying factors in hereditary hemochromatosis. *Nat Rev Gastroenterol Hepatol* 7:50–58
- Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC (2004) Compound mutations: a common cause of severe long-QT syndrome. *Circulation* 109:1834–1841
- Westra D, Volokhina E, van der Heijden E, Vos A, Huigen M, Jansen J, van Kaauwen E, van der Velden T, van de Kar N, van den Heuvel L (2010) Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). *Nephrol Dial Transplant* 25:2195–2202
- Westrick RJ, Ginsburg D (2009) Modifier genes for disorders of thrombosis and hemostasis. *J Thromb Haemost* 7(Suppl. 1):132–135
- Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA, Gayán J, Brocklebank D, Cherny SS, Cardon LR, Gray J, Dlouhy SR, Wiktorski S, Hodes ME, Conneally PM, Penney JB, Gusella J, Cha JH, Izarray M, Rosas D, Hersch S, Hollingsworth Z, MacDonald M, Young AB, Andresen JM, Housman DE, De Young MM, Bonilla E, Stillings T, Negrette A, Snodgrass SR, Martinez-Jaurrieta MD, Ramos-Arroyo MA, Bickham J, Ramos JS, Marshall F, Shoulson I, Rey GJ, Feigin A, Arnheim N, Acevedo-Cruz A, Acosta L, Alvir J, Fischbeck K, Thompson LM, Young A, Dure L, O'Brien CJ, Paulsen J, Brickman A, Krch D, Peery S, Hogarth P, Higgins DS Jr, Landwehrmeyer B, US–Venezuela Collaborative Research Project (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. *Proc Natl Acad Sci USA* 101:3498–3503
- Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR (2006) Screening for hereditary hemochromatosis: systematic review. *Ann Intern Med* 145:209–223
- Wijsman EM, Daw EW, Yu X, Steinbart EJ, Nochlin D, Bird TD, Schellenberg GD (2005) *APOE* and other loci affect age-at-onset in Alzheimer's disease families with *PS2* mutation. *Am J Med Genet B Neuropsychiatr Genet* 132B:14–20
- Williams RB, Chan EK, Cowley MJ, Little PF (2007) The influence of genetic variation on gene expression. *Genome Res* 17:1707–1716
- Williams KL, Fifita JA, Vucic S, Durnall JC, Kiernan MC, Blair IP, Nicholson GA (2013) Pathophysiological insights into ALS with *C9ORF72* expansions. *J Neurol Neurosurg Psych* (in press)
- Wilmotte R, Maréchal J, Morlé L, Baklouti F, Philippe N, Kastally R, Kotula L, Delaunay J, Alloisio N (1993) Low expression allele alpha LELY of red cell spectrin is associated with mutations in exon 40 (alpha V/41 polymorphism) and intron 45 and with partial skipping of exon 46. *J Clin Invest* 91:2091–2096
- Wirth B, Brichta L, Schrank B, Lochmüller H, Blick S, Baasner A, Heller R (2006) Mildly affected patients with spinal muscular atrophy are partially protected by an increased *SMN2* copy number. *Hum Genet* 119:422–428
- Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, Karlan BY, Friedman E, Kaufman B (2010) Functional variant of *KLOTHO*: a breast cancer risk modifier among *BRCA1* mutation carriers of Ashkenazi origin. *Oncogene* 29:26–33
- Wong AH, Gottesman II, Petronis A (2005) Phenotypic differences in genetically identical organisms: the epigenetic perspective. *Hum Mol Genet* 14 Spec no 1:R11–R18
- Xu T, Yang Z, Vatta M, Rampazzo A, Beffagna G, Pilichou K, Scherer SE, Saffitz J, Kravitz J, Zareba W, Danieli GA, Lorenzon A, Nava A, Bauce B, Thiene G, Basso C, Calkins H, Gear K, Marcus F, Towbin JA, Multidisciplinary Study of Right Ventricular Dysplasia Investigators (2010) Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. *J Am Coll Cardiol* 55:587–597
- Xu N, Kim HG, Bhagavath B, Cho SG, Lee JH, Ha K, Melicani I, Wenzel W, Podolsky RH, Chorich LP, Stackhouse KA, Grove AM, Odom LN, Ozata M, Bick DP, Sherins RJ, Kim SH, Cameron RS, Layman LC (2011) Nasal embryonic LHRH factor (*NELF*) mutations in patients with normosmic hypogonadotropic hypogonadism and Kallmann syndrome. *Fertil Steril* 95:1613–1620
- Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, Mort M, Phillips AD, Shaw K, Stenson PD, Cooper DN, Tyler-Smith C, the 1000 Genomes Project Consortium (2012) Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. *Am J Hum Genet* 91:1022–1032
- Yan H, Dobbie Z, Gruber SB, Markowitz S, Romans K, Giardiello FM, Kinzler KW, Vogelstein B (2002) Small changes in expression affect predisposition to tumorigenesis. *Nat Genet* 30:25–26
- Yan X, Zhang T, Wang Z, Jiang Y, Chen Y, Wang H, Ma D, Wang L, Li H (2011) A novel mutation in the *MITF* may be digenic with *GJB2* mutations in a large Chinese family of Waardenburg syndrome type II. *J Genet Genomics* 38:585–591
- Yang T, Gurrola JG 2nd, Wu H, Chiu SM, Wangemann P, Snyder PM, Smith RJ (2009) Mutations of *KCNJ10* together with mutations of *SLC26A4* cause digenic nonsyndromic hearing loss associated with enlarged vestibular aqueduct syndrome. *Am J Hum Genet* 84:651–657
- Yang Z, Wu S, Zheng T, Lu H, Ma X, Jia W, Hu R (2010) Gender-dependent penetrance of small heterodimer partner (*SHP*) gene deficiency in overweight/obese Chinese pedigrees. *J Int Med Res* 38:142–149
- Yang T, Li X, Huang Q, Li L, Chai Y, Sun L, Wang X, Zhu Y, Wang Z, Huang Z, Li Y, Wu H (2013) Double heterozygous mutations of *MITF* and *PAX3* result in Waardenburg syndrome with increased penetrance in pigmentary defects. *Clin Genet* 83:78–82
- Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ (2003) Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. *Hum Mutat* 22:486–492
- Yatsenko AN, Shroyer NF, Lewis RA, Lupski JR (2001) Late-onset Stargardt disease is associated with missense mutations that map outside known functional regions of *ABCR* (*ABCA4*). *Hum Genet* 108:346–355
- Yigit S, Karakus N, Tasliyurt T, Kaya SU, Bozkurt N, Kisacik B (2012) Significance of *MEFV* gene R202Q polymorphism in Turkish familial Mediterranean fever patients. *Gene* 506:43–45
- Yoshikane Y, Yoshinaga M, Hamamoto K, Hirose S (2013) A case of long QT syndrome with triple gene abnormalities: digenic mutations in *KCNH2* and *SCN5A* and gene variant in *KCNE1*. *Heart Rhythm* 10:600–603
- Zaghloul NA, Katsanis N (2009) Mechanistic insights into Bardet-Biedl syndrome, a model ciliopathy. *J Clin Invest* 119:428–437
- Zaghloul NA, Liu Y, Gerdes JM, Gascue C, Oh EC, Leitch CC, Bromberg Y, Binkley J, Leibel RL, Sidow A, Badano JL, Katsanis N (2010) Functional analyses of variants reveal a significant role for dominant negative and common alleles in oligogenic Bardet-Biedl syndrome. *Proc Natl Acad Sci USA* 107:10602–10607
- Zaks N, Shinar Y, Padeh S, Lidar M, Mor A, Tokov I, Pras M, Langevitz P, Pras E, Livneh A (2003) Analysis of the three most

- common *MEFV* mutations in 412 patients with familial Mediterranean fever. *Isr Med Assoc J* 5:585–588
- Zangen S, Kidron D, Gelbart T, Roy-Chowdhury N, Wang X, Kaplan M (2009) Fatal kernicterus in a girl deficient in glucose-6-phosphate dehydrogenase: a paradigm of synergistic heterozygosity. *J Pediatr* 154:616–619
- Zareba W, Moss AJ, Locati EH, Lehmann MH, Peterson DR, Hall WJ, Schwartz PJ, Vincent GM, Priori SG, Benhorin J, Towbin JA, Robinson JL, Andrews ML, Napolitano C, Timothy K, Zhang L, Medina A, International Long QT Syndrome Registry (2003) Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. *J Am Coll Cardiol* 42:103–109
- Zhang W, Bleibel WK, Roe CA, Cox NJ, Dolan ME (2007) Gender-specific differences in expression in human lymphoblastoid cell lines. *Pharmacogenet Genomics* 17:447–450
- Zhang X, Chen S, Zhang L, Liu M, Redfearn S, Bryant RM, Oberti C, Vincent GM, Wang QK (2008) Protective effect of *KCNH2* single nucleotide polymorphism K897T in LQTS families and identification of novel *KCNQ1* and *KCNH2* mutations. *BMC Med Genet* 9:87
- Zhang CK, Stein PB, Liu J, Wang Z, Yang R, Cho JH, Gregersen PK, Aerts JM, Zhao H, Pastores GM, Mistry PK (2012) Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of *CLN8* gene as a genetic modifier contributing to extreme phenotypic variation. *Am J Hematol* 87:377–383
- Zheng QY, Yan D, Ouyang XM, Du LL, Yu H, Chang B, Johnson KR, Liu XZ (2005) Digenic inheritance of deafness caused by mutations in genes encoding cadherin 23 and protocadherin 15 in mice and humans. *Hum Mol Genet* 14:103–111
- Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, Scheidtmann K, Kern P, Winkelmann J, Müller-Myhsok B, Riedel L, Bauer M, Müller T, Castro M, Meitinger T, Strom TM, Gasser T (2001) Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. *Nat Genet* 29:66–69
- Zinman L, Liu HN, Sato C, Wakutani Y, Marvelle AF, Moreno D, Morrison KE, Mohlke KL, Bilbao J, Robertson J, Rogaeva E (2009) A mechanism for low penetrance in an ALS family with a novel *SOD1* deletion. *Neurology* 72:1153–1159
- Zlotogora J (2003) Penetrance and expressivity in the molecular age. *Genet Med* 5:347–352
- Zlotogora J, van Baal S, Patrinos GP (2007) Documentation of inherited disorders and mutation frequencies in the different religious communities in Israel in the Israeli National Genetic Database. *Hum Mutat* 28:944–949
- Zou Y, Wang J, Liu X, Wang Y, Chen Y, Sun K, Gao S, Zhang C, Wang Z, Zhang Y, Feng X, Song Y, Wu Y, Zhang H, Jia L, Wang H, Wang D, Yan C, Lu M, Zhou X, Song L, Hui R (2013) Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy. *Mol Biol Rep* 40:3969–3976
- Zschocke J, Kohlmüller D, Quak E, Meissner T, Hoffmann GF, Mayatepek E (1999) Mild trimethylaminuria caused by common variants in *FMO3* gene. *Lancet* 354:834–835